{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2018/reseptregisteret-2013_2017-temadel-om-legemidler-og-eldre.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "in the elderlyLEGEMIDDELSTATISTIKKReseptregisteret 2013-2017 eldre The Norwegian Prescription Database 2013-2017 Topic: Drug use in the elderly ned som pdf p\u00e5 Folkehelseinstituttets use in the elderly 2013: Legemiddelstatistikk D\u00f8gndose (DDD) ........................................................................................................................................ 46 2.6 WHO Collaborating Centre for Drug Statistics Methodology .................................................................................. 47 3. Reseptregisteret 52 3.3 av hovedtabellene ............................................................................................................................... 56 3.4 ATC main groups ...................................................................................................................................................... 60 3.5 ATC group A - Alimentary tract and metabolism ..................................................................................................... 61 3.6 ATC group B - Blood and bloodforming organs ....................................................................................................... 72 3.7 ATC group C - Cardiovascular system ..................................................................................................................... 75 3.8 ATC group D - Dermatologicals ............................................................................................................................... 83 3.9 ATC group G - Genito urinary system and sex hormones ........................................................................................ 89 3.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ............................................... 94 3.11 ATC group J - Antiinfectives for systemic use ........................................................................................................ 97 3.12 ATC group L - Antineoplastic and immunomodulating agents ............................................................................ 104 3.13 ATC group M - Musculo-skeletal system ............................................................................................................ 107 3.14 ATC group N - Nervous system ........................................................................................................................... 110 3.15 ATC group P - Antiparasitic products, insecticides and repellents ...................................................................... 120 3.16 ATC group R - Respiratory system ...................................................................................................................... 122 3.17 ATC group S - Sensory organs ............................................................................................................................. 127 3.18 ATC-group V - Various Drug use in the elderly ............................................................................................................................................ 8 1.1 Drug use in the elderly ( 65 years) - some key figures ............................................................................................ 8 1.2 Use of anti-dementia drugs in the elderly ............................................................................................................... 15 1.3 Use of cardiovascular drugs and antithrombotic drugs in the elderly ..................................................................... 19 1.4 Use of drugs for osteoporosis in the elderly ........................................................................................................... 24 1.5 Use of analgesics in the elderly ............................................................................................................................. 30 1.6 Use of hypnotics and anxiolytics in the elderly ...................................................................................................... 34 1.7 Use of antibiotics in the elderly .............................................................................................................................. 37 2. General information about the Norwegian Prescription Database (NorPD) and drug statistics ............................. 40 2.1 About the NorPD ..................................................................................................................................................... 40 2.2 Prescription statistics in the other Nordic countries ............................................................................................... 44 2.3 The Norwegian Drug Wholesales Statistics ............................................................................................................ 44 2.4 The Anatomical Therapeutic Chemical (ATC) classification system ......................................................................... 45 2.5 The Defined Daily Dose (DDD) ................................................................................................................................. 46 2.6 WHO Collaborating Centre for Drug Statistics Methodology .................................................................................. 47 3. The Norwegian Prescription Database (NorPD) 2013-2017 ................................................................................... 48 3.1 Selected key figures from the NorPD ....................................................................................................................... 48 3.2 Prescription categories and re imbursement of medicinal expenses ...................................................................... 52 3.3 Description of the main tables ................................................................................................................................ 56 3.4 ATC main groups ...................................................................................................................................................... 60 3.5 ATC group A - Alimentary tract and metabolism ..................................................................................................... 61 3.6 ATC group B - Blood and bloodforming organs ....................................................................................................... 72 3.7 ATC group C - Cardiovascular system ..................................................................................................................... 75 3.8 ATC group D - Dermatologicals ............................................................................................................................... 83 3.9 ATC group G - Genito urinary system and sex hormones ........................................................................................ 89 3.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ............................................... 94 3.11 ATC group J - Antiinfectives for systemic use ........................................................................................................ 97 3.12 ATC group L - Antineoplastic and immunomodulating agents ............................................................................ 104 3.13 ATC group M - Musculo-skeletal system ............................................................................................................ 107 3.14 ATC group N - Nervous system ........................................................................................................................... 110 3.15 ATC group P - Antiparasitic products, insecticides and repellents ...................................................................... 120 3.16 ATC group R - Respiratory system ...................................................................................................................... 122 3.17 ATC group S - Sensory organs ............................................................................................................................. 127 3.18 ATC-group V - Various ......................................................................................................................................... 131 Some abbreviations and definitions ........................................................................................................................ 133 Definitions ............................................................................................................................................................. 134 Population in Norway 2013-2017 (as of 1st July) ................................................................................................... 134 Population by age in 2017 (as of 1st July) ............................................................................................................... 134 List of publications based on data from the Norwegian Prescription Database (NorPD) as of 31.12.2017 ............... 135ContentsLegemiddelstatistikk 2018:2 Folkehelseinstituttet 7Forord The use of drugs in the population is increasing. An important goal of the health policies regarding phar - maceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parlia - ment decided to establish a national prescription database in Norway (NorPD). The task of building up the registry was given to the Norwegian Institute of Public Health (NIPH). Since January 1st 2004, the institute has received monthly data on drug dispensed to patients, prescribers and institutions from all Norwegian pharmacies. This report is the eleventh edition of the annual statistics from the NorPD. This year's report is a theme issue focusing on drug use in the elderly population. Part 1 of the report presents some key figures on drug use in the elderly 65 years and focuses on selected drug groups and the use of these in the elderly population. General information about the NorPD, drug statistics, classification of drugs and measurement methods is included in part 2 of the report. Part 3 contains selected key figures from the NorPD and the main tables with information about the number of indi - viduals who had drugs prescribed and dispensed from pharmacies in Norway during the last five years (2013-2017). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. The ATC/DDD version of January 2018 is used in the report, see also www.whocc.no. The NorPD also has a website where you can find additional information: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from the NorPD for research or for other purposes which meet the objectives of the NorPD. More informa- tion can be found in part 3 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no). Department of Drug Statistics, Norwegian Institute of Public Health, June 2018Bruken av legemidler i befolkningen til andre som 1. Drug use in the elderly 1.1 Drug use in the elderly ( 65 years) - some key figures This report is a theme issue focusing on the use of drugs in the elderly. In the theme section, we chose 65 years as a definition of elderly. Most developed world countries have accepted the chronological age of 65 years as a definition of 'elderly' or an older person (1). In the tables in part 3 of this report we chose a definition of 70 years for the oldest age group. This definition has been used in similar tables in all previous editions of the report. To be able to compare with previous years and to follow the trends in drug use over time in all the reports, we chose to keep this definition in part 3. Extensive medicinal treatment is common in the elderly and the use of drugs in the population increases with age. Drug consumption by individuals in hospitals and nursing homes is not included at an individual level in the Norwegian Prescription Database (NorPD). This will often provide artificially low figures for the number of drug users, particu- larly in the oldest age groups. Table 1.1.a shows the proportion of men and women 65 years who lived in institutions (nursing homes) in 2016 by five-year age groups. The figures are provided by Statistics Norway and have been relatively stable over recent years. Since the figures for 2017 are not yet available, we also used the proportion for 2016 for 2017. The 1. Legemidler og eldre 2018:2 Folkehelseinstituttet 9proportion is less than one per cent in the 65-69 age group and increases to 25% among those over 90 years. Overall, just below 4% of people 65 years or older lived in a nursing home in 2016. The figures are based on the number of people living in nursing homes as of 31 December 2016. There is always a certain degree of relocation over the year, and some of the people will have lived at home for part of the year (2). The proportion of the population living in nursing homes given in table 1.1.a will therefore be higher than the proportion who lived in a nursing home for the entire year. We have no information on the number of people living in nursing homes throughout the entire year. Adjusting the popula - tion figures by subtracting number of people living in nursing homes will give an overestimation of the prevalence of drug users because some individuals will have lived at home for part of the year and will already be registered in NorPD the year they move into a nursing home. However, this overestimation will be relatively smaller than the underestimation by not accounting for the proportion of elderly living in nursing homes increasing with age. In this theme section we have estimated the prevalence of drug use for the population living outside institutions in many drug groups. All figures and tables in the theme section will state if this population is used (adjusted population).publisering, derfor er andelen for Totalt er i 1.1.a. Total population in Norway in 2017 65 years and proportion living in institutions. Source: Statistics Norway. Women Men Total AgePopulation July 2017% living in institutions*Population July 2017% living in institutions*Population July 2017% living in institutions* 65-69 136 606 0.5 137 028 0.4 273 634 0.5 70-74 126 668 0.9 121 468 0.9 248 136 0.9 75-79 84 349 2.0 73 320 2.0 157 669 2.3 80-84 61 890 6.2 46 714 4.4 108 604 5.4 85-89 47 364 12.6 28 803 8.8 76 167 11.2 90 35 755 27.8 14 649 17.0 50 404 24.8 65 492 631 4.7 421 982 2.3 914 612 3.6 * data from 31 Dec 2016 (tjeneste 21 = langtidsopphold i institusjon)Legemiddelstatistikk 2018:2 Folkehelseinstituttet 10Figures from NorPD show that in the 65 year age group, 92% of the population had at least one drug dispensed on prescription in 2017. If we adjust according to the elderly living at home, the prevalence increases to 95%. In the general popula - tion, the prevalence of drug use was nearly 70% in 2017 (Table 3.1.a). Figure 1.1.a shows that the proportion was lower among the oldest age groups because prescriptions for patients in institutions are excluded. The proportion of women living in institu- tions is higher than for men, especially in the oldest age groups (see table 1.1.a). This may explain why the prevalence of drug use is higher for men than women when the unadjusted population is used (Figure 1.1.a). Adjusting the population by excluding people living in institutions, the prevalence of drug use is increasing with age and will be around 100 % for elderly people over 80 years. The exact total prevalence of drug use is impossible to calculate due to the problems with overestimation described above. The proportion of drug users is highest in the oldest age groups, with more frequent use of multiple drugs and a higher quantity of each in terms of DDDs. In 2017, the 65 year age group constituted a share of 23% of all drug users, but only 17% of the population. Elderly people over 65 years had 48% of the total number of DDDs dispensed on prescrip- tion in 2017 (Table 1.1.b). The largest proportion of elderly is in ATC group B (anti-thrombotic medi - cines) and ATC group C (drugs for cardiovascular disease) where the proportion of drug users 65 years are 61% and 55%, respectively, and they use 65% and 64% of the total number of 23 av befolkningen. Eldre \u00e5r fikk utlevert andelen eldre legemiddelbrukere er 61 % og 55 %, og de bruker henholdsvis 65 % og 64 % av totalt antall DDD.Figure 1.1.a. One year prevalence (%) of dispensed prescriptions in 2017 for men and women aged 65 years. Unadjusted population.65-69100 90 80 70 60 50 40 30 20 10 0 70-74 75-79 80-84 Age groups (years)Proportion MenLegemiddelstatistikk 2018:2 Folkehelseinstituttet 11Table 1.1.c shows the 30 most used prescription drugs by the elderly. Acetylsalicylic acid (Albyl-E\u00ae), used to prevent thrombosis, has been on top of the list for several years even if the use has been slowly decreasing over recent years. 29% of people over 65 years received acetylsalicylic acid on prescription in 2017. Number two on the list is paracetamol (pain- killer), used on prescription by 24% over 65 years. Paracetamol is number one on the list of the most used prescription drugs in the general population (see table 3.1.c), and it is also widely sold without prescription (OTC) in smaller packages (20 tablets). The third drug on the list is metoprolol (Seloken\u00ae, Selo-Zok\u00ae), a beta blocker for the treatment of high blood pressure, heart failure and other cardiovas- cular diseases. Number four and six are atorvastatin (Lipitor\u00ae) and simvastatin (Zocor\u00ae) respectively, both are lipid modifying drugs used to prevent cardio- vascular disease, see chapter 1.3. The most used hypnotic in Norway, zopiclone (Imovane\u00ae), was used by 17% of the elderly and is number five on the list. Among the 30 most commonly prescribed drugs, in addition to zopiclone we find four other addictive drugs (codeine and paracetamol in combination, tramadol, oxazepam and ethylmorphine). Diazepam is no longer on the list of the 30 most used drugs. The proportion of people over 65 years who were prescribed diazepam declined by 40% over the last decade, from nearly 8% to around 4.5%. This is a positive development since the long half-life makes diazepam especially unsuitable for use in elderly people. See also chapter 1.6 regarding use of hypnotics and av eldre over 65 topper ogs\u00e5 listen eldre som % over siste 10-\u00e5rs periode, fra nesten 8 % til midler.Table Number of individuals having a prescription dispensed in 2017 in the major ATC groups and the corresponding sales in total number of DDDs. Proportion (%) in the age group 65 years and older is given in brackets. Total number of individualsProportion (%) 65 yearsTotal million DDDsProportion (%) 65 years A - Alimentary tract and metabolism 1 081 420 39% 357 47% B - Blood and blood forming organs 699 782 61% 252 65% C - Cardiovascular system 1 117 743 55% 790 64% G - Genito urinary system and sex hormones 876 600 24% 213 20% H - Systemic hormonal preparations, excl. sex hormones and insulins463 794 39% 78 43% J - Antiinfectives for systemic use 1 177 724 24% 32 36% M - Musculo-skeletal system 963 353 26% 96 42% N - Nervous system 1 450 941 31% 380 35% R - Respiratory system 1 374 981 most commonly prescribed drugs (defined as ATC 5th level codes) dispensed to individuals aged 65 years in Norway in 2017. Adjusted population (i.e. excl. the population in nursing homes) Women Men Total # ATC code Active ingredient Use n (%) n (%) n (%) 1B01AC06 Acetylsalicylic acid Antithrombotic 117 203 25.0 140 880 34.2 258 083 29.3 2N02BE01 Paracetamol1)Analgesic 137 369 29.3 71 138 17.3 208 507 23.6 3C07AB02 Metoprolol Antihypertensive/ cardiovascular diseases 95 245 194 353 22.0 4C10AA05 Atorvastatin Lipid-modifying 79 335 16.9 90 614 22.0 169 949 19.3 5N05CF01 Zopiclone Hypnotic 104 899 22.3 47 834 11.6 152 733 17.3 6C10AA01 Simvastatin Lipid-modifying 73 788 15.7 74 534 18.1 148 322 16.8 7A02BC02 Pantoprazole1)Reflux oesophagitis 62 053 13.2 50 711 12.3 112 764 12.8 8N02AJ06 Codeine and paracetamol Opioid analgesic 58 267 12.4 39 900 9.7 98 167 11.1 9A12AX>> Calsium, combinations1)Calcium/vitamin D supplement 77 957 16.6 16 945 4.1 94 902 10.8 10 H03AA01 Levothyroxine sodium Thyroxine supplement 74 135 15.8 19 403 4.7 93 538 10.6 11 C08CA01 Amlodipine Antihypertensive/ cardiovascular diseases 45 320 9.7 45 348 11.0 90 668 10.3 12 H02AB06 Prednisolone Corticosteroid 47 323 10.1 35 863 8.7 83 186 9.4 13 J01CE02 Phenoxymethylpenicillin Antibacterial 38 297 8.2 34 736 8.4 73 033 8.3 14 J01CA08 Pivmecillinam Antibacterial 54 737 11.7 15 419 3.7 70 156 8.0 15 N02AX02 Tramadol Opioid analgesic 42 484 9.0 26 402 6.4 886 7.8 16 A02BC05 Esomeprazole Reflux oesophagitis 40 751 8.7 27 923 6.8 68 674 7.8 17 R03AC02 Salbutamol Asthma/COPD 38 929 8.3 27 465 6.7 66 394 7.5 18 G03CA03 Estradiol Hormone therapy in postmenopausal women 64 487 13.7 14 0.0 64 501 7.3 19 R05DA01 Ethylmorphine Cough suppressant 37 024 7.9 27 181 6.6 64 205 7.3 20 A11EA Vitamin B-complex1)Vitamin B 33 811 7.2 29 487 7.2 63 298 7.2 21 A10BA02 Metformin Diabetes 26 906 5.7 34 328 8.3 61 234 6.9 22 C09CA06 Candesartan Antihypertensive/ cardiovascular diseases 32 413 6.9 27 478 6.7 59 891 6.8 23 N05BA04 Oxazepam Anxiolytic 42 155 9.0 16 779 4.1 58 934 6.7 24 R06AE07 Cetirizine1)Anti-allergic 38 035 8.1 19 802 4.8 57 837 6.6 25 C03CA01 Furosemide Diuretic 33 452 7.1 22 489 5.5 55 941 6.3 26 S01XA20 Artificial tears and other indifferent preparations1)Dry eyes 36 171 7.7 12 406 3.0 48 577 5.5 27 M01AB05 Diclofenac1)NSAID/analgesic 25 651 5.5 21 336 5.2 46 987 5.3 28 R05CB01 Acetylcysteine1)Mucolytic 25 121 5.4 21 364 5.2 46 485 5.3 29 C09AA05 Ramipril Antihypertensive/ cardiovascular diseases 17 535 3.7 28 367 6.9 45 902 5.2 30 B01AF02 Apixaban Antithrombotic 21 096 4.5 23 580 5.7 44 676 5.1 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2018:2 Folkehelseinstituttet 13Figure 1.1.b shows the percentage distribution of the total number of individuals by the number of drugs (defined as different ATC 5th levels) that were dispensed during 2017 to users 65 years or older, compared to the rest of the population (0-64 years). 58% of the elderly drug users used more than five drugs compared to 21% for those under 65 years. In 2017, 23% of drug users over 65 years were prescribed more than 10 different drugs during the year. This percentage has increased from 19% in 2007. For those under 65 years, the proportion was 5% in 2017. Figure 1.1.c shows the proportion of drug users over 65 years with more than 15 different drugs dispensed per year in the period 2004-2017 compared to drug users 0-64 years. It is important to emphasise that use of many drugs during a year does not necessarily mean that all the drugs are used simultaneously. Some drugs may be prescribed for short-term use or for acute treatment, for example a course of antibi - otics for infections. Changes of treatment during a year will also increase the total number of drugs per patient. The proportion of female drug users over 65 years with 15 or more drugs increased in the period from 7% to 10%. The increase for elderly men in the same period was from 5% to 8%. For drug users under 65 years, the proportion using 15 drugs or more has been about one per cent for men and two per cent for women, and there has been an increase also in this age group in this period. Evidence-based guidelines often recommend several medicines to treat or prevent disease. Individuals treated for several illnesses will often use multiple drugs. The Figur 1.1.b viser fordelingen enn fem lege - midler, mens for de under 65 \u00e5r var andelen 21 %. I 2017 fikk 23 % av legemiddelbrukere 65 \u00f8kt fra 19 % i 2007. For de under 65 \u00e5r var andelen som brukte over 10 til perioden. \u00d8kningen for eldre menn i samme periode var fra 5 % til 8 %. For de under 65 \u00e5r har andelene som bruker Figure Proportion (%) of total drug users according to number of drugs dispensed (ATC 5th level codes) in 2017 in the age groups 0-64 and 65 years.100 90 80 70 60 50 40 30 20 10 0Proportion (%) of drug users 65+ years 0-64 years 1 17 19 3 5 7 N = number of drugs (ATC-codes)9 11 13 15 21Legemiddelstatistikk 2018:2 Folkehelseinstituttet 14figures from NorPD show that many elderly people will need to cope with many drugs, increasing the risk of misuse. Several studies using data from NorPD have focused on this issue (3,4,5,6). Polypharmacy in elderly people imposes a risk of inappropriate drug use and increases the risk of adverse drug reac - tions, interactions, hospital admissions and death (7). The single most important predictor of inappro- priate prescribing in older patients is the number of prescribed drugs. In recent years, there has been an increased focus on deprescribing, a process which may be important in elderly people to define cases where the risk of taking multiple drugs outweighs the benefit (8).det 3. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206 4. Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly - a modern epidemic? Eur J Clin Pharmacol. 2012 ;68:1085-94. 5. Kann IC, Lundqvist C, Lur\u00e5s H. Polypharmacy Among the Elderly in a List-Patient System. Drugs - Real World Outcomes. 2015;2(3):193-8. doi: 10.1007/ s40801-015-0036-3 6. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. Epilepsy Res 2017;139:35-42. 7. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014; 13: 57 - 65. 8. Scott IA, Hilmer SN, Reeve E et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015; 175: 827 - 34.Figure 1.1.c. Proportion of drug users who were dispensed 15 drugs (ATC 5th level codes) in 2004-2017 in the age groups 0-64 and 65 years by gender.2004 2012 201312 10 8 6 4 2 0 2005 2014 2006 2015 2007 2016 YearProportion (%) of drug users 2008 2009 2010 2011 2017 Women 65+ years Men 65+ 2018:2 Folkehelseinstituttet Use of anti-dementia drugs in the elderly Around 60% of patients with dementia have Alz heimer's disease, the most common form of dementia. Vascular dementia due to cardiovascular disease is the second most common and accounts for 20% (1-3). The number of patients with dementia in Norway is estimated to be around 80 000-104 000 (3). The first drugs for the treatment of Alzheimer's disease were introduced in Norway around the year 2000. Four drugs are currently approved; donepezil (Aricept\u00ae), rivastigmine (Exelon\u00ae) and galantamine (Reminyl\u00ae) similar way (cholinesterase inhibitors), whereas memantine (Ebixa\u00ae) has a different mechanism of action. All drugs have limited efficacy and cannot halt disease progression, only improve the symptoms. Results from randomised clinical trials with anti-dementia drugs have shown great variation in efficacy that implies that some patients show a positive effect, while others have little or no effect. However, it is impossible to know in advance which patients will have positive effects of treatment. The requirement for reimbursement of anti-dementia drugs set by the Norwegian authorities is that \"the effect of treatment should be monitored and documented in the patient's medical records at least every 6 months\". In 2017, there were a total of 14 564 users of anti- dementia drugs (ATC group N06D) in the elderly popu - lation aged 65 years living at home. The number of users has remained relatively stable over time. 95% of all patients using anti-dementia drugs in 2017 were older than 65 years. The proportion of users in the population above 65 years has been slightly reduced from 1.8% in 2013 to 1.6% in 2017. 60% of all patients using anti-dementia drugs in 2017 were women. Based on the estimated numbers of dementia patients of around 80 000-104 000, a relatively low proportion are treated with anti-dementia drugs. The number of new users of anti-dementia drugs was 1.2 Bruk av legemidler mot aldersdemens Rundt % (1-3). svakt ned fra 1,8 % i 2013 til 1,6 % i 2017. 60 % av 484 in 2017. New users of anti-dementia drugs were defined as those who had not been dispensed drugs in this class in the preceding year, i.e. 2016. The annual number of new users and the total number of users have remained relatively unchanged in the period 2013-2017, implying that there is a balance between the numbers who start and stop treatment during a year. Lack of efficacy and adverse events can be reasons for stopping treatment. In addition, patients who are admitted to nursing homes or those who die in the course of the year will not be registered in the NorPD. 80 % of the patients with long-term stay in nursing home have a dementia diagnosis (2). Data on drug prescriptions to individuals in nursing homes are not included in the figures presented in this report. Based on the sales in number of doses (DDD) in 2017, it is estimated that around 30% of total sales of anti-dementia drugs can be attributed to use in nursing homes. This figure is based on the total sales of anti-dementia drugs from the Norwegian Drug Wholesale Statistics (5). This proportion was also around 30% in 2011 (4). The number of users for the various anti-dementia drugs are given in table 3.13, p 117. Data from Sweden showed that the proportion of users of anti-dementia prescriptions among the elderly over 65 years was 1.9% in 2016 with a slight increase over time, and that there are geographical differences in use (6). The figures in Sweden are slightly higher than in Norway. However, it is difficult to assess what would be the optimal level of drug treatment of dementia patients.disse legemidlene tatt % de langtidsplass syke- hjem har en for de ulike demenslegemidlene er vist % i 2016, og bruken har \u00f8kt svakt over tid og det er forskjeller (6). Tallene i Sverige er men som ling av demenspasienter.Table 1.2.a. Number of men and women (65 years) with at least one dementia drug dispensed in 2017, distributed according to the total number of drugs (ATC codes) dispensed during 2017. Unadjusted population. Gender 1-5 drugs n (%)6-10 drugs n (%)11-15 drugs n (%) 16 drugs n (%)Total Men 1556 (27) 2588 (44) 1207 (21) 475 (8) 5826 (100) Women 2278 (26) 3731 (43) 1939 (22) 790 (9) 8738 (100) NorPD show that patients using anti-dementia drugs also use many other drugs. Table 1.2.a shows the distribution of women and men according to the number of drugs that were dispensed in 2017, where at least one was an anti- dementia drug (N06D). The number of drugs is based on counting the different ATC codes (active ingredient level) dispensed. Some of the drugs dispensed can be used for acute short-term disease e.g. antibiotics for treatment of infections, while other drugs are intended for chronic diseases. This implies that not all drugs are necessarily prescribed for concurrent use. Changes to drug therapy will also influence the total number of drugs dispensed to a patient during a year. Overall, around 30% of all dementia patients had more than 10 drugs dispensed during 2017. This proportion is similar to the figures presented for 2011 (4). The use of multiple drugs will increase the risk of drug-related problems. Figure 1.2.a shows the proportion who had at least one antipsychotic (N05A), anxiolytic (N05B), hypnotic and sedative (N05C) and/or among elderly users of anti-dementia drugs in 2017 compared to the total population aged 65 years or older. The use of the specified drug groups was higher in the dementia population compared to the total population. The differences were particularly visible for the use of antidepressants and antipsy - chotics. In the dementia group, 33% of women used antidepressants compared to 14 % in the total population. For men, the corresponding figures for antidepressants were 23 and 7% (Figure 1.2.a). As expected, the use of psychotropic drugs is higher in Tall fra Reseptregisteret viser at de som midler mot depresjon, mens gjennomsnittet i befolkningen var 14 %. For menn var tilsvarende andeler 23 og 7 % (figur at s\u00e5rbar gruppe med mye angst, depresjon Figure 1.2.a. population who were dispensed anti-dementia drugs in 2017 compared to the total Norwegian population aged 65 years. Unadjusted population.Total populationTotal populationTotal patients35 30 25 20 15 10 5 0Proportion (%) of the population Women Men Anxiolytics Antipsychotics Hypnotics and sedatives AntidepressantsLegemiddelstatistikk 2018:2 Folkehelseinstituttet 18the dementia group as this is a particularly vulner - able group of patients with a lot of anxiety and depression. Focus on the optimal use of psychotro- pics among dementia patients is important to avoid unfavourable over-treatment. The proportions using psychotropics have been slightly reduced compared to 2011 among the patents using anti-dementia drugs. There are fewer gender differences in the use of psychotropics in those using anti-dementia drugs compared to the general population.og uro. Diskusjon drugs and anti- thrombotic drugs in the elderly Cardiovascular disease increases with age and this chapter focuses on the use of medicines among the elderly aged 65 years or older. Drugs classified in the ATC group C are used to treat different diseases such as hypertension, heart failure, angina pectoris and high cholesterol levels. Agents classified in group B01 include medicines used to treat and prevent thrombosis. In 2017, a total of 610,022 elderly men and women had at least one prescription dispensed for a drug in ATC group C. This corresponds to a one-year preva- lence of 68% in women and 70% in men in the popu - lation living outside institutions. These proportions have been relatively stable over the latest five years. The proportion using these drugs increases with age (Figure 1.3.a). Use of drugs to treat hypertension and other cardio \u00ad vascular disease Drugs in groups such as diuretics (C03), (C07), renin blockers) (C09) are used to treat different diseases, most commonly hypertension, angina, oedema and heart failure. In 2017, over half of the elderly population living at home had at least one prescription dispensed for a drug in one of the these groups (59% women and 62% men).1.3 prevalens p\u00e5 og 62 % menn). Figure 1.3.a. Proportion (%) of the population in Norway 65 years with cardiovascular prescriptions (ATC group C) dispensed in 2017. Adjusted population (i.e. excl. the population living in nursing homes).65-69100 90 80 70 60 50 40 30 20 10 0 70-74 75-79 80-84 Age groups (years)Proportion Folkehelseinstituttet 20Figure 1.3.b shows the prevalence of use of the various groups in the period 2013-2017 in women and men. The updated guidelines for prevention of cardiovascular disease were published in 2017 (3). This is an update of the 2009 guidelines and is based on a new risk score table, NORRISK 2 (4, 5). Pharma - cological treatment is important both in primary and secondary prevention of cardiovascular disease. The proportion of elderly patients using diuretics (ATC C03) has gradually decreased over time. The greatest reduction is observed for the high-ceiling diuretics (furosemide /bumetanide). Thiazides in fixed combi - nation with ACE inhibitors /ARB (C09) have become more common (see table page 79.) The proportion of users of beta-blockers has also decreased somewhat over time. Beta-blockers are important to treat heart failure, but are no longer the drug of choice to treat hypertension. The proportion of users of calcium channel blockers (C08) has been stable, while more users receive fixed combinations of calcium channel blockers with an ARB / thiazide (see table page 80). In total, the proportion using ACE-inhibitors / ARB (C09) has been relatively stable in women, while the proportion is increasing in men. Treatment of hypertension in new users An article based on 2009 data from the NorPD showed that thiazides and ARB were the most common drugs prescribed at the initiation of treat - ment in new patients with hypertension (6). The latest guidelines provide no recommendations related to selection of drugs. The most important is the reduction of the blood pressure. However, the increase in the number of ARB users indicates that Figur 1.3.b viser (3). Dette er en oppdatering av retningslinjene fra 2009 og de nye retningslinjene er basert p\u00e5 en ny Reseptregisteret fra ARB var de lege- midlene som ble foreskrevet ved 1.3.b. Proportion (%) of the population in Norway 65 years with prescriptions of diuretics (C03), beta blockers (C07), calcium channel (including combinations) (C09) and lipid modifying agents (C10) dispensed in the period 2013-2017. Unadjusted population.2013 201350 40 30 20 10 0 2014 2014 2015 2015 2016 2016 Women MenProportion (%) of the population 2017 2017 Lipid modifying agents Agents acting on the renin-angiotensin system Calcium channel blockers Beta blocking agents DiureticsLegemiddelstatistikk 2018:2 Folkehelseinstituttet 21these drugs are still often the first choice in the treat - ment of hypertension. Lipid-modifying agents (statins) Treatment of hypercholesterolemia is important to prevent cardiovascular disease. 98% of patients on lipid-modifying treatment use statins. The use of statins varies between countries in Europe, and Norway has a relatively high consumption (7). Among the elderly population, 35% women and 43% men in Norway were dispensed at least one statin prescription in 2017 (figure 1.3.c). The proportion using statins has increased steadily over time and men use more than women. Usage increases with age up to 84 years. In the 75-79 year age group, the proportion was 43% in women and 50% in men. The prevalence of statin use declines in the oldest age groups and particularly in those aged over 90 years. This may indicate that there is less secondary prevention with statins for reducing new cardiovas- cular events and mortality among the oldest popula - tion. The population is adjusted by the number of people living in nursing homes, so the proportion of the population refers to the elderly people living at home. The new guidelines recommend atorvastatin 20 mg as the drug of choice when starting statin treatment (3). The number of patients receiving atorvastatin is increasing and the new guidelines may have contrib- uted to this increase. For a detailed overview of Lipidsenkende legemidler et relativt h\u00f8yt forbruk (7). I 2017 fikk 35 % av Andel 75-79 var og karlegemidler. Figure 1.3.c. Proportion (%) of the population in Norway 65 years with prescriptions of lipid-modifying agents (C10) dispensed in 2017. Adjusted population (i.e. excl. the population living in nursing homes).65-6960 50 40 30 20 10 0 70-74 75-79 80-84 Age groups (years)Proportion Folkehelseinstituttet see table page 81. Many statin users are also dispensed other cardiovascular drugs. Around 80% of statin-users had at least one other ATC group C drug dispensed in 2017. Antithrombotic drugs The proportion of users of antithrombotic drugs among the elderly 65 years have been relatively stable over the period 2010-2017 (see figure 1.3.d). However, there has been a shift in the choice of drugs being used. The new direct-acting oral antico- agulants (DOAC) are increasingly used and in 2017, the proportion of users of DOAC among the elderly was 8%. The proportion of users of warfarin is nearly halved from 9% in 2010 to 5% by 2017. Overall, the proportion of users of warfarin or DOAC increased during the same period. Low dose acetylsalicylic acid is also used to prevent the risk of thrombosis. The proportion of users of ASA has decreased in the period 2010-2017. In the elderly population around 90% of those using and antithrombotic drug (ATC B01) had at least one other ATC group C drug dispensed in 2017.Rundt 80 % warfarin er nesten halvert fra 9 % i 2010 til 5 % Totalt perioden 2010-2017. 90 % av Proportion (%) of the population in Norway 65 years with prescriptions of the antithrombotic drugs warfarin, dispensed in 2010-2017. Unadjusted population.2010 201345 40 35 30 25 20 15 10 5 0 2011 2014 2012 2015 2016Proportion (%) of the population 2017 ASA age (Figure 1.3.e). In 2017, the proportion of warfarin users was around 2% among 65-69 year olds, and 11% for the elderly over 90 years, while the propor - tion of DOAC users was approximately 4% and 18% respectively in the same age groups. The Norwegian Institute of Public Health recently published the Public Health Report - Health Status in Norway (8). The report includes a chapter on cardiovascular disease in Norway. The chapter is comprehensive and provides useful information on the current situation and the development of cardio - vascular disease in Norway, including statistics.Bruken av antitrombotiske de \u00e5r, mens andelen DOAC brukere var henholdsvis hjerte- og folkehelseinstitutt, rapport Reseptregisteret 2005-2008 (The Ariansen I m.fl. NORRISK 2: A Norwegian risk model for acute cerebral stroke and myocardial infarction Eur J Prev Cardiol 2017;773-783. Eur J Selmer R, HS, Landmark K, Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use \u2014 a 4-year follow-up of 78,453 incident users. Eur J Clin Pharmacol 2012. 7. OECD Health Data: Pharmaceutical market, 2016. (http://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_PHMC) 8. Folkehelserapporten - Helsetilstanden i (in Norwegian) https://www.fhi.no/nettpub/hin/ ikke-smittsomme/Hjerte-kar/Figure 1.3.e. Proportion (%) of the population in Norway 65 years with prescription for anti-coagulation drugs warfarin and DOAC (dabigatran, rivaroxaban, excl. the popula - tion living in nursing homes).65-6920 18 16 14 12 10 8 6 4 2 0 70-74 75-79 80-84 Age groups drugs for osteoporosis in the elderly Every year, adult Norwegians suffer about 9 000 hip fractures and 15 000 forearm fractures. A large number also experience vertebral fractures (1). In the period 1999-2013, there was a decline in the rate of hip fractures, but the number is expected to rise in the coming years due to the increase in number of elderly people (2). Hip fractures are the most serious fractures among osteoporosis patients, and approximately 250 surgical ward beds will be occupied by hip frac- ture patients at any time. The mortality after hip fractures is high, and one third of those 85 years or older who lived at home before the fracture, lived in a nursing home one year after the fracture (3-5). Prevention of these fractures is possible, both through lifestyle changes and drug therapy. This could potentially save unnecessary expenses for society and pain, suffering and loss of quality of life for individual patients. Several drugs against osteoporosis have been marketed in Norway in only oestrogen was available for treating osteoporosis but this is no longer recommended to be used for extended periods because of side effects. Strontium ranelate has not been marketed in Norway and is therefore not presented in the statistics. In this report the following drugs are The active drug denosumab is licensed with several indications. Since only the drug Prolia\u00ae has osteoporosis as an approved indication, this drug is the only included in the statistics. To get the drug for osteoporosis reimbursed, different criteria must be met (6). Alendronate is the drug for which fewest criteria need to be met, but if the treatment with alendronate gives side effects or other conditions require it, other drugs can be prescribed.1.4 Bruk av hoftebruddpasient. D\u00f8delig - etter osteoporose i andre land, men er ikke of the elderly ( 65) not living in nursing homes that had prescrip- tions dispensed for anti-osteoporosis drugs in 2008 and 2013-2017. Overall, the use of these drugs has been stable in the last part of the period, slightly below 10% of the female population and 1% of the male population each year. However, among women there is a decline compared to the use in 2008 (figure 1.4.a) and a small increase among men. Most of both women and men use bisphosphonates, and alendronate dominates. Use of the bisphosphonate zoledronate and the drug denosumab (Prolia\u00ae ) has increased in the period 2008-2017. noe under 10 % av den kvinnelige befolkningen og vel 1 % and proportion of the population 65 years using anti-osteoporosis drugs in Norway in 2008 and 2013-2017. Adjusted population (i.e. excl. the population in nursing homes). 2008 2013 2014 2015 2016 2017 Women Number % Number % Number % Number % Number % Number % Adjusted population (i.e. excl. the population in nursing homes) 386 701 432 480 441 729 451 629 460 230 469 646 All anti-osteoporosis drugs1 41 135 10,6 42 278 9,8 42 161 9,5 42 266 9,4 42 849 915 077 731 37 401 8 Alendronate336 467 9,4 37 219 8,6 36 279 8,2 35 424 7,8 34 477 7,5 33 811 7,2 Zoledronate4100 0 2 004 0,5 2 350 0,5 2 480 0,5 2 901 0,6 3 325 0,7 Other bisphosphonates53 921 338 461 % Number % Number % Number % Number % Adjusted population (i.e. excl. the population in nursing homes) 303 366 364 566 376 821 388 525 399 980 412 082 All anti-osteoporosis drugs14 017 1,3 4 780 5 762 1,4 6 122 005 694 879 143 0 424 0,1 Other bisphosphonates5227 0,1 97 0 52 0 56 0 47 0 44 0 Teriparatide715 0 19 0 27 0 32 0 38 0 48 0 Denosumab80 0 83 0 115 0 173 0 247 0,1 299 0,1 1) data for calcitonin (ATC code H05BA01) are not shown because of very few users, but are included in the figures for \"All anti-osteoporosis drugs\".Legemiddelstatistikk 2018:2 Folkehelseinstituttet 26In general, it is recommended to use calcium and vitamin D-supplements to prevent osteoporosis, but since these drugs often are sold over the counter (OTC) in pharmacies and through other sales channels than pharmacies, they are not included in the table. In 2017, approximately 95 000 individuals 65 years or older were registered in the NorPD with at least one dispensed drug with the ATC-code A12AX (calcium, combinations with vitamin D and/or other drugs). However, the use of these drugs does not necessarily mean that the individual has osteoporosis. The different anti-osteoporosis drugs have different dosing regimens. The bisphosphonate Aclasta\u00ae (zoledronate) is an infusion administered once a year and has been on the Norwegian market since 2005. Prolia\u00ae (denosumab) has the indication osteoporosis and is administered subcutaneously twice a year. Teriparatide is given as a daily subcutaneous injection during a treatment period of maximum 24 months (only once in life). Thereafter, another treatment for osteoporosis should be considered. Oral bisphosphonate therapy has been associated with caustic injury in the oesophagus and poor compliance because of a complex dosing regimen. There are fewer side effects and compliance is expected to be better with zoledronate and denosumab. From the figures 1.4.a and 1.4.b it appears that the overall proportion of users among elderly not living in nursing homes is declining, while the proportion of new users is increasing. This may indicate that more people discontinue than start treatment. However, Generelt anbefales inntak av kalsium og tabellen. I det 95 000 individer over tabellen Figure 1.4.a. Proportion of the female population 65 years in Norway using anti-osteoporosis drugs in 2008-2017. Adjusted population (i.e. excl. the population Prolia\u00ae.200812 10 8 6 4 2 0 2009 2010 2011 2012 2013 YearProportion (%) of the population 2014 2015 2017 drugs Alendronate Zoledronate DenosumabLegemiddelstatistikk 2018:2 Folkehelseinstituttet 27some considerations need to be taken. In the table and figures showing use of anti-osteoporosis drugs in this report, only drugs dispensed by prescription in the pharmacies are included. Drugs given directly to the patient in an institution or drugs used in clinical trials are not included. This means that drugs given to the elderly living in nursing homes are not included. Comparison of data from the NorPD and the Norwe - gian Drug Wholesale Statistics shows that almost all the anti-osteoporosis drugs were dispensed by prescription (measured in DDD) in 2017. The difference was larger for drugs with the active ingredient zoledronate. For all the anti-osteoporosis drugs in 2017, approximately 4% were not registered in the NorPD, but for the active ingredient zoledronate this was as much as 79%. The estimate for the number of users of zoledronate not registered in the NorPD is 21 000 in 2017. It has to be taken into account that the active drug zoledronate is also used for indications other than osteoporosis. The NoFRACT project (7), conducted among fracture patients at 7 Norwegian hospitals to prevent new fractures, may have contributed to increased use of zoledronate (Aclasta\u00ae), both through prescription and as a drug used in the relevant hospitals. Figure 1.4.b illustrates the proportion (%) of new male and female users of anti-osteoporosis drugs in the population over 65 years, each year in the period 2008-2017. A new user is defined as someone who has not been dispensed prescrip- tions for any of the anti-osteoporosis drugs in the last 365 days. Except for the first few years, the proportion of new users is increasing slightly throughout the period, for both genders.og figurene om antiosteoporosemedisin i denne data ikke registrert registrert i Reseptregisteret er av zoledronat 21 000 i nytt kan perioden 2008-2017. Her er en bruker har Figure 1.4.b. Proportion of new users of anti-osteoporosis drugs in the Norwegian population 65 years in the period 2008- 2017. The individual is defined as a new user if she/he has not been dispensed prescriptions for any of the anti-osteoporosis drugs the last 365 days. Adjusted population (i.e. excl. the population in 2009 2010 2011 2012 2013 YearProportion (%) of new users in the population2014 2015 2017 2016 Women MenLegemiddelstatistikk drugs different This may mean that some individ - uals are defined as new users more than once. Even though the dosing regimen for zoledronate is once a year, the doctor can consider it sufficient for some individuals to administer it for several years between each injection. Therefore, if it is more than 365 days between the dispensings of zoledronate, they will count as a new user more than once. The proportion of users of anti-osteoporosis drugs among elderly people not living in nursing homes is highest in the age group 75-84 years among women, but in 2017 the two oldest age groups (75-84 and 85+) are at the same level, see figure 1.4.c. Among men use increases with age. This is expected, since age is an important risk factor for osteoporosis and the propor - tion of individuals with osteoporosis increases with age. In all of the three age groups the proportion of new users is increasing over time for both men and women as shown in figure 1.4.c (white bars).Det er ulikt doseringsregime (hvite strek-s\u00f8yler).Figure 1.4.c. Proportion of users (red and blue bars) and proportion of new users (white bars) of anti-osteoporosis drugs in the Norwegian population aged 65 years in 2008, 2012 and 2017 in three age groups. The individual is defined as a new user if she/he has not had filled prescriptions for any of the anti-osteoporosis drugs the last 365 days. Adjusted population (i.e. excl. the population in 200814 12 10 8 6 4 2 0 2012 2012 2012 2017 2017 2017 65-74 75-84 85+Proportion (%) of the population Women Men Proportion of new users, women Proportion of new users, men Age groupsLegemiddelstatistikk 2018:2 Folkehelseinstituttet 29Figure 1.4.d shows the relationship between the age standardised proportion of users in each county and the proportion of users in Norway for individuals over 65 years (the numbers are age standardised, but not adjusted for individuals living in nursing homes). There are large differences in the use of anti-osteo- porosis drugs between the counties, and the county differences follow roughly the same pattern in men and women. The large differences in use cannot be explained by differences in the occurrence of hip fractures. A study with data from the HUNT Study - a longi - tudinal population health study in Norway and the Norwegian Prescription Database concludes that indi - viduals with high risk for fracture (8). Referanser/References: 1. Falch JA, Meyer HE. [Osteoporosis and fractures in Norway. Occurrence and risk factors] Osteoporose og brudd TK. Continued decline in hip fracture incidence in Norway: NOREPOS study. Osteoporos Int. 2016 Tverdal A, S\u00f8gaard AJ, Meyer HE. Mortality following the first hip fracture in Norwegian women and men (1999-2008). A NOREPOS study. Bone. 2014 Jun;63:81-6. HE, Falch JA, Nordsletten L, Cappelen I, Kristiansen IS. Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 2004;15:567-74. Capture the Fracture\u00ae Initiative (NoFRACT). The 6th Fragility Fracture Network Global Congress 2017, Malm\u00f6, Sweden 24.-26. Aug 2017. S et al: Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway. Osteoporosis International. May 2018. Epub 2018 May 17. doi: 10.1007/s00198-018-4560-3Figure 1.4.d. The ratio between age standardised proportion of users in each county and the proportion of users in Norway (%) (women and men aged 65 years, unadjusted population) by county in 2017. The national average is Women MenLegemiddelstatistikk 2018:2 Folkehelseinstituttet 301.5 Use of drugs non-opioid (mainly paracetamol, ATC group N02B). Total consumption of analgesics The proportion of elderly who receive analgesics increases with age. In the age group 65-69 years, 41% of women and 33% of men living at home were dispensed an analgesic drug at least once in 2017, while the corre- sponding figures for the age group 90 years were 64% of women and 46% of men (figure 1.5a). The use of the various analgesics has changed some- what in the last 5-year period (figure 1.5.b). The propor - tion of users of NSAIDs has decreased slightly, while the smertestillende aldersgruppen 90 \u00e5r var 64 % av kvinnene og 46 % av menn (figur 1.5a). Figure 1.5.a. Proportion (%) of the population by age groups 65 years and gender who had at least one prescription of analgesics dispensed in 2017. Adjusted population (i.e excl. the population in nursing homes). Figure 1.5.b. Proportion (%) of the population 65 years who had at least one prescription of different analgesics (ATC groups M01A, N02A and N02B) dispensed in 2013-2017. Unadjusted population. 65-6970 60 50 40 30 20 10 0 70-74 75-79 80-84 Age groups (years)Proportion (%) of the population 85-89 90+ Women Men 201324 23 22 21 20 19 18 17 16 2014 2015 2016 YearProportion (%) of the population 2017 analgesic users increases. This is in line with the recommendation for caution when using NSAIDS in the elderly due to the increased bleeding risk and gastrointestinal side effects. (1). The proportion of opioid users has been relatively stable. NSAIDs (ATC group M01A) NSAIDs have both anti-inflammatory and anal - gesic effects. Many elderly people are prescribed NSAIDs for short-term use, while others use them over a long time. In 2017, approximately 19% of all subjects 65 years received at least one NSAID. Of all the NSAIDs dispensed to individuals 65 years, 63% were on non-reimbursed prescriptions whereas 36% were reimbursed. The most common reim - bursement codes were rheumatic disorders such as arthritis and various types of inflammatory condi - tions (arthrosis). In the period 2013-2017 the use of diclofenac (ATC-code M01AB05) has been reduced in line with recommendations from the Norwegian Medicines Agency (2). Data show that diclofenac increases the risk of cardiovascular disease, and the Norwe - gian Medicines Agency warns against the use of diclofenac in patients at high risk of cardiovascular diseases. The combination of naproxen and esome - prazole (which reduces the risk of gastrointestinal side effects) has had a strong increase (figure 1.5.c). Bruken av de 1.5.c). Figure 1.5.c. Proportion (%) of the population 65 years who had at least one prescription of different NSAIDs (M01A) dispensed in 2013, 2015 and 2017 (only NSAIDs with more than 1000 users are included). Unadjusted population. 0 1 2 3 4 5 6 Folkehelseinstituttet 32Opioids (ATC into weaker opioids (codeine, tramadol light analgesic buprenorphine, phen - tanyl, morphine, etc.). Measured weaker opioids accounted for 67% of all opioid use in 2017. Between 2013 and 2017, the use of tramadol among individuals 65 years of age has increased slightly, while combinations of codeine and paracetamol has decreased. Among the stronger opioids, oxycodone in particular showed an increased proportion of users in this period (figure 1.5.d).Opioider (ATC-gruppe - perioden 1.5.d). Figure 1.5.d. Proportion (%) of the population 65 years who had at least one prescription of different opioids (N02A) dispensed in 2013, 2015 and 2017 (only opioids with more than 1000 users are included). Unadjusted population.0 1 2 3 4 6 5 8 7 10 9 13 12 11 Proportion (%) of the population 2017 2015 contributes to almost all of the total use of weaker analgesics in elderly 65 years, and also accounts for the increase seen in total consump - tion over the last 10 years. Figure 1.5.e shows the trend in the use of paracetamol in the period 2008 to 2017, measured in the number of DDDs according to non-reimbursement prescriptions and reimbursed prescriptions. The use of prescribed paracetamol in the age group 65 has almost tripled. While the total number of DDDs for paracetamol prescribed on non-reimbursement prescriptions has been virtually unchanged, the DDDs for reimbursed prescriptions has increased significantly. The proportion of indi - viduals who were dispensed reimbursed paracetamol has increased 5-fold over the period, mainly because paracetamol can be reimbursed for chronic pain and is the first drug of choice for this condition. Andre of daily doses (DDD) dispensed for paracetamol (ATC code N02BE01) in the population 65 years in 2008-2017, according to non-reimbursement and reimbursement prescriptions.25 20 15 10 5 0 YearMillion of DDDs DDD - reimbursement prescriptions DDD - non-reimbursement prescriptions 2013 2013 2014 2014 2015 2015 2016 2016 2017 2017Legemiddelstatistikk 2018:2 Folkehelseinstituttet 341.6 Use of hypnotics and anxiolytics in the elderly Sleep problems increase with age. Insomnia among the elderly is not always resolved with non-medical treatments such as good sleep hygiene advice, so it is often treated with medicines. Hypnotics should only be used for short periods. This is particularly important in older age groups because the elderly may have both an altered drug metabolism and increased sensitivity to drugs. Therefore, lower doses and hypnotics with a shorter half-life are recommended for the elderly. Z-hypnotics and certain benzodiazepines are the drugs most commonly used as hypnotics. Z-hypnotics, which dominate the market, are recommended as the first choice (1), Figure 1.6.a shows the proportion of the population aged 65 years who used hypnotics in 2017. In this overall figure, we have chosen to also include anxiolytic benzodiazepines (diazepam and oxazepam), even though these are not used as hypnotics. Certain antihistamines with sedative effects that are being used as hypnotics are also included. The following drugs are included: Figure 1.6.a. Proportion (%) of the population 65 years in Norway who had at least one prescription of hypnotics and/or anxiolytics* dispensed in 2017, according to age groups and gender. Adjusted population (i.e. excl. the population in 70-74 75-79 80-84 Age groups (years)Proportion MenLegemiddelstatistikk 2018:2 Folkehelseinstituttet 35The group of elderly 65 years) outside institutions uses 46% of all hypnotics and/or anxiolytics measured in DDD, while they constitute 17% of the population. Overall, 28% of the population aged 65 years were dispensed these drugs from pharmacies in 2017. This is a decline from 2011, where the proportion was 32%. The proportion is increasing from 22% in 65-69 year olds to 49% in those over 90 years. For all age groups included, more women than men used hypnotics (figure 1.6.a). The proportion is increasing from 28% in 65-69 year old women to 55% in women aged over 90 years. For men, the corresponding numbers were 15% and 37%. Z-hypnotics are the most used hypnotic (figure 1.6.b). In the age group 65 years, 25% of women received z-hypnotics in 2017, compared with 13% among men. Overall, the proportion of users of z-hypnotics has fallen slightly since 2013. The use of anxiolytic benzo- diazepines (N05BA) and benzodiazepine hypnotics (N05CD) has also shown a slight decrease over the same period. However, for other agents than benzo- diazepines and z-hypnotics there is a slight increase, mainly due to increasing use of melatonin (N05CH01) among the elderly. According to the product information for z-hypnotics, the duration of treatment with z-hypnotics should be as short as possible and not more than 2-4 weeks. A cohort of approximately 28 000 new users of z-hypnotics in 2013 in the age group 65 years was followed for four consecutive years (365 day periods). More than half (52%) of these received one or more z-hypnotics during the first 365 day period after their first dispension (figure 1.6.c). About 25% continued i DDD mens andel p\u00e5 17 % av var 32 %. Andelen \u00f8ker fra 22 % hos 65-69-\u00e5ringene til 49 % hos de som er 90 \u00e5r og eldre og bor 28 hos kvinner 55 % hos kvinner 90 \u00e5r. For menn er andelene 15 og 1.6.b). nye brukerne Figure 1.6.b. Proportion (%) of the population 65 years in Norway who had at least one prescription of hypnotics and/or anxiolytics dispensed in 2013, 2015 and 2017, by gender. Unadjusted population.2013 2013 2013 2013 2015 2015 the population Women MenLegemiddelstatistikk 2018:2 Folkehelseinstituttet 36to use z-hypnotics throughout the study period of 4 years. The proportion of recurrent users are at the same level as seen in a comparable study of new users in 2009 (2). The average amount dispensed measured in DDDs indicates long-term use of z-hypnotics. The number of DDDs is increasing over time to an average amount of just under 200 DDDs in the fourth year of follow- up (figure 1.6.d).i over tid, Benzodiazepines and Opioids. users 65 years of z-hypnotics (ATC group N05CF) in 2013 who also were dispensed z-hypnotics in the following four years of follow-up. The individual was defined a new user if he/she had not filled any prescriptions for z-hypnotics the last 730 days. Unadjusted population. Figure 1.6.d. Average annual amount dispensed in defined daily doses (DDDs) of z-hypnotics (ATC group N05CF), in new users ( 65 years) in 2013, in the four years of follow-up. Unadjusted population.0100 80 60 40 20 0 1 years 2 years 3 years Time of follow-upProportion (%) of users 4 years 195 190 185 180 175 170DDDs/year 0 2 years 3 years Time of follow-up4 yearsLegemiddelstatistikk 2018:2 Folkehelseinstituttet 371.7 Use of antibiotics in the elderly Use of antibiotics increases with increasing age (1). Elderly people with impaired immune system and severe comorbidity are more likely to need antibiotics and treatment will then take place in hospital/municipal emergency care beds. The NorPD only provides information on prescribing outside health institutions such as hospitals and nursing homes. In this section, we have tried to account for this by estimating the proportion of the population living outside institutions. This estimate forms the basis for calculating the annual prevalence of antibi - otic use in the elderly population. In 2017, 30% of the population 65 years received prescribed antibiotics (ATC group J01) at least once during the year, 33% women and 26% men. Figure 1.7.a shows that the proportion of antibiotics dispensed increases with increasing age; from 25% (28% of women and 21% of men) in people aged 65-69 years, to 40% (41% of women and 39% of men) in those over 90-years-old. More women than men receive antibiotics in all the included age groups but the gender difference is getting smaller with increasing age. Figure 1.7.a also shows the use of the urinary tract antiseptic drug methenamine. Unlike other antibacterial agents, the use of methenamine has increased since 2012. The use increases with age in both women and men but the increase is more pronounced in women.1.7 Bruk av fra 25 % (28 % av kvinnene og 21 % av mennene) hos aldersgruppen 65-69 \u00e5r, til 40 % (41 % av kvinnene og 39 % av mennene) hos de over 1.7.a. Proportion (%) of the population 65 years in Norway who had at least one prescription of antibacterials for systemic use (J01 excl. methenamine) and methenamine (J01XX05) dispensed in 2012 and 2017, according to age groups and gender. Adjusted population (i.e. excl. the population in nursing homes).65-69 65-6945 40 35 30 25 20 15 10 70-74 70-74 75-79 75-79 strategy against antibiotic resistance 2015-2020 uses antibiotic consumption statistics to measure the impact of interventions (2). 2012 was a peak year for antibiotic use, so it is used as a reference year for the interventions that have been introduced. In 2012, 35% of the population 65 years received prescribed antibiotics (ATC group J01) at least once. Since 2012, there has been a decrease in the use of antibacterial agents (J01, excluding methenamine) throughout the population, also among the elderly, but the decrease in the elderly 65 years, measured in prescriptions / 1000 inhabit - ants, was lower (-19%) than in the age group < 65 years (-26%). Respiratory tract infections (RTI) and urinary tract infections (UTI) are the main reason for the prescribing of antibacterial agents (3). Today it is not required for antibiotic prescriptions to include the indication for use, but because most antibiotics are attributable to one major indication (like RTI or UTI), it is possible to group different antibiotics by the likely main indication. We have grouped anti- biotics into four main groups based on information in the summary of product characteristics (SPC) for the different substances and information from the National Guidelines on Antibiotic Use for the Primary Health Care Service (4). Respiratory tract antibiotics (RTI-AB) are defined as doxycycline, de intervensjoner er igangsatt. I 2012 fikk % og figur Figur 1.7.b. Dispensed antibiotic prescriptions according to indication groups in the elderly population 65 years in Norway in 2017. Adjusted population (i.e. excl. the population in 300 0Prescriptions/1000 inhabitants Methenamine J01 all other AB Urinary other antibi - otics are grouped together. Figure 1.7.b shows that agents used for urinary tract infections predomi - nate among the oldest age groups and that this increases with increasing age in both women and men. Methenamine is used to prevent urinary tract infections. The use has increased dramatically in recent years (5) and Figure 1.7.b shows that espe- cially elderly women are prescribed methenamine. There is a need for cost -benefit analysis to evaluate the use, as methenamine is not well documented for prolonged prophylaxis, nor is it used much outside the Nordic Dalen I, Fetveit A, Str\u00f8m H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother. 2011 Usage of Antimicrobial Antimicrobial Resistance in Norway. Troms\u00f8/Oslo 2017 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 40 2. General information about the Norwegian Prescription Database (NorPD) and drug statistics 2.1 About the NorPD From March 1st 2001 the new legislation in the Norwegian pharmacy sector came into force. This legislation obliged all pharmacies in Norway to forward prescription data to a new national drug database. The regulation covering the \u00abcollection and handling of health information in the Norwegian Prescription Database (Reseptregisteret)\u00bb, under the provision of the Personal Health Data Filing System Act, was approved in October 2003 (1). The regula- tion states which information the register can collect from the pharmacies and administrative registers. The objectives of the NorPD, as defined in authorative regulations, are to collect and process data on drug use in individuals and animals in Norway to: 1. map usage trends and monitor trends over time 2. be a resource for research in order to see positive and negative effects of drug consumption 3. give health authorities a statistical manage- ment tool for quality control of drug use and for steering and planning 4. give prescribers a basis for internal control and quality improvement of their prescribing practices2. Generelt om kraft 1. alle apotek i Norge til \u00e5 utredning kvalitetsforbedringPart 2 Del 2Legemiddelstatistikk 2018:2 Folkehelseinstituttet 41Data collection and variables in the NorPD Since January 1st 2004, the Norwegian Institute of Public Health (NIPH) has received data on prescrip- tions and requisition from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. The NorPD contains information about all drugs prescribed and dispensed to individual patients living outside institutions, i.e. ambulant care. Unli - censed drugs are also included if they are regis- tered in \u00abVareregisteret\u00bb (the Norwegian Article Number Registry) (https://www.farmalogg.no/en/ The-Article-Number-Register/). Drugs sold over- the-counter (OTC) are not recorded in the NorPD. However if the OTC drugs are prescribed by a physi - cian and dispensed, then they will be recorded in the database. The key data in the NorPD are based on prescriptions to individual humans, but dispensed prescriptions to animals from veterinarians and drugs delivered to a prescriber's own practice are also collected in the registry. For patients in nursing homes and hospitals, the register collects data on drug use at the level of the institution or the department, i.e. on an aggregate level. The NorPD contains the following variables: Patient Person-identifier (encrypted), month/year of birth, month/year of death, gender and place of resi- dence (municipality & county) Prescriber Person-identifier (encrypted), year of birth, gender, profession and speciality Drug Nordic article number, brand name, strength, dosage form, package size, ATC code, DDD value and DDD unit, prescription category and pharmacy retail price Information about each dispensed drug Number of packages dispensed, number of Defined Daily Doses (DDD), prescription category (see chap. 3.2), prescription regulation, reimbursement code (see below), dispensing date, price per filled prescription and species of animal (if prescription from a veterinary) Pharmacy Name, license number, municipality and countyDatainnsamling og variabler tilrettelagt is the key link to other registries providing detailed information about the drugs. The NorPD also contains information on reimburse- ment codes registered associated with general reimbursement prescriptions (according to the \"Blue prescription Regulation\") and Health Trust Financed Prescriptions (according to the \"Regulation for Health Trust Financed medicinal products\"). General reim- bursement prescriptions were previously registered with general and wide reimbursement codes, which in some cases could act as a proxy of diagnosis for certain drugs. New reimbursement regulations came into force in March 2008 and was fully implemented from March 2009. Under the new reimbursement regulation, valid reimbursement codes are available on a separate reimbursement list. Reimbursement codes are based on either the International Classifica- tion of Diseases version 10 (ICD-10) or International Classification of Primary Care Version 2 (ICPC-2). In addition, NoMA assigns special codes for general reimbursement. For Health Trust Financed Prescrip- tions there are no list of pre-approved reimbursement codes. This means that all codes in the International Classification of Diseases version 10 (ICD-10) or International Classification of Primary Care version 2 (ICPC-2) can be used. The first reimbursement codes for Health Trust Financed Prescriptions were regis- tered in the NorPD in August 2016. About 30 percent of all Health Trust Financed Prescriptions in 2017 were registered with a reimbursement code in the NorPD. Data protection As illustrated in figure 2.1 the pharmacy\u00b4s records of dispensed drugs are automatically transferred (electronically) through Statistics Norway before they arrive at NIPH and are included in the NorPD. i kraft mars 2008, og ble fullstendig implementert fra mars 2009. I 10 (ICD-10) eller International Clas - sification Inter - national Classification of Diseases versjon 10 (ICD- 10) eller International Classification of det registrert for Reseptregisteret. SSB Figure 2.1. Data flow, the Norwegian Prescription Database (NorPD).All pharmacies in NorwayDispensed prescriptions encryptedPrescriptions with pseudo- nymised transform Institute of Public Norway act as so-called \"trusted third part\" and is part of the data protection to ensure confiden - tiality of personal information. Statistics Norway only has access to the patients\u00b4s Personal Identity Number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The principle of pseudonymisation is that no one, not even the trusted third part should have simultaneously access to pseudonym, health data and the person's iden - tity. In the regulation of the NorPD, pseudonymous health data is defined as: \u00abHealth information where the identity is encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person without disclosing the iden - tity\u00bb. This means that the identity of patients and prescribers has been encrypted according to Norwe- gian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries. Quality assurance To identify possible errors or missing data in the NorPD several checks are performed in connec- tion with each monthly update of the database, in addition to a more comprehensive annual quality control. A control to verify that each open pharmacy has submitted their report, and that the report is of reasonable size, is performed every month (quantity control). NIPH initiates necessary actions to retrieve missing reports. Various quality control checks are performed, including control of categorization, prescription types etc. Each time a new version of the pharmacy software (FarmaPro) is applied the NIPH controls that the received data is correctly read into the NorPD. Statistics Norway verifies the Personal Identity Number against the Central Popula- tion Registry before the reports are transmitted to the NIPH. If Personal Identity Number is invalid or missing, Statistic Norway creates a special Pseud- onym. These individuals are not possible to track over time, and it is not possible to link these to other data sources, however the reported total number of ordinations and DDDs related to these individuals can be included in the overall statistics. Each month the NIPH checks that the NorPD is updated with the latest available version of the \"basis registries\", i.e. registries the NorPD som en s\u00e5kalt tiltrodd er the pharmacies (e.g. the Central Population Registry, Vareregisteret (the Article Number Register) and Helsepersonellregisteret (The Register for Health Personell). For instance, the NorPD only receives information about the national article number of the medicinal product from the pharmacy, while information on valid ATC codes and DDD values is obtained from the Article Number Register (3). 2.2 Prescription statistics in the other Nordic countries During the late 1980s, pharmacies in the Nordic coun- tries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, independent of socioeconomic status, have access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 26 million inhabitants (Denmark: 5.8 million; and Sweden: 10 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The data- bases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utiliza- tion. An article from 2010 provides an overview of the data collection procedures and content of the Nordic countries' prescription databases (4). 2.3 The Norwegian Drug Wholesales Statistics Statistics based on total sales of drugs from whole- salers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwegian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-phar - macy outlets and others with permission to sell medi - cines. Total sales of prescription and non-prescription human and veterinary medicines are included in the henter informasjon fra i 2004 Norge, siden 2005 The statistics give an overview of develop - ments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user. Drug Consumption in Norway - published annually Data from the Norwegian Drug Wholesales Statis- tics Database have been published annually in Drug Consumption in Norway (5) since 1977. Each issue includes total sales data for 5 year periods for both prescription and non-prescription drugs in Norway. The book is available from the website www. drugconsumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no. 2.4 The Anatomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmaco- logical/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/thera- peutic sub-groups and the 5th level is the chemical substance. The ATC code A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system: C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic pharmacological sub-group) C03DA01 Spironolactone (5th level, chemical substance) All medicinal products containing plain spironolactone (Aldactone\u00ae and Spirix\u00ae) are thus assigned the code C03DA01. The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C - Cardiovas\u00ad cular system (1st level), figures for the various sub- groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient.tikken. niv\u00e5), tall for de ulike undergruppene (2., 3. og 4. niv\u00e5) og ned virkestoff.Legemiddelstatistikk 2018:2 all pharmaceuticals on the Norwe- gian market can be retrieved from the pharmacy medicinal product register , SPC at the Norwegian Medicines Agency's website and in the monographs of the national drug catalogue \u00ab Felleskatalogen \u00bb. The yellow section of the latter, entitled The Anatomical Therapeutic Chemical Medicines Register or Felleska- talogens website (http://felleskatalogen.no/medisin/ atc-register), lists all medicinal products belonging to each of the ATC 5th level codes. 2.5 The Defined Daily Dose (DDD) In some tables in part 3 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults . The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indi - cations, dosages) often differ greatly. Each DDD should therefore be regarded as a technical measuring unit. Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their admin - istration route will have more than one DDD, each of them linked to a specific dosage form. For medica- tions where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. When this is impossible, as is the case with combination preparations and some liquid prepara- tions, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. Accordingly it will often be difficult to estimate the number of users by using the ATC-kode volum de nasjonale 47DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows: Total consumption measured in number of DDDs x 1000 365 x number of inhabitants This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose. 2.6 WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Drug Statistics at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (6). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (7). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no. The ATC/DDD publica- tions can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology. ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2018 has been used in this book. doseringsanbefalingene kan variere tallet gi som faktisk brukes. 2.6 WHO Collaborating Centre for Drug Statistics Methodology ATC-/DDD-systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av publika- sjonen Guidelines for ATC classification and DDD assignment (6). ATC Index with DDDs, som inne - holder en liste over alle Collaborating Centre for Drug Statistics Methodology. ATC- og DDD-endringer som M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. Italian J Public Health 2006;3(1):30-35. 4. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic countries as research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94. Norway 2013-2017. [Legemiddelforbruket i Norge 2013-2017] Oslo: Norwegian Institute of Public Health, 2018. 6. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2018. Oslo, 2017. 7. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2018. Oslo, 2017Legemiddelstatistikk 2018:2 Folkehelseinstituttet 48 3. The Norwegian Prescription Database (NorPD) 2013-2017 3.1 Selected key figures from the NorPD The NorPD contains information from all Norwegian pharmacies of drugs dispensed to individuals, to a prescriber's own practice and to institutions. In 2017, about 96% of DDDs in the NorPD were dispensed to individuals in ambulatory care. Deliveries to institu- tions (hospitals and nursing homes) amounted to 3% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in the NorPD. OTC sales constitute 13% of total sales of pharmaceuti - cals in Norway in 2017, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health). 3. Reseptregisteret % 3.1.a. Number of individuals and one-year prevalence (%) of the population who had at least one drug dispensed in Norway 2013-2017. Women n (%)Men n (%)Both genders n (%) 2013 1 910 183 (75.5) 1 574 382 (61.7) 3 484 565 (68.6) 2014 1 939 431 (75.9) 1 605 342 (62.1) 3 544 773 (69.0) 2015 1 956 001 (75.9) 1 622 534 (62.1) 3 578 535 (69.0) 2016 1 981 012 (76.2) 1 649 902 (62.6) 3 630 914 (69.3) 2017 1 680 approximately 5.7 million indi - viduals have been included in NorPD with at least one prescribed drug dispensed from a pharmacy. The number of drugs dispensed to patients in the same period (2004-2017) is near 573 millions. In 2017, 69,9% of the Norwegian population had at least one prescription dispensed, 76,7% of women and 63,2% of men (table 3.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identity number was 3.7%. In the period 2005-2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identity number has declined further to just below 1.4% in 2008 and 2009. In 2010-2017 the proportion was less than 1% (0.21% in 2017). The age-specific one year prevalence for being dispensed a drug in 2017 was lowest for women at about 5-9 years of age and for men at the same age (figure32.1). About 93% of individuals aged 70 years and older received prescribed drugs. About 81% of women aged 15-29 years received prescribed drugs in 2017. If women who only received hormonal contraception (ATC code G02B and G03A) are excluded, the prevalence was 68%. The proportion of drug users among women over 15 years of age was still higher than in men.Reseptregisteret ble opprettet 1. januar 2004 og 2009 har den ligget p\u00e5 i underkant om de ekskluderes.Figure 3.1. One-year prevalence (%) of the population who had at least one drug dispensed in 2017 in Norway according to age and gender. The pink line shows the one-year prevalence (%) for women excluding contraceptives for topical use (ATC code G02B) and hormonal contraceptives for systemic use (ATC code G03A).100 80 60 40 20 0Proportion (%) of 50Table 3.1.b shows the one-year prevalence of the entire population, and among men and women, who received at least one drug in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R). Table 3.1.c shows an overview of medicines (defined as ATC 5th levels) with the highest number of users in Norway in 2017. Paracetamol (analgesic) is used by the highest numbers of indi - viduals, followed by phenoxymethylpenicillin (anti- bacterial). Diclofenac is found in 5th place, same as last year. Paracetamol and diclofenac are also sold OTC. This use is not covered by the NorPD. The list contains essentially the same drugs as in previous years, but there are some changes in order. New on the list compared with last year is the Vitamin D supplement cholecalciferol in 24th place.Tabell 3.1.b plass. Table 3.1.b. One-year prevalence (%) of the population who had at least one drug dispensed in Norway in 2017 according to the main ATC groups. ATC Women %Men %Both genders % A Alimentary tract and metabolism 23.4 17.6 20.5 B Blood and blood forming organs 13.4 13.2 13.3 C Cardiovascular system 21.3 21.1 21.2 D Dermatologicals 15.6 12.7 14.2 G Genito urinary system and sex hormones 25.7 7.7 16.6 H Systemic hormonal preparations, excl. sex hormones and insulins 11.8 5.8 8.8 JAnti-infectives for systemic use 26.9 17.8 22.3 LAnti-neoplastic and immunomodulating agents 2.4 1.8 2.1 M Musculo-skeletal system 21.0 15.5 18.3 N Nervous system 32.7 22.4 27.5 P Anti-parasitic products, insecticides and repellents 2.2 1.4 1.8 R Respiratory system 29.5 22.7 26.1 S Sensory organs 14.6 10.8 12.7 V Various 0.7 0.7 0.7Legemiddelstatistikk 2018:2 Folkehelseinstituttet 51Table 3.1.c. Drugs with the highest number of users in Norway in 2017. ATC code Active ingredient UseNumber of individualsProportion (%) of the population 1 N02BE01 paracetamol 1) Analgesic 524 901 9.9 2 J01CE02 phenoxymethylpenicillin 394 344 7.5 3 6.9 4 N02AJ06 codeine Opioid combinations 351 291 6.7 5 M01AB05 diclofenac 1) NSAID/analgesic 323 120 6.1 6 modifying 295 715 5.6 7 N05CF01 290 210 5.5 8 R06AE07 cetirizine 1) Anti-allergic 286 302 5.4 9 C07AB02 disease 283 411 5.4 10 R03AC02 499 5.2 11 785 4.6 14 829 4.4 15 225 4.3 312 190 781 3.6 inhibitor) 176 disorders/eczema/ psoriasis171 090 152 705 2.9 24 colecalciferol Vitamin 147 090 2.6 136 950 2.6 28 G03CA03 estradiol women 136 672 2.6 29 J01AA02 doxycycline Antibacterial 122 266 2.3 30 A10BA02 metformin Diabetes 120 061 2.3 1) The ATC-level comprises OTC-medicinal products. The number of individuals is registered prescription only.Legemiddelstatistikk categories and re imbursement of medicinal expenses NorPD contains information about dispensed prescriptions based on the following prescription categories: Non-reimbursed prescriptions General reimbursement prescriptions (according to the \"Blue Prescription Regulation\" (FOR-2007- 06-28-814)) Health Trust financed prescription (according to the \"Regulation for Health Trust Financed medicinal products\", FOR 2015-06-12-646) The following prescription categories are not included in the tables: Contribution to cover the cost of healthcare when expenses are not otherwise covered by other laws (according to the National Insurance Act \u00a7 5-22). Contribution to conscripted military and indi - viduals with occupational injury (according to the National Insurance Act \u00a7 5-25) Special contribution, for instance membership in Jernbanepersonalets Helsefond (Railways Workers Health Fund) Non-reimbursed prescriptions Prescriptions paid in full by the patient. General reimbursement prescriptions The costs under the various reimbursement schemes (\u00a7\u00a7 2, 3a, 3b, 4, 5) according to the \"Blue Prescription Regulation\" are combined in the tables. Reimbursement according to \u00a7 2 Drugs listed on the reimbursement list \u00a7 2 will always be reimbursed when prescribed for the diagnoses (indicated by the ICPC and ICD codes) specified in the reimbursement list. The Norwegian Medicines Agency decides which medicines are included in the list and which diagnostic codes/conditions should be subject to reimbursement prescribing. Individual reimbursement according to \u00a7 \u00a7 3a and 3b The Health Economics Administration (HELFO) will make decisions regarding individual reimbursement for drugs not included in the reimbursement list according to \u00a7 2. Individual reimbursement requires either that the indication for use of the drug is covered by a diagnostic code in the 3a) or the drug will be used to treat a rare or serious chronic disease not listed in the reimburse- ment list (\u00a7 3b). Decisions are made for each patient on the basis of application from the treating physi - cian. NorPD does not provide a complete overview of reimbursement according to \u00a7\u00a7 3a and 3b. Reimbursement according to \u00a7 4 Drugs used for communicable diseases are reimbursed according to \u00a7 4 according to a specified disease list. The reimbursement is granted for anti-infectives, immunostimulants and vaccines. This support is provided to all who live in Norway, regardless of citizenship. The physician may self- prescribe these drugs in order to preserve patient anonymity; such prescriptions will not be available on an individual level in the NorPD. Health Trust financed prescriptions The regional health trusts provide dedicated funding for certain expensive drugs. This applies to defined drugs used in the treatment of rheumatic disorders, multiple sclerosis, various cancer types, skin diseases, hepatitis C, kidney failure and gastrointestinal diseases. Only drugs that are dispensed by prescription to individuals are included in the table. A list of all health trust financed medicinal products is available in the \"Regulation for Health Trust Financed medicinal products\".Legemiddelstatistikk 2018:2 Folkehelseinstituttet 54Table 3.2.a. Sales of drugs by prescription categories, overview 2017. Number of individuals Proportion (%) of the population Number of DDDs (in 1000) Sales in 1000 NOK Non-reimbursable prescriptions 3 144 537 59.6 660 822 3 294 125 Reimbursement prescriptions 2 477 356 46.9 1 864 628 12 056 203 Health trust financed prescriptions 46 020 0.9 11 822 4 169 008 Table 3.2.b. Sales of reimbursed drugs (\u00a7\u00a7 2, 3a, 3b, 4, 5) by ATC main groups in 2017. ATC main groups Number of individuals Proportion (%) of the population Number of DDDs (in 1000) Sales in 1000 NOK A Alimentary tract and metabolism 579 492 11.0 229 819 1 916 637 B Blood and blood forming organs 358 891 6.8 114 983 1 290 979 C Cardiovascular system 1 055 918 20.0 780 402 1 657 072 D Dermatologicals 324 095 6.1 2 030 257 002 G Genito urinary system and sex hormones 157 561 3.0 48 610 382 750 H Systemic hormonal preparations, excl. sex hormones and insulins 359 501 6.8 68 768 379 043 JAntiinfectives for systemic use 127 822 2.4 12 080 745 436 LAntineoplastic and immunomodulating agents 84 378 1.6 25 945 1 004 864 M Musculo-skeletal system 308 680 5.8 59 157 312 212 N Nervous system 720 386 13.7 220 847 2 099 842 P Antiparasitic products, insecticides and repellents 7 478 0.1 843 4 534 R Respiratory system 905 340 17.2 266 383 1 520 476 S Sensory organs 322 839 6.1 34 395 300 472 V Various 20 618 0.4 367 184 882Legemiddelstatistikk 2018:2 Folkehelseinstituttet 55Table 3.2.c. Reimbursed drugs 5) with the highest number of users in 2017. ATC code Active ingredient Use Number of individuals Proportion (%) of the population Number of DDDs (in 1000)Sales Antihypertensive/ cardiovascular disease279 148 597 3 R06AE07 cetirizine Anti-allergic 243 278 4.6 50 899 59 066 4 R03AC02 salbutamol Asthma/COPD 221 347 4.2 20 877 83 473 5 R06AX27 desloratadine Anti-allergic 216 599 4.1 36 704 61 420 6 N02BE01 paracetamol Analgesic 216 511 4.1 24 798 65 401 7 C10AA01 simvastatin Lipid modifying 210 605 64 492 64 506 8 H03AA01 levothyroxine sodium Thyroxine supplement 207 938 3.9 43 pantoprazole Reflux amlodipine Antihypertensive/ cardiovascular disease135 988 2.6 A02BC05 esomeprazole Reflux oesofagitis ( protonpump inhibitor)133 108 050 12 R01AD09 mometasone Anti-allergic, nose spray 122 846 2.3 14 972 33 074 13 A10BA02 metformin Diabetes 116 105 2.2 27 825 58 202 14 C09CA06 candesartan Antihypertensive/ cardiovascular disease113 605 2.2 56 062 61 589 15 N06AB10 escitalopram Antidepressant 108 227 2.1 36 311 53 446 16 H02AB06 prednisolone Antiinflammatory/ corticosteroid102 S01GX02 levocabastine Anti-allergic, eye drops 90 277 1.7 * 23 328 18 B03BA03 hydroxocobalamin Vitamin B-12 supplement 79 802 1.5 25 921 54 895 19 R01AD12 fluticasone furoate Anti-allergic, nose spray 78 173 1.5 16 048 20 R03AK06 salmeterol and fluticasone Asthma/COPD 76 860 21 R03AK07 formoterol and budesonide Asthma/COPD 76 341 1.4 14 22 D07AC13 mometasone Inflammatory skin disorders/ eczema/psoriasis71 C03CA01 furosemide Antihypertensive/cardio- vascular disease/oedema70 274 1.3 24 C09AA05 ramipril Antihypertensive/ cardiovascular disease68 997 1.3 54 277 34 223 25 S01XA20 artificial tears and other indif - ferent preparationsDry eyes 68 681 1.3 * 62 231 26 D02AE01 carbamide Softener, atopic eczema 68 141 1.3 * 64 951 27 C09CA01 losartan Antihypertensive/ cardiovascular disease66 815 1.3 26 700 C09DA01 losartan and diuretics Antihypertensive/ cardiovascular hydrocortisone butyrate Inflammatory skin disorders/ eczema/psoriasis61 30 C09DA06 candesartan and diuretics Antihypertensive/ cardiovascular disease59 207 1.1 19 323 40 501 * No DDD assigned for this ATC 5th levelLegemiddelstatistikk 2018:2 Folkehelseinstituttet 563.3 og spesielt for i tabellen)3.3 Description of the main tables The tables in section 3 of this book provide an over - view of the number of individuals who have had drugs dispensed from pharmacies in Norway. Anyone who has had at least one drug dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same drug several times, he or she is counted as a user only once. Only dispensing datato individuals with a personal identity number are included in the tables. In NorPD the complete personal identity number is missing for 0.21% of the dispensed drugs to individuals in 2017. The tables contain figures for the period 2013-2017. In addition, the following information for 2017 includes: Prevalence per 1 000 inhabitants The number of individuals who have had at least one drug dispensed in the following age groups: <15, 15-44, 45-69, 70. If the number of individ - uals is less than five, <5 is used in the tables. Sales in 1 000 Norwegian kroner (NOK), i.e. for prescriptions dispensed to individuals with a personal identity number. The amount in NOK corresponds to the actual retail price from the pharmacy. The tables are arranged according to the ATC system (see further description in p. 45). The majority of ATC groups containing drugs on the Norwegian market are included. Drug use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of drug users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or other institutions. The following ATC groups have been omitted: B05 Blood substitutes and perfusion S01J Diagnostic agents S01L Ocular vascular disorder agents V Various (ATC group V01 Allergens and V03 All other therapeutic products (se ogs\u00e5 s. 45). I tabellene i del 3 i denne antall Non-prescription drugs are sometimes prescribed, but the majority of the OTC drug sales will not be included in the tables in this book. Sales of OTC drugs are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in \u00abDrug Consumption in Norway\u00bb (see also p. 45). A footnote is used in the tables in part 3 of this book in the various ATC codes where OTC medicines are avail - able in Norway. In 2017, OTC medicines had a share of 13% of total sales measured in DDDs. This share has remained almost unchanged over time. Most prescribed drugs have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some drugs that are part of a so-called \u00abnegative list\u00bb which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these drugs is often low. Many individuals use more than one drug . Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of Figure 3.3. The report generator at www.norpd.no (Norwegian version ATC systemet og nye ATC-koder/DDD inkludert two or more drugs. Statistics on the aggregate level in the tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of hypnotics (ATC group N05C) is lower than the sum of the number of users of the individual drugs that are classified in N05C. This means that some individuals have been given more than one type of hypnotic during a year, either through the use of more than one simultaneously or by switching from one agent to another. Changes in ATC classification In ATC Index 2018 (current version of this report), ATC changes have been made of significance for statistics: In the ATC 3rd level J05A, a new ATC 4th level has been created: J05AP Antivirals for treatment of HCV infections. Here, both single-agent and combinations available for the treatment of hepatitis C are gath- ered. Some single-agent/combinations have been moved from other ATC 4th levels (change of codes), and new drugs are included in this group. An additional code for benzydamine lozenges has been created in R02AX03. ATC code R03AL has altered name to include new triple combinations with corticosteroids for the treatment of COPD. New name: R03AL Adrenergics combinations incl. triple combi \u00ad nations with corticosteroids. For more information regarding alterations in the ATC system and new ATC codes / DDD included in the 2018 Index, see updates on the WHO Centre's website www.whocc.no . Historical data has been updated in this report and the statistics bank (www.norpd.no). The NorPD website: www.norpd.no The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 3.3), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name.Legemiddelstatistikk 2018:2 Folkehelseinstituttet kroner som 1 117 743 x 1000 Antall innbyggere = 5 276 847 = 211,8 individer som i 2017: 1 117 743 Antall innbyggere i Norge per 1. juli 2017: 5 276 847 Beregning av prevalens (per 1000) brukere av hjerte-/ 2017: P\u00e5 befolkningstallet slutten av \u00e5ret (utleverings\u00e5r minus f\u00f8dsels\u00e5r).The following data on drug use can be extracted from the website: Number of users, split by gender, 5-year age groups, county or health region Number of users per 1 000 population (prevalence per 1 000) Turnover in NOK (pharmacy retail price) Turnover in doses (DDD - defined daily doses) Population base for the statistics, split by gender, age, county or health region Data are available from 2004 with an annual update for the preceding year. The figures in this book may differ slightly from the numbers found on the website. This is because indi - viduals without known address are included in the tables in this book but not on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Access to data from NorPD It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required. Calculation of prevalence per 1000 inhabitants Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one drug dispensed in a pharmacy during a specific time period. Please read the following example for the calculation: 211.8 individuals per 1000 inhabitants The number of individuals x 1000 1 117 743 x 1000 The number of inhabitants = 5 276 847 = The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2017: 1 117 743 The number of inhabitants in Norway as of 1st July 2017: 5 276 847 Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2017: The population in Norway for the years 2013-2017 is shown on p. 134. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).Legemiddelstatistikk 2018:2 Folkehelseinstituttet 603.4 ATC main 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales in 1000 NOK<15 15-44 45-69 70 A ALIMENTARY TRACT AND METABOLISM 832 937 884 462 942 934 1 010 906 1 081 420 204.9 44 155 265 731 457 365 314 169 2 322 730 B BLOOD AND BLOOD FORMING ORGANS 629 097 640 857 658 262 678 638 699 782 132.6 4 920 79 288 280 250 335 324 1 831 416 C CARDIOVASCULAR SYSTEM 1 040 279 1 060 407 1 076 271 1 100 521 1 117 743 211.8 9 702 100 154 553 183 454 704 1 794 102 D DERMATOLOGICALS 645 692 674 324 686 915 713 156 747 278 141.6 102 824 277 104 241 159 126 191 405 264 G GENITO URINARY SYSTEM AND SEX HORMONES 785 601 814 970 835 075 859 359 876 600 166.1 3 888 447 213 278 099 147 400 1 164 181 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 422 537 437 511 445 510 452 531 463 794 87.9 17 922 114 393 196 870 134 609 512 630 J ANTIINFECTIVES FOR SYSTEMIC USE 1 288 914 1 252 912 1 239 437 1 209 403 1 177 724 223.2 127 743 457 401 381 958 210 622 1 501 250 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 90 729 95 220 99 426 104 942 111 469 21.1 1 512 25 218 51 335 33 404 4 028 825 M MUSCULO-SKELETAL SYSTEM 925 319 928 438 942 067 946 467 963 353 182.6 15 305 325 959 446 233 175 856 491 216 N NERVOUS SYSTEM 1 327 510 1 354 299 1 380 890 1 412 242 1 450 941 275.0 32 190 459 701 620 719 338 331 3 245 094 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 96 547 97 581 94 698 93 310 93 329 17.7 4 347 40 992 35 652 12 338 28 124 R RESPIRATORY SYSTEM 1 220 112 1 259 843 1 296 928 1 330 147 1 374 981 260.6 162 413 500 922 498 654 212 992 1 210 612 646 107 039 192 919 213 636 155 156 401 363 V VARIOUS 23 985 27 789 30 050 32 701 35 380 6.7 4 807 11 601 11 429 7 543 193 097Legemiddelstatistikk 2018:2 Folkehelseinstituttet 61A ALIMENTARY TRACT AND METABOLISM 832 937 884 462 942 934 1 010 906 1 081 420 204.9 44 155 265 731 457 365 314 169 2 322 730 A01 STOMATOLOGICAL PREPARATIONS 18 959 23 893 30 608 37 008 43 992 8.3 833 16 644 14 546 11 969 10 462 A01A STOMATOLOGICAL PREPARATIONS 18 959 23 893 30 608 37 008 43 992 8.3 833 16 644 14 546 11 969 10 462 A01AA Caries prophylactic agents 14 642 18 919 25 108 31 112 37 554 7.1 304 13 745 12 512 10 993 8 820 A01AA01 sodium fluoride1)14 642 18 919 25 108 31 112 37 554 7.1 304 13 745 12 512 10 993 8 820 A01AB Antiinfectives and antisep - tics for local oral treatment 2 441 2 870 3 344 3 577 3 937 0.8 243 1 918 1 170 606 554 A01AB03 chlorhexidine1)2 390 2 808 3 272 3 523 3 861 0.7 239 1 900 1 137 585 501 A01AB04 amphotericin B 25 29 28 24 30 0.0 0 7 12 11 32 A01AB09 miconazole 10 7 15 8 14 0.0 <5 5 5 <5 4 A01AB11 various1)17 27 30 26 33 0.0 <5 6 17 7 17 A01AC Corticosteroids for local oral treatment 1 465 1 705 1 731 1 893 2 244 0.4 255 740 853 396 841 A01AC01 triamcinolone 1 435 1 651 1 673 1 772 2 098 0.4 254 725 765 354 516 A01AC03 hydrocortisone <5 <5 5 <5 <5 - 0 0 <5 0 2 A01AD Other agents for local oral treatment 519 534 593 629 563 0.1 37 347 124 55 247 A01AD01 epinephrine 14 10 15 8 6 0.0 0 <5 <5 <5 10 A01AD02 benzydamine1)477 500 552 592 528 0.1 18 340 119 51 233 A01AD11 various 28 24 26 29 29 0.0 19 6 <5 <5 4 A02 DRUGS FOR ACID RELATED DISORDERS 417 708 441 259 467 772 493 407 521 160 98.8 10 465 108 923 241 178 160 594 321 729 A02A ANTACIDS 4 719 5 498 6 152 6 361 6 351 1.2 121 1 228 2 181 2 821 10 667 A02AA Magnesium compounds 12 26 30 69 84 0.0 0 15 22 47 29 A02AA04 magnesium hydroxide 12 26 30 69 84 0.0 0 15 22 47 29 A02AC Calcium compounds 928 810 724 600 600 0.1 14 128 223 235 371 A02AC01 calcium carbonate1)928 810 724 600 600 0.1 14 128 223 235 371 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1 179 1 612 1 824 1 771 1 489 0.3 29 744 453 263 230 A02AD01 ordinary salt combinations1)1 179 1 612 1 824 1 771 1 489 0.3 29 744 453 263 230 A02AH Antacids with sodium bicarbonate 2 837 3 258 3 707 3 996 4 249 0.8 40 342 1 525 2 342 9 397 A02B DRUGS FOR PEPTIC ULCER AND GASTRO- OESOPHAGEAL REFLUX DISEASE (GORD) 415 383 438 777 465 024 490 594 518 289 98.2 10 386 108 395 240 264 159 244 311 062 A02BA H2-receptor antagonists 53 694 53 151 49 974 45 877 45 543 8.6 1 431 11 923 20 597 11 592 19 913 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.5 ATC group A - Alimentary tract and metabolism ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales <5 18 A02BA02 ranitidine1)52 431 52 116 49 574 45 523 45 163 8.6 1 410 11 821 20 426 11 506 19 637 A02BA03 famotidine1)1 312 1 103 629 434 441 0.1 22 121 187 111 258 A02BB Prostaglandins 346 358 264 371 476 0.1 <5 28 152 A02BB01 misoprostol 346 358 264 371 476 0.1 <5 382 65 28 152 A02BC Proton pump inhibitors 377 400 402 262 433 679 461 724 490 510 93.0 9 177 100 698 228 569 152 066 289 491 A02BC01 omeprazole 45 183 44 226 43 645 42 405 41 463 7.9 3 370 8 660 16 962 12 471 37 630 A02BC02 pantoprazole1)171 451 193 342 217 244 239 547 263 785 50.0 1 108 56 923 121 327 84 427 109 322 A02BC03 lansoprazole 43 483 40 451 38 477 36 516 34 983 6.6 378 4 989 17 388 12 228 23 959 A02BC05 esomeprazole 142 299 148 765 159 846 168 378 176 064 33.4 4 972 37 070 84 588 49 434 118 580 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 2 724 3 210 3 788 4 273 5 367 1.0 528 1 901 1 841 1 097 1 505 A02BX02 sucralfate 470 488 471 461 <5 121 216 168 435 A02BX12 bismuth subnitrate 29 36 34 37 58 0.0 0 28 23 7 60 A02BX13 alginic acid1)2 239 2 705 3 300 3 788 4 824 0.9 525 1 755 1 608 936 1 010 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 72 122 67 041 66 786 68 127 70 684 13.4 940 23 612 26 600 19 532 15 009 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 4 373 4 619 4 773 5 059 5 738 1.1 212 1 059 1 946 2 521 2 506 A03AA Synthetic anticholinergics, esters with tertiary amino group 30 35 41 36 56 0.0 <5 28 19 8 67 A03AA04 mebeverine 30 34 40 33 53 0.0 <5 26 19 7 48 A03AA05 trimebutine 0 0 0 <5 Synthetic anticholinergics, quaternary ammonium compounds 497 680 936 1 155 1 382 0.3 <5 31 378 970 434 A03AB02 glycopyrronium bromide 491 676 930 1 148 1 373 <5 27 376 967 407 A03AB05 propantheline 6 <5 6 6 0.0 0 16 methantheline <5 0 <5 11 A03AD Papaverine and derivatives 39 49 36 42 45 0.0 0 11 17 17 49 A03AD01 papaverine 39 49 36 42 45 0.0 0 11 17 17 49 A03AX Other drugs for functional gastrointestinal disorders 3 815 3 872 3 777 3 848 4 284 0.8 208 992 1 542 1 542 1 956 A03AX13 silicones1)3 815 3 872 3 777 3 848 4 284 0.8 208 992 1 542 1 542 1 956 A03B BELLADONNA AND DERIVATIVES, PLAIN 2 376 2 517 2 595 2 680 3 108 0.6 19 1 328 1 247 514 1 470 A03BA Belladonna alkaloids, tertiary amines 1 811 1 857 1 879 1 850 1 919 0.4 6 825 735 353 787ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales in 1000 NOK<15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2018:2 Folkehelseinstituttet 63A03BA01 atropine 24 28 21 21 8 0.0 0 <5 6 <5 9 A03BA03 hyoscyamine 1 787 1 829 1 858 1 830 1 911 0.4 6 824 729 352 778 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 578 672 729 842 1 202 0.2 13 512 514 163 684 A03BB01 butylscopolamine 564 659 716 842 1 202 0.2 13 512 514 163 684 A03BB03 methylscopolamine 14 14 14 0 0 0.0 0 0 0 0 0 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 14 17 14 19 22 0.0 0 6 9 7 26 A03CA Synthetic anticholinergic agents in combination with psycholeptics 14 17 14 19 22 0.0 0 6 9 7 26 A03CA02 clidinium and psycholeptics 14 17 14 19 22 0.0 0 6 9 7 26 A03F PROPULSIVES 66 521 61 033 60 678 61 727 63 378 12.0 713 21 507 24 021 17 137 11 007 A03FA Propulsives 66 521 61 033 60 678 61 727 63 378 12.0 713 21 507 24 021 17 137 11 007 A03FA01 metoclopramide 66 391 60 932 60 583 61 627 63 262 12.0 698 21 477 23 982 17 105 10 712 A03FA02 cisapride 59 14 0 0 0 0.0 0 0 0 0 0 A03FA03 domperidone 80 96 97 110 133 0.0 17 42 42 32 278 A03FA05 alizapride 9 13 9 6 <5 - 0 <5 17 A04 ANTIEMETICS AND ANTINAUSEANTS 16 026 17 291 18 971 19 680 20 854 4.0 573 4 725 9 572 5 984 46 716 A04A ANTIEMETICS AND ANTINAUSEANTS 16 026 17 291 18 971 19 680 20 854 4.0 573 4 725 9 572 5 984 46 716 A04AA Serotonin (5HT3) antagonists 12 856 14 013 15 454 16 470 18 169 3.4 496 3 776 8 379 5 518 42 719 A04AA01 ondansetron 12 840 13 992 15 366 15 859 15 811 3.0 491 3 489 6 873 4 958 30 613 A04AA02 granisetron <5 13 62 80 85 0.0 18 8 33 26 711 A04AA03 tropisetron 26 <5 <5 0 0 0.0 0 0 0 0 0 A04AA05 palonosetron 16 51 107 83 52 0.0 0 6 28 18 240 A04AA55 palonosetron, combinations 0 0 0 983 3 760 0.7 0 466 2 407 887 11 156 A04AD Other antiemetics 5 735 6 100 6 483 5 953 3 785 0.7 81 1 071 1 892 741 3 997 A04AD01 scopolamine 2 424 2 393 2 487 2 355 2 572 0.5 79 924 1 118 451 1 025 A04AD12 aprepitant 3 323 3 724 4 008 3 605 1 223 0.2 <5 148 781 291 2 972 A05 BILE AND LIVER THERAPY 2 728 2 890 3 012 3 210 3 373 0.6 112 981 1 519 761 9 642 A05A BILE THERAPY 2 728 2 890 3 012 3 210 3 373 0.6 112 981 1 519 761 9 642 A05AA Bile acids and derivatives 2 728 2 890 3 012 3 210 3 373 0.6 112 981 1 519 761 9 642 A05AA01 chenodeoxycholic acid 0 0 0 <5 <5 - 0 <5 0 0 625 A05AA02 ursodeoxycholic acid 2 728 2 890 3 012 3 209 3 373 0.6 112 981 1 519 761 7 907 A05AA04 obeticholic acid 0 0 0 0 7 0.0 0 <5 6 0 1 110 A06 DRUGS FOR CONSTIPATION 55 321 65 798 73 407 83 960 94 189 17.9 19 100 15 173 27 238 32 678 68 250 A06A DRUGS FOR CONSTIPATION 55 321 65 798 73 407 83 960 94 189 17.9 19 100 15 173 27 238 32 678 68 250ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 1 056 1 111 1 295 1 344 0.3 127 149 421 647 883 A06AA01 liquid paraffin1)699 1 056 1 111 1 295 1 344 0.3 127 149 421 647 883 A06AB Contact laxatives 24 463 27 607 28 653 30 656 30 836 5.8 517 3 653 12 608 14 058 9 818 A06AB02 bisacodyl1)5 666 5 701 5 586 5 667 5 533 1.1 89 721 1 897 2 826 1 914 A06AB06 senna glycosides1)2 216 1 760 1 475 1 462 1 329 0.3 5 158 333 833 744 A06AB08 sodium picosulfate1)12 659 14 083 15 123 16 038 16 766 3.2 362 2 014 5 879 8 511 4 302 A06AB20 contact laxatives in combination1)<5 27 22 21 16 0.0 0 <5 6 7 11 A06AB56 senna glycosides, combinations 8 38 58 <5 0 0.0 0 0 0 0 0 A06AB58 sodium picosulfate, combinations1)5 410 7 639 7 993 9 198 8 889 1.7 76 888 5 127 2 798 2 847 A06AC Bulk-forming laxatives 2 266 2 512 3 049 3 643 4 717 0.9 90 1 321 1 811 1 495 1 928 A06AC01 ispaghula (psylla seeds)1)2 266 2 511 3 049 3 643 4 717 0.9 90 1 321 1 811 1 495 1 928 A06AC51 ispaghula, combinations1)0 <5 0 0 0 0.0 0 0 0 0 0 A06AD Osmotically acting laxatives 32 340 39 680 46 203 54 417 64 136 12.2 18 625 9 848 14 755 20 908 31 535 A06AD11 lactulose1)14 837 16 269 16 701 17 324 18 482 3.5 904 2 525 6 208 8 845 5 442 A06AD12 lactitol 39 34 37 36 23 0.0 15 7 0 <5 36 A06AD15 macrogol 221 239 212 33 28 0.0 25 <5 <5 <5 94 A06AD17 sodium phosphate 2 015 1 687 1 055 671 801 0.2 0 199 414 188 189 A06AD65 macrogol, combinations1)16 618 23 193 30 257 38 581 47 418 9.0 17 918 7 383 9 032 13 085 25 773 A06AG Enemas 5 498 6 203 6 095 6 254 6 790 1.3 798 1 431 2 129 2 432 13 279 A06AG02 bisacodyl1)1 699 1 808 1 674 1 556 1 452 0.3 46 346 613 447 776 A06AG04 glycerol1)763 939 894 819 1 024 0.2 189 284 251 300 7 145 A06AG06 oil 44 59 64 129 114 0.0 14 28 29 43 306 A06AG10 docusate sodium, incl. combinations1)1 412 1 626 1 578 1 709 1 900 0.4 125 397 622 756 2 426 A06AG11 sodium lauryl sulfoacetate, incl. combinations1)1 920 2 197 2 276 2 470 2 779 0.5 447 480 765 1 087 2 626 A06AH Peripheral opioid receptor antagonists 177 173 194 637 801 0.2 <5 103 363 334 3 144 A06AH01 methylnaltrexone bromide 177 173 138 153 132 0.0 0 12 65 55 842 A06AH03 naloxegol 0 0 59 498 693 0.1 <5 93 313 286 2 302 A06AX Other drugs for constipation 474 1 174 1 811 2 478 2 676 0.5 15 997 1 165 499 7 662 A06AX01 glycerol1)0 0 40 137 134 0.0 0 6 54 74 52 A06AX04 linaclotide 216 769 1 362 1 927 2 160 0.4 14 882 938 326 6 076 A06AX05 prucalopride 271 452 475 504 480 0.1 <5 143 217 118 1 534 A07 ANTIDIARRHEALS, INTESTINAL ANTI- INFLAMMATORY/ANTI- INFECTIVE AGENTS 76 993 81 037 83 068 85 501 88 869 16.8 8 943 22 605 35 398 21 923 186 975 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 905 35 631 35 552 36 202 36 965 7.0 8 405 8 521 11 871 8 168 18 345 A07AA Antibiotics 33 905 35 631 35 552 36 202 36 965 7.0 8 405 8 521 11 871 8 168 18 345 A07AA01 neomycin1)37 28 <5 0 <5 - 0 0 <5 1 A07AA02 nystatin 33 307 35 091 35 068 35 641 36 290 6.9 8 389 8 367 11 553 7 981 11 841 A07AA06 paromomycin 322 343 174 77 42 0.0 <5 23 17 0 65 A07AA09 vancomycin 238 239 264 277 391 0.1 7 81 139 164 1 285 A07AA11 rifaximin 230 174 197 276 303 0.1 8 61 192 42 4 953 A07AA12 fidaxomicin 7 6 8 5 11 0.0 0 <5 <5 7 200 A07B INTESTINAL ADSORBENTS 103 127 176 173 196 0.0 10 70 89 27 54 A07BA Charcoal preparations 88 87 94 94 65 0.0 9 17 24 15 16 A07BA01 medicinal charcoal1)88 87 94 94 65 0.0 9 17 24 15 16 A07BB Bismuth preparations 15 40 82 79 131 0.0 <5 53 65 12 37 A07C ELECTROLYTES WITH CARBOHYDRATES 449 490 451 444 445 0.1 208 96 85 56 1 748 A07CA Oral rehydration salt formulations1)442 482 441 427 426 0.1 189 96 85 56 369 A07D ANTIPROPULSIVES 18 647 19 771 20 595 21 467 23 288 4.4 102 4 194 10 122 8 870 11 474 A07DA Antipropulsives 18 647 19 771 20 595 21 467 23 288 4.4 102 4 194 10 122 8 870 11 474 A07DA01 diphenoxylate <5 <5 <5 <5 0 0.0 0 0 0 0 0 A07DA02 opium 143 224 223 268 306 0.1 0 17 156 133 837 A07DA03 loperamide1)18 322 19 567 20 232 21 098 22 778 4.3 100 4 017 9 913 8 748 10 183 A07DA06 eluxadoline 0 0 0 0 119 0.0 0 69 43 7 308 A07DA53 loperamide, combinations1)361 197 362 400 437 0.1 <5 151 171 113 146 A07E INTESTINAL ANTI- INFLAMMATORY AGENTS 25 601 26 754 28 206 29 560 30 654 5.8 227 10 134 14 588 5 705 154 182 A07EA Corticosteroids acting locally 5 537 5 811 6 043 6 834 7 507 1.4 62 2 318 3 352 1 775 22 857 A07EA01 prednisolone 1 163 1 122 69 0 10 0.0 0 <5 5 <5 12 A07EA02 hydrocortisone 327 324 339 390 322 0.1 <5 86 179 55 664 A07EA06 budesonide 4 153 4 476 5 720 6 500 7 230 1.4 61 2 248 3 195 1 726 22 182 A07EB Antiallergic agents, excl. corticosteroids 35 43 46 42 47 0.0 <5 14 24 5 1 094 A07EB01 cromoglicic acid 35 43 46 42 47 0.0 <5 14 24 5 1 094 A07EC Aminosalicylic acid and similar agents 22 091 23 005 24 109 25 111 25 797 4.9 191 9 018 12 335 4 253 130 067 A07EC01 sulfasalazine 5 666 5 737 5 768 5 683 5 457 1.0 8 1 240 3 012 1 197 6 677 A07EC02 mesalazine 16 050 16 912 18 009 19 121 20 045 3.8 184 7 723 9 165 2 973 120 585 A07EC03 olsalazine 381 346 343 281 273 0.1 <5 47 160 65 939 A07EC04 balsalazide 589 555 528 479 471 0.1 0 119 244 108 1 867 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales ANTIDIARRHEAL MICROORGANISMS 1 228 1 334 1 181 725 559 0.1 14 226 233 86 1 039 A07FA Antidiarrheal microorganisms 1 228 1 334 1 181 725 559 0.1 14 226 233 86 1 039 A07FA01 lactic acid producing organisms 806 882 737 370 294 0.1 9 129 143 13 865 A07FA02 saccharomyces boulardii 505 556 528 377 287 0.1 5 109 100 73 153 A07FA51 lactic acid producing organisms, combinations 14 13 20 53 <5 - 0 <5 0 <5 10 A07X OTHER ANTIDIARRHEALS 43 29 67 7 <5 - 0 <5 0 0 2 A07XA Other antidiarrheals 43 29 67 7 <5 - 0 <5 0 0 2 A07XA04 racecadotril 0 18 57 <5 0 0.0 0 0 0 0 0 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 7 245 6 716 6 361 6 293 6 256 1.2 <5 1 998 3 583 674 12 563 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 7 245 6 716 6 361 6 293 6 256 1.2 <5 1 998 3 583 674 12 563 A08AA Centrally acting antiobesity products 0 0 0 0 265 0.1 0 115 141 9 330 A08AA62 bupropion and naltrexone 0 0 0 0 265 0.1 0 115 141 9 330 A08AB Peripherally acting antiobesity products 7 245 6 716 6 361 6 293 6 019 1.1 <5 1 896 3 457 665 12 233 A08AB01 orlistat 7 245 6 716 6 361 6 293 6 019 1.1 <5 1 896 3 457 665 12 233 A09 DIGESTIVES, INCL. ENZYMES 5 720 5 758 5 926 6 091 6 597 1.3 122 840 2 967 2 668 19 804 A09A DIGESTIVES, INCL. ENZYMES 5 720 5 758 5 926 6 091 6 597 1.3 122 840 2 967 2 668 19 804 A09AA Enzyme preparations 5 637 5 683 5 850 6 022 6 364 1.2 120 5 676 5 840 6 012 6 359 1.2 120 750 2 855 2 634 19 552 A09AB Acid preparations 63 64 50 64 65 0.0 <5 17 17 30 54 A09AB01 glutamic acid hydrochloride 45 35 36 53 51 0.0 0 10 12 29 43 A09AB02 betaine hydrochloride 10 22 10 9 9 0.0 0 11 1 A09AC Enzyme and acid preparations, combinations 33 23 31 31 195 0.0 <5 80 104 10 189 A09AC01 pepsin and acid preparations 0 0 5 28 194 0.0 <5 80 103 10 188 A09AC02 multienzymes and acid preparations 33 23 26 <5 <5 - 0 0 <5 0 1 A10 DRUGS USED IN DIABETES 165 315 170 495 176 609 183 452 192 542 36.5 2 042 25 920 96 703 67 877 971 126 A10A INSULINS AND ANALOGUES 58 187 59 804 61 558 63 529 65 733 12.5 2 015 14 958 28 825 19 935 433 652 A10AB Insulins and analogues for injection, fast-acting 38 386 39 557 40 728 42 145 43 534 8.3 2 012 13 534 18 560 9 428 161 896 A10AB01 insulin (human) 1 144 1 024 911 825 742 0.1 <5 67 386 287 1 982 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 9 804 10 212 10 717 11 202 2.1 500 3 920 4 923 1 859 43 806 A10AB05 insulin aspart 28 325 29 231 30 073 31 059 32 700 6.2 1 642 10 066 13 661 7 331 114 415 A10AB06 insulin glulisine 408 419 430 456 459 0.1 <5 145 241 71 1 692 A10AC Insulins and analogues for injection, intermediate- acting 32 559 33 082 33 618 34 174 33 804 6.4 427 4 137 15 477 13 763 105 993 A10AC01 insulin (human) 32 559 33 082 33 618 34 174 33 804 6.4 427 4 137 15 477 13 763 105 993 A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting 7 154 6 561 5 938 5 323 4 678 0.9 <5 242 1 808 2 624 23 092 A10AD03 insulin (pork) 0 <5 0 0 0 0.0 0 0 0 0 0 A10AD04 insulin lispro 645 616 541 481 405 0.1 <5 52 173 179 1 720 A10AD05 insulin aspart 6 522 5 957 5 404 4 853 4 278 0.8 <5 191 1 637 2 447 21 372 A10AE Insulins and analogues for injection, long-acting 17 686 18 621 19 708 21 381 25 315 4.8 1 018 8 247 11 610 4 440 142 670 A10AE02 insulin (beef) <5 <5 0 <5 0 0.0 0 0 0 0 0 A10AE04 insulin glargine 11 727 12 570 13 617 15 044 16 352 3.1 416 5 462 7 538 2 936 77 130 A10AE05 insulin detemir 6 207 6 261 6 284 6 126 5 721 1.1 595 1 969 2 272 885 30 647 A10AE06 insulin degludec 0 5 127 1 087 3 386 0.6 74 1 328 1 558 426 17 334 A10AE56 insulin degludec and liraglutide 0 0 0 46 1 642 0.3 0 157 1 072 413 17 559 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 128 629 133 286 139 066 145 510 154 588 29.3 34 12 887 82 572 59 095 537 474 A10BA Biguanides 106 357 108 031 110 643 113 917 120 061 22.8 23 11 105 65 386 43 547 59 376 A10BA02 metformin 106 357 108 031 110 643 113 917 120 061 22.8 23 11 105 65 386 43 547 59 376 A10BB Sulfonylureas 38 381 36 011 34 200 32 265 29 721 5.6 8 1 160 14 754 13 799 13 722 A10BB01 glibenclamide 1 098 981 813 677 615 0.1 7 31 268 309 321 A10BB07 glipizide 3 413 3 057 2 790 2 466 2 109 0.4 0 52 847 1 210 1 247 A10BB12 glimepiride 34 007 32 089 30 774 29 212 27 064 5.1 <5 1 085 13 666 12 312 12 154 A10BD Combinations of oral blood glucose lowering drugs 15 765 18 377 20 715 23 050 26 294 5.0 <5 1 495 16 161 8 637 115 318 A10BD05 metformin and pioglitazone 30 34 36 27 23 0.0 0 <5 16 5 111 A10BD07 metformin and sitagliptin 6 295 7 749 9 170 10 815 13 391 2.5 <5 817 8 214 4 359 55 089 A10BD08 metformin and vildagliptin 9 360 10 113 10 627 10 786 10 655 2.0 0 516 6 433 3 706 48 567 A10BD10 metformin and saxagliptin 43 81 109 117 110 0.0 0 6 73 31 523 A10BD11 metformin and linagliptin 166 369 533 632 669 0.1 42 403 224 2 946 A10BD15 metformin and dapagliflozin 0 165 436 588 852 0.2 0 63 600 189 4 015 A10BD20 metformin and empagliflozin 0 0 <5 331 881 0.2 71 604 206 3 669 A10BD21 saxagliptin and dapagliflozin 0 0 0 0 91 0.0 0 8 52 31 400 A10BF Alpha glucosidase inhibitors 597 519 495 463 442 0.1 0 37 225 180 609ATC group A level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 37 225 180 609 A10BG Thiazolidinediones 1 579 1 552 1 500 1 492 1 415 0.3 0 56 801 558 3 003 A10BG03 pioglitazone 1 579 1 552 1 500 1 492 1 415 0.3 0 56 801 558 3 003 A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 13 439 16 324 19 047 21 861 25 212 4.8 0 1 063 12 146 12 003 101 254 A10BH01 sitagliptin 7 621 8 852 10 157 12 060 14 903 2.8 0 734 7 739 6 430 57 437 A10BH02 vildagliptin 2 289 2 519 2 540 2 500 2 374 0.5 0 96 1 057 1 221 9 095 A10BH03 saxagliptin 1 684 1 547 1 438 1 351 1 233 0.2 0 47 673 513 5 673 A10BH05 linagliptin 2 145 3 716 5 225 6 268 7 066 1.3 0 194 2 808 4 064 29 050 A10BJ Glucagon-like peptide-1 (GLP-1) analogues 6 595 8 101 9 715 11 074 12 861 2.4 <5 1 244 8 704 2 911 158 624 A10BJ01 exenatide 972 1 067 1 317 1 324 1 251 0.2 0 95 856 300 11 544 A10BJ02 liraglutide 5 666 6 715 7 488 7 980 9 083 1.7 <5 876 6 181 2 025 117 602 A10BJ03 lixisenatide 73 488 940 725 525 0.1 0 48 368 109 4 125 A10BJ05 dulaglutide 0 0 335 1 432 2 314 0.4 <5 244 1 530 539 25 353 A10BK Sodium-glucose co- transporter 2 (SGLT2) inhibitors 1 311 5 713 9 442 14 041 20 330 3.9 0 1 454 13 837 5 039 85 294 A10BK01 dapagliflozin 1 311 5 713 8 475 9 437 10 588 2.0 0 756 7 292 2 540 43 174 A10BK03 empagliflozin 0 0 1 102 4 910 10 105 1.9 0 727 6 805 2 573 42 120 A10BX Other blood glucose lowering drugs, excl. insulins 213 208 184 172 163 0.0 0 5 80 78 274 A10BX02 repaglinide 213 208 184 172 163 0.0 0 5 80 78 274 A11 VITAMINS 128 838 156 279 186 886 226 346 265 039 50.2 4 721 89 451 97 508 73 359 157 983 A11A MULTIVITAMINS, COMBINATIONS 138 162 175 183 223 0.0 113 98 12 0 1 125 A11AA Multivitamins with minerals 138 162 175 183 223 0.0 113 98 12 0 1 125 A11AA03 multivitamins and other minerals, incl. combinations 138 162 175 183 223 0.0 113 98 12 0 1 125 A11B MULTIVITAMINS, PLAIN 44 52 56 43 71 0.0 67 <5 <5 0 45 A11BA Multivitamins, plain 44 52 56 43 71 0.0 67 <5 <5 0 45 A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO 34 758 59 145 86 055 116 905 155 272 29.4 4 006 69 505 55 622 26 139 76 317 A11CA Vitamin A, plain 51 77 75 94 96 0.0 <5 32 55 6 131 A11CA01 retinol (vit A) 35 58 63 79 85 0.0 <5 25 51 6 53 A11CA02 betacarotene 16 19 12 15 11 0.0 0 7 <5 0 78 A11CC Vitamin D and analogues 34 722 59 091 86 014 116 856 155 234 29.4 4 003 69 491 55 603 26 137 76 186 A11CC01 ergocalciferol 49 26 44 35 115 0.0 0 47 51 17 76 A11CC03 alfacalcidol 4 730 4 733 4 850 4 880 4 960 0.9 113 607 1 860 2 380 7 760 A11CC04 calcitriol 3 068 2 972 3 119 3 265 3 267 0.6 <5 435 1 325 1 504 4 189ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 659 78 509 109 295 147 685 28.0 3 888 68 554 52 722 22 521 64 160 A11D VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 784 930 1 029 984 1 140 0.2 29 166 625 320 1 200 A11DA Vitamin B1, plain 774 920 1 020 976 1 131 0.2 29 164 620 318 1 196 A11DA01 thiamine (vit B1)1)774 920 1 020 976 1 131 0.2 29 164 620 318 1 196 A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12 10 10 9 8 9 0.0 0 <5 5 <5 4 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 93 711 100 038 107 797 120 911 126 088 23.9 494 25 635 48 277 51 682 75 983 A11EA Vitamin B-complex, plain1)92 410 98 596 106 246 119 520 124 436 23.6 442 25 318 47 660 51 016 74 583 A11EB Vitamin B-complex with vitamin C1)270 593 713 597 807 0.2 8 233 312 254 261 A11EX Vitamin B-complex, other combinations 1 083 961 942 897 976 0.2 44 105 366 461 1 138 A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS 3 502 3 425 3 033 2 933 2 702 0.5 8 337 673 1 684 1 055 A11GA Ascorbic acid (vitamin C), plain 3 502 3 425 3 033 2 933 2 702 0.5 8 337 673 1 684 1 055 A11GA01 ascorbic acid (vit C)1)3 502 3 425 3 033 2 933 2 702 0.5 8 337 673 1 684 1 055 A11H OTHER PLAIN VITAMIN PREPARATIONS 1 757 1 808 1 502 1 472 1 577 0.3 208 836 383 150 1 865 A11HA Other plain vitamin preparations 1 757 1 808 1 502 1 472 1 577 0.3 208 836 383 150 1 865 A11HA01 nicotinamide1)11 20 29 35 35 0.0 0 6 21 8 21 A11HA02 pyridoxine (vit B6)1)1 374 1 459 1 165 1 168 1 296 0.3 114 772 308 102 690 A11HA03 tocopherol (vit E)1)289 266 257 222 195 0.0 70 43 44 38 627 A11HA04 riboflavin (vit B2)1)21 20 18 18 5 7 <5 9 A11HA05 biotin <5 8 13 19 27 0.0 15 10 <5 0 331 A11HA06 pyridoxal phosphate 56 35 7 0.0 7 0 0 0 164 A11J OTHER VITAMIN PRODUCTS, COMBINATIONS 79 70 74 71 70 0.0 60 9 0 <5 386 A11JA Combinations of vitamins 62 63 71 71 70 0.0 60 9 0 <5 386 A11JB Vitamins with minerals 17 7 <5 0 0 0.0 0 0 0 0 0 A12 MINERAL SUPPLEMENTS 134 703 141 418 149 611 159 592 169 017 32.0 472 11 749 68 037 88 759 139 100 A12A CALCIUM 113 030 120 026 128 584 138 349 147 490 28.0 262 10 323 60 943 75 962 110 507 A12AA Calcium 987 1 088 1 183 1 193 1 233 0.2 81 225 463 464 1 439 A12AA02 calcium glubionate <5 <5 0 <5 0 0.0 0 0 0 0 0 A12AA03 calcium gluconate 0 0 <5 8 5 0.0 5 0 0 0 12 A12AA06 calcium lactate gluconate1)984 1 083 1 175 1 184 1 228 0.2 76 225 463 464 1 426 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Calcium, D and/or other drugs1)112 275 119 209 127 679 137 414 146 576 27.8 183 10 167 60 589 75 637 109 069 A12B POTASSIUM 21 980 21 269 20 553 20 684 20 365 3.9 104 1 119 6 411 12 731 17 712 A12BA Potassium 21 980 21 269 20 553 20 684 20 365 3.9 104 1 119 6 411 12 731 17 712 A12BA01 potassium chloride1)19 870 19 263 18 468 18 437 18 209 3.5 21 892 5 700 11 596 12 017 A12BA02 potassium citrate1)2 446 2 358 3 048 2 705 2 647 0.5 91 282 872 1 402 5 647 A12BA30 combinations 5 <5 6 <5 5 0.0 0 <5 <5 <5 48 A12C OTHER MINERAL SUPPLEMENTS 5 736 6 770 7 479 8 088 8 996 1.7 142 635 2 992 5 227 10 880 A12CA Sodium 1 182 1 443 1 851 2 277 2 554 0.5 9 109 724 1 712 3 234 A12CA01 sodium chloride1)1 182 1 443 1 851 2 277 2 554 0.5 9 109 724 1 712 3 234 A12CB Zinc 714 712 621 607 566 0.1 39 137 192 198 394 A12CB01 zinc sulfate 714 712 621 607 566 0.1 39 137 192 198 394 A12CC Magnesium 3 941 4 747 5 144 5 385 6 063 1.2 94 389 2 142 3 438 7 111 A12CC01 magnesium chloride 0 0 <5 0 0 0.0 0 0 0 0 0 A12CC04 magnesium citrate 0 0 18 27 53 0.0 9 7 18 19 98 A12CC10 magnesium oxide 164 158 189 222 289 0.1 13 25 107 144 314 A12CC30 magnesium (different salts in combination)1)3 792 4 615 4 938 5 139 5 750 1.1 49 361 2 032 3 308 6 042 A12CX Other mineral products <5 7 10 16 17 0.0 5 6 <5 <5 141 A13 TONICS 0 0 <5 0 0 <5 0 0 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 1 008 1 239 1 279 1 067 1 017 0.2 <5 299 642 75 896 A14A ANABOLIC STEROIDS 1 008 1 239 1 279 1 067 1 017 0.2 <5 299 642 75 896 A14AA Androstan derivatives 963 1 198 1 230 1 030 974 0.2 <5 284 615 74 716 A14AA07 prasterone 963 1 198 1 228 1 028 973 0.2 <5 283 615 74 693 A14AA08 oxandrolone 0 0 0 0 23 A14AB Estren derivatives 26 29 28 21 20 0.0 0 8 11 <5 50 A14AB01 nandrolone 26 29 28 21 20 0.0 0 8 11 <5 50 A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 507 417 399 404 456 0.1 155 171 98 32 362 440 A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 396 392 397 403 456 0.1 155 171 98 32 362 440 A16AA Amino acids and derivatives 164 186 199 208 229 0.0 114 70 28 17 24 688 A16AA01 levocarnitine 99 129 146 168 186 0.0 107 47 16 16 3 307 A16AA03 glutamine 17 14 16 7 5 0.0 0 <5 <5 0 9 A16AA04 mercaptamine 8 9 9 10 10 0.0 <5 6 0 0 17 583 A16AA05 carglumic acid 0 0 0 <5 5 0.0 5 0 0 0 2 622 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 25 23 24 0.0 <5 15 5 0 1 162 A16AB Enzymes 65 69 80 82 86 0.0 11 35 36 <5 235 697 A16AB02 imiglucerase 7 8 9 8 0 <5 <5 <5 24 943 A16AB03 agalsidase alfa 24 22 20 17 16 0.0 0 6 7 <5 31 424 A16AB04 agalsidase beta 23 30 39 40 41 0.0 0 20 21 0 70 579 A16AB05 laronidase <5 <5 0 0 0 0.0 0 A16AB07 alglucosidase alfa <5 <5 <5 A16AB12 elosulfase alfa 0 0 <5 6 10 0.0 5 <5 <5 0 56 986 A16AX Various alimentary tract and metabolism products 170 144 124 116 149 0.0 37 66 35 11 102 056 A16AX01 thioctic acid 118 82 63 41 42 0.0 <5 16 17 8 47 A16AX04 nitisinone 16 17 16 15 16 0.0 9 7 0 0 15 188 A16AX05 zinc acetate 11 16 13 14 14 0.0 <5 8 <5 0 139 A16AX06 miglustat <5 5 6 6 8 0.0 <5 <5 0 0 6 987 A16AX07 sapropterin 20 23 21 22 33 0.0 9 22 <5 0 24 460 A16AX08 teduglutide 0 0 <5 10 26 0.0 9 5 9 <5 43 819 A16AX10 eliglustat 0 0 <5 <5 0 0 <5 0 3 978 A16AX12 trientine 0 0 0 5 6 0.0 0 <5 <5 0 5 424 A16AX14 migalastat 0 0 0 0 <5 - 0 0 <5 0 1 867ATC group A level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 629 097 640 857 658 262 678 638 699 782 132.6 4 920 79 288 280 250 335 324 1 831 416 B01 ANTITHROMBOTIC AGENTS 519 085 525 381 533 682 542 849 551 056 104.4 503 24 681 217 293 308 579 1 185 931 B01A ANTITHROMBOTIC AGENTS 519 085 525 381 533 682 542 849 551 056 104.4 503 24 681 217 293 308 579 1 185 931 B01AA Vitamin K antagonists 88 089 77 831 69 358 60 605 51 304 9.7 38 1 709 13 051 36 506 49 084 B01AA01 dicoumarol 70 63 51 47 39 0.0 0 7 14 18 221 B01AA02 phenindione <5 <5 0 0 0 0.0 0 0 0 0 0 B01AA03 warfarin 88 017 77 769 69 307 60 561 51 268 9.7 38 1 703 13 039 36 488 48 863 B01AB Heparin group 49 253 50 696 54 116 56 268 56 928 10.8 230 12 843 25 057 18 798 140 766 B01AB01 heparin 1 141 1 209 1 179 1 184 1 327 0.3 156 188 587 396 2 248 B01AB04 dalteparin 28 495 27 592 31 785 34 748 36 168 6.9 54 7 087 16 622 12 405 86 182 B01AB05 enoxaparin 20 454 22 732 21 964 21 078 20 307 3.9 25 5 698 8 299 6 285 52 336 B01AB10 tinzaparin 10 <5 0 0 0 0.0 0 0 0 0 0 B01AC Platelet aggregation inhibitors excl. heparin 400 083 397 622 396 112 395 053 393 102 74.5 250 9 301 165 670 217 881 290 294 B01AC04 clopidogrel 25 620 25 588 26 627 27 618 30 764 5.8 <5 590 12 023 18 149 30 307 B01AC05 ticlopidine 187 180 132 108 104 0.0 0 <5 28 74 289 B01AC06 acetylsalicylic acid 378 066 373 995 370 940 368 557 364 426 69.1 247 8 797 154 860 200 522 95 087 B01AC07 dipyridamole 19 830 19 568 19 030 18 752 17 789 3.4 0 199 6 173 11 417 23 195 B01AC09 epoprostenol <5 <5 <5 B01AC11 iloprost 9 8 <5 5 <5 - 0 0 <5 0 56 B01AC21 treprostinil 15 16 17 20 24 0.0 <5 8 11 <5 38 994 B01AC22 prasugrel 1 711 1 747 1 744 1 627 1 625 0.3 0 87 1 234 304 7 055 B01AC24 ticagrelor 6 773 8 738 9 022 9 476 9 588 1.8 0 341 6 246 3 001 51 459 B01AC27 selexipag 0 0 0 9 13 0.0 0 <5 8 <5 12 057 B01AC30 combinations 14 622 15 573 16 238 16 805 16 809 3.2 0 265 6 369 10 175 30 123 B01AC56 acetylsalicylic acid, combinations with proton pump inhibitors 312 0 0 0 0 0.0 0 0 0 0 0 B01AD Enzymes <5 <5 Direct thrombin inhibitors 13 879 15 365 13 846 13 331 13 118 2.5 0 132 3 279 9 707 100 332 B01AE07 dabigatran etexilate 13 879 15 365 13 846 13 331 13 118 2.5 0 132 3 279 9 707 100 332 B01AF Direct factor Xa inhibitors 15 590 28 940 45 990 65 036 83 783 15.9 <5 2 458 24 379 56 943 604 883 B01AF01 rivaroxaban 13 426 20 804 25 493 28 935 30 795 5.8 <5 1 332 10 126 19 335 231 690 B01AF02 apixaban 2 261 8 651 21 515 37 297 54 002 10.2 <5 1 163 14 526 38 312 370 960 B01AF03 edoxaban 0 0 0 15 448 0.1 0 9 132 307 2 233 B01AX Other antithrombotic agents 6 12 12 18 21 0.0 0 <5 12 6 633.6 ATC group B - Blood and bloodforming organs ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 21 0.0 0 <5 12 6 63 B02 ANTIHEMORRHAGICS 13 981 13 825 13 699 13 711 14 447 2.7 343 7 326 6 017 761 348 294 B02A ANTIFIBRINOLYTICS 13 492 13 321 13 162 13 112 13 819 2.6 207 7 102 5 879 631 6 352 B02AA Amino acids 13 490 13 319 13 160 13 110 13 817 2.6 207 7 100 5 879 631 5 149 B02AA02 tranexamic acid 13 490 13 319 13 160 13 110 13 817 2.6 207 7 100 5 879 631 203 B02B VITAMIN K AND OTHER HEMOSTATICS 564 590 626 697 740 0.1 162 264 172 142 341 943 B02BA Vitamin K 246 259 259 280 269 0.1 75 91 34 69 164 B02BA01 phytomenadione 246 259 259 280 269 0.1 75 164 B02BB Local hemostatics 0 <5 <5 0 0 0.0 0 0 0 0 0 B02BC30 combinations 0 <5 <5 0 0 0.0 0 0 0 0 0 B02BD Blood coagulation factors 258 256 274 280 287 0.1 86 130 65 6 300 054 B02BD01 coagulation factor IX, II, VII and <5 <5 coagulation factor VIII 176 182 189 191 198 0.0 66 87 43 <5 243 360 B02BD03 factor VIII inhibitor bypassing activity 9 9 9 11 0.0 <5 <5 <5 0 15 874 B02BD04 coagulation factor IX 46 38 47 49 51 0.0 14 26 9 <5 20 020 B02BD06 von Willebrand factor and coagulation factor VIII in combination 15 15 16 12 14 0.0 <5 5 <5 B02BD08 coagulation factor VIIa 12 11 10 17 15 0.0 <5 7 <5 0 6 906 B02BX Other systemic hemostatics 59 72 91 137 182 0.0 <5 43 71 67 41 444 B02BX04 romiplostim 20 17 23 30 41 0.0 0 8 19 14 16 194 B02BX05 eltrombopag 39 59 72 113 150 0.0 <5 37 56 56 25 250 B03 ANTIANEMIC PREPARATIONS 146 457 153 378 164 553 180 060 196 585 37.3 3 766 50 597 74 936 67 286 156 328 B03A IRON PREPARATIONS 27 377 30 391 33 871 38 027 41 525 7.9 2 239 14 721 8 918 15 647 15 008 B03AA Iron bivalent, oral preparations 25 635 28 833 32 311 36 331 39 712 7.5 2 235 13 807 8 293 15 377 12 870 B03AA01 ferrous glycine sulfate1)6 968 8 744 9 521 11 113 10 275 2.0 225 3 979 2 338 3 733 5 034 B03AA02 ferrous fumarate1)1 466 1 685 1 626 1 822 1 959 0.4 1 454 193 113 199 438 B03AA07 ferrous sulfate1) 17 470 18 758 21 569 23 850 28 907 5.5 583 9 874 6 089 12 361 7 398 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group B ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 1 869 1 667 1 702 1 853 1 968 0.4 <5 980 673 311 2 138 B03B VITAMIN B12 AND FOLIC ACID 122 663 126 704 134 436 146 564 160 606 30.4 1 668 38 196 67 217 53 525 97 821 B03BA Vitamin B12 (cyanocobal - amin and analogues) 83 417 86 847 97 514 102 261 104 146 19.7 394 24 320 43 017 36 415 70 642 B03BA01 cyanocobalamin 8 210 12 834 15 168 14 032 20 180 3.8 138 6 119 8 307 5 616 10 200 B03BA02 cyanocobalamin tannin complex 43 570 9 833 0 <5 <5 - 0 0 0 <5 0 B03BA03 hydroxocobalamin 33 807 68 907 85 107 91 031 87 855 16.7 262 19 278 36 314 32 001 60 308 B03BA05 mecobalamin 211 253 257 173 179 0.0 <5 58 102 18 132 B03BB Folic acid and derivatives 44 258 44 351 40 765 49 263 62 657 11.9 1 296 15 092 26 455 19 814 27 179 B03BB01 folic acid1)44 258 44 351 40 719 49 204 62 614 11.9 1 296 15 070 26 439 19 809 27 136 B03X OTHER ANTIANEMIC PREPARATIONS 3 287 3 389 3 491 3 591 3 653 0.7 31 298 1 216 2 108 43 498 B03XA Other antianemic preparations 3 287 3 389 3 491 3 591 3 653 0.7 31 298 1 216 2 108 43 498 B03XA01 erythropoietin 255 267 284 259 237 0.0 <5 19 76 139 3 899 B03XA02 darbepoetin alfa 2 778 2 895 2 985 3 190 3 336 0.6 29 268 1 118 1 921 38 440 B03XA03 methoxy polyethylene glycol-epoetin beta 291 261 244 205 109 0.0 0 11 37 61 1 159 B06 OTHER HEMATOLOGICAL AGENTS 84 95 110 117 135 0.0 12 62 51 10 94 311 B06A OTHER HEMATOLOGICAL AGENTS 84 95 110 117 135 0.0 12 62 51 10 94 311 B06AA Enzymes <5 10 10 5 8 0.0 0 <5 5 0 14 B06AA03 hyaluronidase <5 10 10 5 8 0.0 0 <5 5 0 14 B06AB Other hem products <5 0 0 <5 <5 - 0 0 <5 0 330 B06AC Drugs used in hereditary angioedema 80 85 100 111 126 0.0 12 59 45 10 93 967 B06AC01 c1-inhibitor, plasma derived 55 58 63 72 88 0.0 11 43 27 7 64 502 B06AC02 icatibant 57 58 65 73 87 0.0 6 39 37 5 29 465 B06AC04 conestat alfa <5 <5 0 0 0 0.0 0 0 0 0 0 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group B ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 75C CARDIOVASCULAR SYSTEM 1 040 279 1 060 407 1 076 271 1 100 521 1 117 743 211.8 9 702 100 154 553 183 454 704 1 794 102 C01 CARDIAC THERAPY 113 974 113 053 108 885 110 225 109 551 20.8 7 201 10 588 35 984 55 778 108 077 C01A CARDIAC GLYCOSIDES 16 077 14 063 12 900 11 878 11 153 2.1 15 61 1 709 9 368 4 900 C01AA Digitalis glycosides 16 077 14 063 12 900 11 878 11 153 2.1 15 61 1 709 9 368 4 900 C01AA04 digitoxin 3 070 935 657 525 398 0.1 0 <5 47 350 143 C01AA05 digoxin 14 333 13 215 12 279 11 377 10 769 2.0 15 60 1 664 9 030 4 758 C01B ANTIARRHYTHMICS, CLASS I AND III 13 951 14 593 15 233 16 006 16 810 3.2 82 593 7 461 8 674 40 662 C01BA Antiarrhythmics, class Ia 114 103 91 100 100 disopyramide 112 101 89 96 96 0.0 0 <5 30 63 216 C01BB Antiarrhythmics, class Ib 17 26 33 37 39 0.0 0 9 21 9 831 C01BB02 mexiletine 17 26 33 37 39 0.0 0 9 21 9 831 C01BC Antiarrhythmics, class Ic 7 373 7 600 7 755 7 890 8 152 1.5 78 436 4 297 3 341 15 887 C01BC03 propafenone <5 6 16 C01BC04 flecainide 7 371 7 594 7 750 7 885 8 145 1.5 78 435 4 293 3 339 15 871 C01BD Antiarrhythmics, class III 6 750 7 167 7 717 8 315 8 871 1.7 <5 156 3 316 5 397 23 684 C01BD01 amiodarone 5 593 5 784 5 978 6 232 6 551 1.2 <5 113 2 268 4 168 4 715 C01BD07 dronedarone 1 269 1 526 1 924 2 253 2 520 0.5 0 45 1 156 1 319 18 969 C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES 19 662 22 904 21 927 25 873 27 585 5.2 7 104 9 196 8 874 2 411 29 312 C01CA Adrenergic and dopaminergic agents 19 662 22 904 21 927 25 873 27 585 5.2 7 104 9 196 8 874 2 411 29 312 C01CA01 etilefrine 100 116 78 66 59 0.0 <5 22 25 11 126 C01CA03 norepinephrine 0 0 0 <5 0 0.0 0 0 0 0 0 C01CA06 phenylephrine <5 <5 0 0 2 C01CA17 midodrine 28 29 44 54 69 0.0 0 18 21 30 524 C01CA24 epinephrine 19 530 22 754 21 811 25 751 27 454 5.2 7 103 9 156 8 825 2 370 28 449 C01CA26 ephedrine 6 8 <5 0 17 C01CA27 droxidopa 0 0 0 0 <5 - 0 0 <5 0 194 C01D VASODILATORS USED IN CARDIAC DISEASES 69 136 65 806 62 792 60 017 57 317 10.9 0 753 18 632 37 932 32 302 C01DA Organic nitrates 69 136 65 805 62 792 60 017 57 316 10.9 0 753 18 631 37 932 32 301 C01DA02 glyceryl trinitrate 53 076 50 736 48 661 46 507 44 297 8.4 0 707 16 243 27 347 9 576 C01DA08 isosorbide dinitrate 1 377 1 153 933 722 231 0.0 0 <5 18 211 43 C01DA14 isosorbide mononitrate 28 711 27 093 25 699 24 237 23 752 4.5 0 103 4 889 18 760 22 682 C01DX Other vasodilators used in cardiac diseases 0 <5 <5 <5 <5 <5 - 0 0 <5 0 13.7 ATC group C - Cardiovascular system ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 76C01E OTHER CARDIAC PREPARATIONS 29 62 83 172 286 0.1 0 44 182 60 901 C01EB Other cardiac preparations 29 62 83 172 286 0.1 0 44 182 60 901 C01EB15 trimetazidine 8 5 5 6 10 0.0 0 0 7 <5 12 C01EB17 ivabradine 15 42 58 141 249 0.1 0 44 162 43 547 C01EB18 ranolazine 6 15 20 25 28 0.0 0 0 14 14 343 C02 ANTIHYPERTENSIVES 17 267 16 939 16 820 17 147 17 723 3.4 333 949 7 433 9 008 112 869 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 6 532 6 485 6 468 6 644 7 025 1.3 324 414 3 199 3 088 9 833 C02AB Methyldopa 65 65 58 57 46 0.0 0 26 12 8 135 C02AB01 methyldopa (levorotatory) 65 65 58 57 46 0.0 0 26 12 8 135 C02AC Imidazoline receptor agonists 6 476 6 430 6 419 6 592 6 982 1.3 324 388 3 190 3 080 9 698 C02AC01 clonidine 92 107 100 125 200 0.0 7 73 98 22 369 C02AC02 guanfacine 0 0 0 96 417 0.1 317 93 7 0 3 511 C02AC05 moxonidine 6 385 6 324 6 320 6 373 6 367 1.2 0 224 3 085 3 058 5 818 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 10 952 10 638 10 486 10 610 10 818 2.1 <5 467 4 340 6 008 13 994 C02CA Alpha-adrenoreceptor antagonists 10 952 10 638 10 486 10 610 10 818 2.1 <5 467 4 340 6 008 13 994 C02CA01 prazosin 35 64 79 95 140 0.0 <5 101 37 0 232 C02CA04 doxazosin 10 920 10 574 10 410 10 517 10 681 2.0 <5 368 4 304 6 008 13 763 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 335 337 360 383 383 0.1 <5 26 146 210 590 C02DB Hydrazinophthalazine derivatives 316 306 312 330 322 0.1 <5 14 106 201 227 C02DB02 hydralazine 316 306 312 330 322 0.1 <5 14 106 201 227 C02DC Pyrimidine derivatives 20 31 48 56 62 0.0 0 12 41 9 362 C02DC01 minoxidil 20 31 48 56 62 0.0 0 12 41 9 362 C02K OTHER ANTIHYPERTENSIVES 193 230 268 304 326 0.1 7 81 160 78 88 452 C02KD Serotonin antagonists 13 12 11 11 10 0.0 0 <5 5 <5 395 C02KD01 ketanserin 13 12 11 11 10 0.0 0 <5 5 <5 395 C02KX Antihypertensives for pulmonary arterial hypertension 182 219 258 294 317 0.1 7 79 156 75 88 057 C02KX01 bosentan 132 133 117 111 106 0.0 7 36 43 20 25 508 C02KX02 ambrisentan 50 56 55 55 58 0.0 0 17 31 10 14 235 C02KX04 macitentan 0 38 87 114 144 0.0 0 27 75 42 42 255 C02KX05 riociguat 0 7 11 19 21 0.0 0 <5 11 9 6 059 C03 DIURETICS 194 790 187 618 180 736 175 921 170 540 32.3 229 6 376 58 406 105 529 108 308ATC group C ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 40 871 37 626 35 304 32 893 6.2 19 1 022 14 961 16 891 16 274 C03AA Thiazides, plain 14 014 13 434 12 992 12 857 12 495 2.4 16 520 5 770 6 189 3 664 C03AA01 bendroflumethiazide 0 0 0 0 <5 - <5 0 <5 <5 3 C03AA03 hydrochlorothiazide 14 014 13 434 12 992 12 857 12 492 2.4 15 520 5 769 6 188 3 661 C03AB Thiazides and potassium in combination 30 853 27 546 24 716 22 519 20 465 3.9 <5 507 9 214 10 741 12 610 C03AB01 bendroflumethiazide and potassium 30 853 27 546 24 716 22 519 20 465 3.9 <5 507 9 214 10 741 12 610 C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES <5 <5 <5 23 C03BA Sulfonamides, plain 9 17 0.0 0 <5 <5 <5 23 C03BA04 chlortalidone 7 10 5 C03BA08 metolazone <5 18 C03C HIGH-CEILING DIURETICS 124 184 122 417 119 814 118 174 115 668 21.9 192 4 066 33 723 77 687 56 970 C03CA Sulfonamides, plain 124 184 122 417 119 814 118 174 115 668 21.9 192 4 066 33 723 77 687 56 970 C03CA01 furosemide 90 249 86 842 82 938 79 694 75 970 14.4 190 3 173 24 212 48 395 19 135 C03CA02 bumetanide 38 766 40 285 41 465 42 921 44 130 8.4 <5 978 10 438 32 712 37 835 C03CA04 torasemide <5 <5 <5 0 0 0.0 0 0 0 0 0 C03D POTASSIUM-SPARING AGENTS 19 007 19 299 20 003 21 421 22 492 4.3 40 1 334 8 484 12 634 13 428 C03DA Aldosterone antagonists 18 990 19 280 19 981 21 406 22 476 4.3 40 1 332 8 476 12 628 13 330 C03DA01 spironolactone 18 084 18 221 18 794 20 091 20 980 4.0 40 1 250 7 643 12 047 8 176 C03DA02 potassium canrenoate <5 0 <5 0 0 0.0 0 0 0 0 0 C03DA04 eplerenone 1 030 1 208 1 339 1 489 1 671 0.3 0 97 916 658 5 154 C03DB Other potassium-sparing agents 19 21 23 16 18 0.0 0 <5 9 6 98 C03DB01 amiloride 19 21 23 16 18 0.0 0 <5 9 6 98 C03E DIURETICS AND POTASSIUM- SPARING AGENTS IN COMBINATION 23 234 20 874 18 854 16 977 15 279 2.9 8 267 6 071 8 933 2 924 C03EA Low-ceiling diuretics and potassium-sparing agents 23 234 20 874 18 854 16 977 15 279 2.9 8 267 6 071 8 933 2 924 C03EA01 hydrochlorothiazide and potassium-sparing agents 23 234 20 874 18 854 16 977 15 279 2.9 8 267 6 071 8 933 2 924 C03X OTHER DIURETICS 35 61 55 78 160 0.0 0 33 80 47 18 688 C03XA Vasopressin antagonists 35 61 55 78 160 0.0 0 33 80 47 18 688 C03XA01 tolvaptan 35 61 55 78 160 0.0 0 33 80 47 18 688 C04 PERIPHERAL VASODILATORS 810 739 655 634 567 0.1 0 33 162 372 597 C04A PERIPHERAL VASODILATORS 810 739 655 634 567 0.1 0 33 162 372 597 C04AB Imidazoline derivatives <5 0 0 0 0 0.0 0 0 0 0 0 C04AB01 phentolamine <5 0 0 0 0 0.0 0 0 0 0 0ATC group C ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 33 160 372 571 C04AD03 pentoxifylline 808 737 654 631 565 0.1 0 33 160 372 571 C04AX Other peripheral vasodilators 0 <5 <5 26 C05 VASOPROTECTIVES 66 461 72 167 71 990 69 880 55 372 10.5 669 22 603 21 646 10 454 18 246 C05A AGENTS FOR TREAT - MENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE 60 385 65 990 65 838 63 639 48 839 9.3 631 21 417 18 903 7 888 13 207 C05AA Corticosteroids 57 822 63 521 63 228 60 591 45 308 8.6 612 19 592 17 553 7 551 9 440 C05AA01 hydrocortisone1)6 121 4 107 3 214 3 254 2 993 0.6 78 1 161 1 220 534 466 C05AA04 prednisolone1)53 098 60 659 60 923 58 216 42 937 8.1 537 18 696 16 573 7 131 8 975 C05AE Muscle relaxants 3 568 4 037 4 287 4 826 4 896 0.9 21 2 518 1 888 469 3 717 C05AE01 glyceryl trinitrate 3 568 4 037 4 287 4 826 4 896 0.9 21 2 518 1 888 469 3 717 C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use 841 160 62 76 86 0.0 <5 40 23 19 50 C05AX03 other preparations, combinations1)819 148 49 68 69 0.0 <5 32 17 16 16 C05B ANTIVARICOSE THERAPY 6 294 6 430 6 395 6 467 6 741 1.3 38 1 237 2 824 2 642 5 029 C05BA Heparins or heparinoids for topical use 6 288 6 419 6 385 6 457 6 729 1.3 38 1 233 2 817 2 641 5 016 C05BA01 organo-heparinoid1) 6 249 6 382 6 328 6 397 6 668 1.3 38 1 220 2 784 2 626 1 043 C05BA04 pentosan polysulfate sodium 40 37 58 60 61 0.0 0 13 33 15 3 973 C05BB Sclerosing agents for local injection 6 11 10 10 12 0.0 0 <5 7 <5 13 C05BB02 polidocanol 6 11 10 10 12 0.0 0 <5 7 <5 13 C05C CAPILLARY STABILIZING AGENTS 8 7 7 12 8 0.0 0 <5 <5 <5 10 C05CA Bioflavonoids 8 7 0 <5 <5 <5 10 C05CA01 rutoside 8 7 0.0 0 <5 <5 <5 10 C07 BETA BLOCKING AGENTS 371 668 373 049 375 425 378 400 71.7 685 23 015 151 975 202 725 218 472 C07A BETA BLOCKING AGENTS 367 435 369 031 369 644 372 172 375 321 71.1 685 22 911 150 279 201 446 216 271 C07AA Beta blocking agents, non-selective 24 423 23 139 20 979 20 165 20 491 3.9 321 4 817 8 323 7 030 22 352 C07AA03 pindolol 12 11 12 13 11 0.0 0 <5 6 <5 18 C07AA05 propranolol 18 262 17 453 15 716 15 274 15 992 3.0 295 4 598 6 955 4 144 16 077 C07AA06 timolol 7 13 11 8 13 0.0 0 0 8 5 134 C07AA07 sotalol 6 098 5 608 5 228 4 768 4 346 0.8 <5 136 1 319 2 889 2 943 C07AA12 nadolol 88 109 122 139 163 0.0 24 91 48 0 3 180 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group C ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 selective 324 369 328 613 330 826 333 820 336 587 63.8 363 15 850 134 374 186 000 177 323 C07AB02 metoprolol 270 550 274 751 277 452 280 496 283 411 53.7 323 13 583 114 230 155 275 150 103 C07AB03 atenolol 29 679 27 982 26 316 24 654 23 277 4.4 40 1 292 8 581 13 364 6 515 C07AB07 bisoprolol 27 355 29 022 30 298 31 582 33 069 6.3 <5 1 128 12 706 19 233 20 674 C07AB12 nebivolol 9 36 22 41 79 0.0 0 21 41 17 30 C07AG Alpha and beta blocking agents 22 479 22 109 21 959 21 956 22 064 4.2 17 2 631 9 066 10 350 16 596 C07AG01 labetalol 2 442 2 469 2 671 2 789 2 819 0.5 <5 1 966 543 306 2 235 C07AG02 carvedilol 20 062 19 658 19 313 19 189 19 267 3.7 13 672 8 533 10 049 14 361 C07B BETA BLOCKING AGENTS AND THIAZIDES 4 816 4 030 3 728 3 563 3 342 0.6 0 111 1 815 1 416 2 201 C07BB Beta blocking agents, selective, and thiazides 4 816 4 030 3 728 3 563 3 342 0.6 0 111 1 815 1 416 2 201 C07BB07 bisoprolol and thiazides 4 816 4 028 3 724 3 556 3 336 0.6 0 109 1 812 1 415 2 197 C07BB12 nebivolol and thiazides 5 C08 CALCIUM CHANNEL BLOCKERS 235 380 237 478 241 881 249 493 256 070 48.5 147 10 072 113 625 132 226 149 690 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS 218 463 221 504 226 734 234 822 241 764 45.8 139 9 326 108 541 123 758 134 610 C08CA Dihydropyridine derivatives 218 463 221 504 226 734 234 822 241 764 45.8 139 9 326 108 541 123 758 134 610 C08CA01 amlodipine 129 021 129 550 131 315 134 703 137 090 26.0 117 4 436 61 999 70 538 47 630 C08CA02 felodipine 14 850 14 310 13 945 13 522 12 982 2.5 0 251 4 948 7 783 9 289 C08CA03 isradipine 493 458 446 <5 127 214 683 C08CA05 nifedipine 36 991 38 829 42 096 46 124 50 280 9.5 17 3 592 22 896 23 775 53 825 C08CA06 nimodipine 39 38 41 31 45 0.0 <5 12 24 8 35 C08CA13 lercanidipine 40 491 41 539 42 239 43 626 44 738 8.5 <5 1 176 20 111 23 450 23 149 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 18 080 17 062 16 231 15 746 15 374 2.9 8 791 5 493 9 082 15 080 C08DA Phenylalkylamine derivatives 13 847 13 057 12 396 11 965 11 662 2.2 8 684 4 198 6 772 8 336 C08DA01 verapamil 13 847 13 057 12 396 11 965 11 662 2.2 8 684 4 198 6 772 8 336 C08DB Benzothiazepine derivatives 4 281 4 050 3 941 3 850 3 763 0.7 0 110 1 310 2 343 6 744 C08DB01 diltiazem 4 281 4 050 3 941 3 850 3 763 0.7 0 110 1 310 2 343 6 744 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 552 012 565 340 576 981 592 066 607 098 115.1 568 29 800 310 633 266 097 520 555 C09A ACE INHIBITORS, PLAIN 135 072 134 833 134 850 135 955 137 321 26.0 409 6 665 62 114 68 133 66 715 C09AA ACE inhibitors, plain 135 072 134 833 134 850 135 955 137 321 26.0 409 6 665 62 114 68 133 66 715 C09AA01 captopril 1 962 1 718 1 535 1 381 1 339 0.3 175 83 428 653 3 352 C09AA02 enalapril 46 508 45 946 45 637 46 041 46 333 8.8 236 2 861 22 210 21 026 19 431ATC group C ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales lisinopril 394 22 234 21 466 20 709 3.9 <5 993 9 578 10 135 9 450 C09AA04 perindopril 0 14 24 39 52 0.0 0 5 35 12 28 C09AA05 ramipril 62 787 64 292 65 936 67 562 69 406 13.2 <5 2 763 30 076 36 564 34 453 C09AA10 trandolapril 77 62 41 0 0 0.0 0 0 0 0 0 C09AA15 zofenopril 0 <5 <5 0 <5 - 0 <5 0 0 1 C09B ACE INHIBITORS, COMBINATIONS 34 166 32 710 31 300 30 217 29 243 5.5 0 804 13 713 14 726 22 837 C09BA ACE inhibitors and diuretics 32 644 31 140 29 647 28 485 27 337 5.2 0 716 12 679 13 942 20 475 C09BA02 enalapril and diuretics 19 540 18 916 18 211 17 658 17 149 3.3 0 496 8 231 8 422 13 558 C09BA03 lisinopril and diuretics 13 133 12 243 11 448 10 836 10 189 1.9 0 219 4 450 5 520 6 911 C09BA06 quinapril and diuretics 0 0 <5 <5 <5 <5 2 C09BB ACE inhibitors and calcium channel blockers 1 546 1 593 1 669 1 755 1 930 0.4 0 89 1 047 794 2 362 C09BB02 enalapril and lercanidipine 1 546 1 593 1 669 1 755 1 930 0.4 0 89 1 047 794 2 362 C09C ANGIOTENSIN II ANTAGONISTS, PLAIN 206 884 215 131 225 372 236 972 248 444 47.1 171 16 887 132 095 99 291 159 724 C09CA Angiotensin II antagonists, plain 206 884 215 131 225 372 236 972 248 444 47.1 171 16 887 132 095 99 291 159 724 C09CA01 losartan 63 676 64 088 65 537 66 606 67 344 12.8 38 3 290 35 007 29 009 33 185 C09CA02 eprosartan 1 443 1 285 1 183 1 105 988 0.2 0 12 376 600 1 960 C09CA03 valsartan 28 100 30 018 32 325 35 101 38 060 7.2 <5 2 147 20 580 15 332 33 763 C09CA04 irbesartan 19 088 18 711 18 445 18 209 17 853 3.4 0 572 8 763 8 518 17 840 C09CA06 candesartan 88 885 95 249 102 228 110 321 118 609 22.5 132 10 654 64 379 43 444 63 385 C09CA07 telmisartan 5 822 5 699 5 656 5 705 5 680 1.1 0 246 2 976 2 458 6 625 C09CA08 olmesartan medoxomil 1 639 1 600 1 555 1 542 1 538 0.3 0 76 857 605 2 966 C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 217 369 221 086 222 453 226 709 230 147 43.6 0 7 350 121 918 100 879 271 210 C09DA Angiotensin II antagonists and diuretics 182 682 181 504 178 639 178 238 176 742 33.5 0 4 774 90 757 81 211 140 032 C09DA01 losartan and diuretics 67 346 66 303 64 606 64 474 63 337 12.0 0 1 591 31 499 30 247 34 953 C09DA02 eprosartan and diuretics 1 552 1 394 1 267 1 201 1 113 0.2 0 24 508 581 2 441 C09DA03 valsartan and diuretics 26 635 26 794 26 698 26 633 26 833 5.1 0 756 13 972 12 105 30 765 C09DA04 irbesartan and diuretics 27 373 26 036 24 755 23 578 22 301 4.2 0 350 10 542 11 409 24 478 C09DA06 candesartan and diuretics 55 802 56 924 57 398 58 597 59 488 11.3 0 1 975 32 354 25 159 40 675 C09DA07 telmisartan and diuretics 3 785 3 689 3 548 3 414 3 266 0.6 0 87 1 674 1 505 4 661 C09DA08 olmesartan medoxomil and diuretics 1 087 1 087 1 020 992 972 0.2 0 18 518 436 2 058ATC group C ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales and calcium channel blockers 23 699 25 205 26 971 29 272 31 687 6.0 0 1 638 18 360 11 689 57 250 C09DB01 valsartan and amlodipine 23 407 24 907 26 658 28 939 31 375 6.0 0 1 627 18 164 11 584 56 458 C09DB02 olmesartan medoxomil and amlodipine 297 304 315 336 321 0.1 0 13 201 107 792 C09DX Angiotensin II antagonists, other combinations 16 435 19 311 21 559 24 276 26 922 5.1 0 1 210 15 756 9 956 73 928 C09DX01 valsartan, amlodipine and hydrochlorothiazide 16 435 19 311 21 557 23 861 26 003 4.9 0 1 177 15 334 9 492 60 738 C09DX03 olmesartan medoxomil, amlodipine and hydrochlorothiazide 0 0 <5 0 0.0 0 0 0 0 0 C09DX04 valsartan and sacubitril 0 0 0 417 921 0.2 0 33 423 465 13 190 C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 69 53 40 35 32 0.0 0 0 20 12 70 C09XA Renin-inhibitors 69 53 40 35 32 0.0 0 0 20 12 70 C09XA02 aliskiren 69 53 40 35 32 0.0 0 0 20 12 70 C10 LIPID MODIFYING AGENTS 509 945 518 485 530 285 546 563 567 610 107.6 268 20 821 286 613 259 908 557 287 C10A LIPID MODIFYING AGENTS, PLAIN 506 662 514 628 524 924 536 005 553 452 104.9 265 20 135 278 159 254 893 474 327 C10AA HMG CoA reductase inhibitors 499 107 506 319 515 540 524 774 540 449 102.4 238 19 017 271 260 249 934 263 132 C10AA01 simvastatin 290 634 271 504 252 754 232 429 212 312 40.2 22 5 052 91 382 115 856 65 084 C10AA02 lovastatin 930 825 770 705 0 14 249 456 1 116 C10AA03 pravastatin 19 842 19 189 18 616 18 317 17 903 3.4 15 428 7 658 9 802 13 129 C10AA04 fluvastatin 7 372 7 432 7 590 7 731 7 469 1.4 <5 471 3 873 3 123 11 608 C10AA05 atorvastatin 189 401 211 717 237 276 264 578 295 715 56.0 162 12 233 163 185 120 135 128 233 C10AA07 rosuvastatin 9 506 12 552 15 939 20 448 25 959 4.9 48 1 568 15 753 8 590 41 886 C10AA08 pitavastatin 6 24 32 49 48 0.0 0 <5 32 15 2 077 C10AB Fibrates 314 315 311 301 316 0.1 <5 42 223 49 1 590 C10AB02 bezafibrate 47 44 42 36 36 0.0 0 <5 27 8 129 C10AB04 gemfibrozil 85 90 74 68 67 0.0 0 11 43 13 609 C10AB05 fenofibrate 184 182 195 197 215 0.0 <5 31 154 28 852 C10AC Bile acid sequestrants 2 530 2 556 2 754 3 011 3 277 0.6 21 717 1 746 793 10 302 C10AC01 colestyramine 1 864 1 866 2 049 2 328 2 610 0.5 21 636 1 366 587 2 893 C10AC02 colestipol 287 268 256 242 216 0.0 0 19 94 103 631 C10AC04 colesevelam 444 454 471 464 478 0.1 0 69 303 106 6 778 C10AD Nicotinic acid and derivatives 58 25 20 15 13 0.0 0 <5 6 6 599 C10AD02 nicotinic acid 29 18 14 11 10 0.0 0 <5 <5 6 574 C10AD06 acipimox 6 0 0 <5 0 24ATC group 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales nicotinic acid, combinations 27 0 0 0 0 0.0 0 0 0 0 0 C10AX Other lipid modifying agents 24 366 26 228 29 682 33 353 38 964 7.4 11 1 972 23 469 13 512 198 704 C10AX06 omega-3-triglycerides incl. other esters and acids 4 199 4 233 4 400 4 480 4 725 0.9 <5 548 3 290 884 37 714 C10AX09 ezetimibe 20 751 22 561 25 883 29 420 34 729 6.6 8 1 419 20 574 12 728 127 116 C10AX12 lomitapide 0 0 0 <5 0 0 0 4 079 C10AX13 evolocumab 0 0 45 217 317 0.1 <5 46 227 43 16 454 C10AX14 alirocumab 0 0 10 185 280 0.1 0 26 204 50 13 342 C10B LIPID MODIFYING AGENTS, COMBINATIONS 3 215 3 664 8 136 14 974 20 260 3.8 11 1 070 12 541 6 638 77 329 C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents 3 215 3 664 8 136 14 974 20 260 3.8 11 1 070 12 541 6 638 77 329 C10BA02 simvastatin and ezetimibe 3 215 3 664 4 127 4 251 4 555 0.9 0 146 2 577 1 832 20 280 C10BA05 atorvastatin and ezetimibe 0 0 4 136 10 871 15 847 3.0 11 933 10 048 4 855 57 049ATC group C ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 156 747 278 141.6 102 824 277 104 241 159 126 191 405 264 D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 128 325 138 096 141 401 145 187 150 144 28.5 14 316 55 093 53 687 27 048 38 914 D01A ANTIFUNGALS FOR TOPICAL USE 111 180 120 842 124 073 127 061 132 033 25.0 14 031 48 695 44 628 24 679 21 361 D01AA Antibiotics 41 43 32 13 27 0.0 <5 12 6 5 8 D01AA01 nystatin 41 43 32 13 27 0.0 <5 12 6 5 8 D01AC Imidazole and triazole derivatives 87 831 95 521 99 331 102 356 107 077 20.3 11 922 39 168 35 332 20 655 14 556 D01AC01 clotrimazole1)8 572 9 356 9 703 10 096 10 505 2.0 1 522 3 979 2 608 2 396 1 655 D01AC02 miconazole1)2 157 2 421 2 313 2 321 2 309 0.4 370 775 723 441 409 D01AC03 econazole1)732 839 950 975 1 016 0.2 40 183 360 433 157 D01AC08 ketoconazole1)16 928 18 365 18 824 19 256 20 378 3.9 1 321 9 716 6 615 2 726 3 903 D01AC20 imidazoles/triazoles in combination with corticosteroids1)63 529 69 350 72 619 74 981 78 325 14.8 9 124 26 670 26 749 15 782 8 432 D01AE Other antifungals for topical use 26 681 28 894 28 410 28 410 28 823 5.5 2 473 10 995 10 562 4 793 6 797 D01AE02 methylrosaniline1)736 878 907 812 873 0.2 246 201 213 213 118 D01AE14 ciclopirox 841 2 763 3 825 4 645 4 773 0.9 83 1 431 2 350 909 1 808 D01AE15 terbinafine1)19 247 19 949 19 118 19 117 19 520 3.7 2 047 8 336 6 190 2 947 3 412 D01AE16 amorolfine1)6 333 5 820 5 033 4 335 4 152 0.8 108 1 205 2 019 820 1 460 D01B ANTIFUNGALS FOR SYSTEMIC USE 21 092 21 538 21 815 22 551 22 760 4.3 486 8 288 11 023 2 963 17 552 D01BA Antifungals for systemic use 21 092 21 538 21 815 22 551 22 760 4.3 486 8 288 11 023 2 963 17 552 D01BA01 griseofulvin 38 30 22 19 33 0.0 28 5 0 0 39 D01BA02 terbinafine 21 060 21 513 21 798 22 533 22 733 4.3 462 8 285 11 023 2 963 17 513 D02 EMOLLIENTS AND PROTECTIVES 2 548 3 153 3 500 28 189 75 655 14.3 33 852 21 327 13 314 7 162 67 697 D02A EMOLLIENTS AND PROTECTIVES 2 548 3 153 3 500 28 180 75 646 14.3 33 851 21 323 13 311 7 161 67 684 D02AB Zinc products1)9 9 5 10 11 0.0 0 <5 6 <5 3 D02AC Soft paraffin and fat products 0 0 0 0 7 0.0 <5 0 <5 <5 4 D02AE Carbamide products 1 153 1 423 1 665 26 158 73 598 14.0 33 341 20 841 12 608 6 808 66 953 D02AE01 carbamide1)1 153 1 423 1 665 26 158 73 598 14.0 33 341 20 841 12 608 6 808 66 953 D02AF Salicylic acid preparations1)1 179 1 398 1 422 1 611 1 651 0.3 179 469 702 301 390 D02AX Other emollients and protectives1)244 353 463 641 881 0.2 595 111 90 85 334 D02B PROTECTIVES AGAINST UV-RADIATION 0 0 0 <5 <5 13 D02BA Protectives against UV- radiation for topical use 0 0 0 10 9 0.0 <5 <5 <5 <5 13 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.8 ATC group D - Dermatologicals ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 84D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 85 71 63 47 67 0.0 5 15 23 24 18 D03A CICATRIZANTS 85 71 63 47 67 0.0 5 15 23 24 18 D03AX Other cicatrizants 85 71 63 47 67 0.0 5 15 23 24 18 D03AX03 dexpanthenol 85 71 63 47 67 0.0 5 15 23 24 18 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 6 698 8 038 8 387 8 560 8 761 1.7 1 011 3 612 2 250 1 888 1 617 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 6 698 8 038 8 387 8 560 8 761 1.7 1 011 3 612 2 250 1 888 1 617 D04AA Antihistamines for topical use 8 <5 15 17 6 0 <5 <5 <5 2 D04AA13 dimetindene 0 <5 <5 <5 2 D04AB Anesthetics for topical use 5 405 6 538 6 758 6 809 6 949 1.3 649 3 079 1 876 1 345 1 327 D04AB01 lidocaine1)5 405 6 538 6 758 6 809 6 949 1.3 649 3 079 1 876 1 345 1 327 D04AX Other antipruritics 1 307 1 522 1 644 1 765 1 838 0.4 367 539 380 552 287 D05 ANTIPSORIATICS 30 335 29 403 30 300 30 801 31 251 5.9 578 8 804 15 603 6 266 49 186 D05A ANTIPSORIATICS FOR TOPICAL USE 28 872 27 839 28 529 28 920 29 303 5.6 565 8 443 14 392 5 903 39 679 D05AA Tars1)960 1 102 1 299 1 550 1 917 0.4 170 646 615 486 478 D05AC Antracen derivatives 10 11 10 <5 7 0.0 0 5 <5 0 4 D05AC01 dithranol 10 11 10 <5 7 0.0 0 5 <5 0 4 D05AD Psoralens for topical use 0 0 0 0 <5 - 0 <5 0 0 0 D05AD02 methoxsalen 0 0 0 0 <5 - 0 <5 0 0 0 D05AX Other antipsoriatics for topical use 28 055 26 883 27 415 27 610 27 683 5.3 401 7 924 13 893 5 465 39 193 D05AX02 calcipotriol 1 559 902 20 116 369 0.1 6 106 171 86 257 D05AX03 calcitriol 1 170 1 439 1 406 1 284 1 162 0.2 27 273 620 242 873 D05AX52 calcipotriol, combinations 26 578 25 685 26 545 26 701 26 676 5.1 378 7 688 13 363 5 247 38 064 D05B ANTIPSORIATICS FOR SYSTEMIC USE 2 106 2 117 2 360 2 446 2 520 0.5 13 482 1 574 451 9 506 D05BA Psoralens for systemic use 20 14 17 11 16 0.0 0 <5 8 6 13 D05BA02 methoxsalen 20 14 17 11 16 0.0 0 <5 8 6 13 D05BB Retinoids for treatment of psoriasis 2 026 2 047 2 277 2 361 2 442 0.5 13 458 1 530 441 6 620 D05BB02 acitretin 2 026 2 047 2 277 2 361 2 442 0.5 13 458 1 530 441 6 620 D05BX Other antipsoriatics for systemic use 63 60 71 78 68 0.0 0 26 38 <5 2 873 D05BX51 fumaric acid derivatives, combinations 63 60 71 78 66 0.0 0 25 37 <5 2 863 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales THERAPEUTICS FOR DERMATOLOGICAL USE 110 706 114 774 114 325 111 663 108 688 20.6 11 901 39 881 35 449 21 457 33 373 D06A ANTIBIOTICS FOR TOPICAL USE 57 381 58 416 57 382 56 016 54 255 10.3 10 160 16 923 16 706 10 466 5 098 D06AA Tetracycline and derivatives 3 260 3 258 3 341 3 230 3 226 0.6 351 924 1 246 705 425 D06AA02 chlortetracycline 27 25 26 16 29 0.0 0 10 11 8 10 D06AA03 oxytetracycline 3 234 3 235 3 316 3 214 3 198 0.6 351 914 1 235 698 416 D06AX Other antibiotics for topical use 54 292 55 337 54 250 52 966 51 217 9.7 9 832 16 049 15 524 9 812 4 673 D06AX01 fusidic acid 51 166 51 972 50 697 48 979 47 857 9.1 8 689 14 975 14 864 9 329 4 195 D06AX05 bacitracin1)2 231 2 121 2 139 2 357 2 893 0.6 914 910 595 474 359 <5 1 D06AX09 mupirocin 90 97 96 47 43 0.0 11 17 12 <5 17 D06AX13 retapamulin 1 046 1 387 1 552 1 813 640 0.1 304 192 100 44 102 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE 55 283 58 373 58 976 57 534 56 248 10.7 1 841 23 579 19 341 11 487 28 275 D06BA Sulfonamides 3 482 3 577 3 304 3 124 2 866 0.5 462 971 867 566 435 D06BA01 silver sulfadiazine 3 482 3 577 3 304 3 124 2 866 0.5 462 971 867 566 435 D06BB Antivirals 38 980 38 267 36 189 35 673 35 270 6.7 1 125 17 413 10 528 6 204 17 882 D06BB03 aciclovir1)16 801 16 329 15 254 14 818 15 101 2.9 810 6 422 5 901 1 968 2 702 D06BB04 podophyllotoxin 13 095 13 286 12 621 12 096 10 834 2.1 114 9 178 1 449 93 2 383 D06BB06 penciclovir1)1 560 1 385 1 087 958 871 0.2 38 321 354 158 190 D06BB10 imiquimod 8 386 8 079 7 993 8 494 9 299 1.8 163 2 148 2 957 4 031 12 606 D06BB12 sinecatechins 0 102 169 75 0 0.0 0 0 0 0 0 D06BX Other chemotherapeutics 13 197 17 174 20 174 19 386 18 720 3.6 255 5 308 8 178 4 979 9 958 D06BX01 metronidazole1)12 942 14 089 14 666 14 082 13 311 2.5 255 5 199 5 783 2 074 2 754 D06BX02 ingenol mebutate 259 3 132 5 571 5 363 5 459 1.0 0 110 2 419 2 930 7 205 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 368 248 383 757 390 661 406 760 420 091 79.6 64 397 129 050 145 430 81 214 99 498 D07A CORTICOSTEROIDS, PLAIN 314 148 326 739 336 813 349 112 360 719 68.4 58 625 110 105 123 109 68 880 76 876 D07AA Corticosteroids, weak (group I) 29 934 31 278 32 870 34 121 36 466 6.9 17 781 9 467 5 838 3 380 4 310 D07AA02 hydrocortisone1)29 931 31 278 32 870 34 121 36 466 6.9 17 781 9 467 5 838 3 380 4 310 D07AB Corticosteroids, moderately potent (group II) 105 292 108 829 114 464 117 426 124 714 23.6 32 046 37 565 34 448 20 655 17 664 D07AB02 hydrocortisone butyrate 85 367 86 711 90 271 92 705 98 183 18.6 26 098 29 878 26 356 15 851 13 809 D07AB08 desonide 21 365 23 447 25 652 26 249 28 161 5.3 6 595 8 097 8 430 5 039 3 855 D07AC Corticosteroids, potent (group III) 163 406 169 282 169 891 176 406 176 748 33.5 18 213 57 878 63 966 36 691 38 409 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales betamethasone 58 313 61 411 50 587 58 525 55 767 10.6 3 724 18 104 21 544 12 395 8 273 D07AC03 desoximetasone 11 671 11 620 14 876 12 571 11 848 2.3 544 3 065 5 062 3 177 5 084 D07AC04 fluocinolone acetonide 5 421 5 246 7 312 5 773 5 634 1.1 188 1 180 2 503 1 763 994 D07AC08 fluocinonide 541 498 477 446 376 0.1 5 55 186 130 67 D07AC13 mometasone 83 267 86 651 100 753 98 164 102 116 19.4 13 033 35 053 34 566 19 464 22 002 D07AC17 fluticasone 11 613 11 447 5 704 8 791 8 661 1.6 1 357 2 852 2 911 1 541 1 989 D07AD Corticosteroids, very potent (group IV) 60 150 64 294 69 391 71 624 74 810 14.2 2 575 21 661 34 253 16 321 16 493 D07AD01 clobetasol 60 150 64 294 69 391 71 624 74 810 14.2 2 575 21 661 34 253 16 321 16 493 D07B CORTICOSTEROIDS, COMBI - NATIONS WITH ANTISEPTICS 29 528 32 142 26 807 32 087 32 979 6.3 4 403 9 655 11 742 7 179 4 964 D07BB Corticosteroids, moderately potent, combinations with antiseptics 1 955 6 059 10 013 9 621 4 673 0.9 1 237 1 121 1 444 871 699 D07BB02 desonide and antiseptics 1 955 6 059 10 013 9 621 4 673 0.9 1 237 1 121 1 444 871 699 D07BC Corticosteroids, potent, combinations with antiseptics 27 796 26 519 17 797 23 369 28 949 5.5 3 380 8 667 10 470 6 432 4 265 D07BC01 betamethasone and antiseptics 25 387 23 822 12 284 19 354 26 980 5.1 3 243 8 173 9 640 5 924 4 037 D07BC02 fluocinolone acetonide and antiseptics 2 540 3 030 6 371 4 786 2 260 0.4 170 553 944 593 228 D07C CORTICOSTEROIDS, COMBI - NATIONS WITH ANTIBIOTICS 25 078 25 863 26 065 26 192 26 831 5.1 4 933 7 945 8 737 5 216 3 493 D07CA Corticosteroids, weak, combinations with antibiotics 25 072 25 856 25 994 25 707 26 181 5.0 4 819 7 699 8 543 5 120 3 347 D07CA01 hydrocortisone and antibiotics 25 072 25 856 25 994 25 707 26 181 5.0 4 819 7 699 8 543 5 120 3 347 D07CB Corticosteroids, moderately potent, combinations with antibiotics <5 <5 <5 0 0 0.0 0 0 0 0 0 D07CB01 triamcinolone and antibiotics <5 <5 <5 0 0 0.0 0 0 0 0 0 D07CC Corticosteroids, potent, combinations with antibiotics <5 6 77 514 687 0.1 124 259 202 102 147 D07CC01 betamethasone and antibiotics <5 5 76 513 684 0.1 124 257 201 102 D07CC05 fluocinonide CORTICOSTEROIDS, OTHER COMBINATIONS 26 722 28 040 29 013 30 276 31 931 6.1 1 023 11 057 13 278 6 573 14 165 D07XA Corticosteroids, weak, other combinations 7 12 10 5 11 0.0 <5 <5 <5 <5 10 D07XA01 <5 <5 <5 10ATC 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales combinations 26 715 28 028 29 003 30 271 31 920 6.1 1 020 11 056 13 275 6 569 14 155 D07XC01 betamethasone 26 715 28 028 29 003 30 271 31 920 6.1 1 020 11 056 13 275 6 569 14 155 D08 ANTISEPTICS AND DISINFECTANTS 20 441 20 798 20 485 20 934 22 159 4.2 3 813 8 505 6 565 3 276 4 566 D08A ANTISEPTICS AND DISINFECTANTS 20 441 20 798 20 485 20 934 22 159 4.2 3 813 8 505 6 565 3 276 4 566 D08AB Aluminium agents1)429 462 524 570 753 0.1 241 231 168 113 113 D08AC Biguanides and amidines 17 326 17 537 17 159 17 667 18 699 3.5 2 899 7 506 5 706 2 588 3 803 D08AC01 dibrompropamidine1)5 561 6 341 6 359 6 234 6 662 1.3 2 201 2 058 1 371 1 032 1 219 D08AC02 chlorhexidine1)12 076 11 595 11 222 11 815 12 426 2.4 815 5 589 4 415 1 607 2 584 D08AG Iodine products 79 111 118 93 111 0.0 5 21 28 57 30 D08AG02 povidone-iodine 50 78 76 66 83 0.0 0 11 22 50 26 D08AG03 iodine1)29 33 42 27 28 0.0 5 10 6 7 4 D08AJ Quaternary ammonium compounds 124 156 139 180 198 0.0 27 72 45 54 75 D08AJ03 cetylpyridinium1)124 156 139 180 198 0.0 27 72 45 54 75 D08AL Silver compounds 10 26 22 16 12 0.0 0 <5 10 <5 12 D08AL01 silver nitrate 10 26 22 16 12 0.0 0 <5 10 <5 12 D08AX Other antiseptics and disinfectants 2 618 2 683 2 686 2 570 2 596 0.5 717 746 645 488 533 D08AX01 hydrogen peroxide1)1 526 1 442 1 453 1 188 1 166 0.2 301 299 295 271 164 D08AX06 potassium permanganate1)1 103 1 260 1 239 1 391 1 436 0.3 420 449 348 219 366 D09 MEDICATED DRESSINGS 1 718 1 670 1 425 1 330 1 144 0.2 90 189 380 485 398 D09A MEDICATED DRESSINGS 1 718 1 670 1 425 1 330 1 144 0.2 90 189 380 485 398 D09AA Medicated dressings with antiinfectives 1 607 1 539 1 324 1 238 1 067 0.2 85 186 355 441 151 D09AA02 fusidic acid 1 607 1 539 1 324 1 238 1 067 0.2 85 186 355 441 151 D09AB Zinc bandages 112 135 101 92 77 0.0 5 <5 25 44 247 D09AB01 zinc bandage without supplements 112 135 101 92 77 0.0 5 <5 25 44 247 D10 ANTI-ACNE PREPARATIONS 70 355 73 127 75 656 78 061 82 095 15.6 4 892 63 105 11 298 2 800 67 413 D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE 64 217 66 073 67 316 68 595 71 573 13.6 4 693 53 556 10 577 2 747 26 782 D10AD Retinoids for topical use in acne 37 161 38 278 40 392 43 437 46 115 8.7 3 562 38 276 3 330 947 19 886 D10AD01 tretinoin 6 861 2 728 3 113 3 253 3 483 0.7 34 1 489 1 457 503 1 082 D10AD02 retinol 63 0 0 0 0 0.0 0 0 0 0 0 D10AD03 adapalene 6 750 8 037 7 718 7 161 6 883 1.3 494 5 309 740 340 1 493 D10AD51 tretinoin, combinations <5 741 4 942 9 127 10 804 8 738 453 47 3 036 D10AD53 adapalene, combinations 24 781 27 931 26 589 26 519 28 445 5.4 2 495 25 137 752 61 14 274 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 2 886 2 736 2 630 3 390 0.6 405 2 833 127 25 767 D10AE01 benzoyl peroxide1)2 995 2 886 2 736 2 630 3 390 0.6 405 2 833 127 25 767 D10AF Antiinfectives for treatment of acne 17 498 17 315 16 536 15 651 14 791 2.8 929 10 046 3 223 593 2 868 D10AF01 clindamycin 17 450 17 279 16 506 15 619 14 758 2.8 923 10 026 3 216 593 2 855 D10AF02 erythromycin 50 38 31 33 35 0.0 6 22 7 0 13 D10AX Other anti-acne preparations for topical use 15 685 16 600 15 938 14 338 14 562 2.8 461 8 533 4 342 1 226 3 260 D10AX03 azelaic acid 15 673 16 593 15 934 14 334 14 554 2.8 461 8 530 4 337 1 226 3 259 D10AX30 various combinations1)12 7 <5 <5 8 0.0 0 <5 5 0 2 D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE 9 255 10 676 12 523 14 285 15 925 3.0 417 14 519 926 63 40 631 D10BA Retinoids for treatment of acne 9 255 10 676 12 523 14 285 15 925 3.0 417 14 519 926 63 40 631 D10BA01 isotretinoin 9 255 10 676 12 523 14 285 15 925 3.0 417 14 519 926 63 40 631 D11 OTHER DERMATOLOGICAL PREPARATIONS 19 641 23 400 27 566 32 631 38 672 7.3 4 163 17 353 13 357 3 799 42 585 D11A OTHER DERMATOLOGICAL PREPARATIONS 19 641 23 400 27 566 32 631 38 672 7.3 4 163 17 353 13 357 3 799 42 585 D11AC Medicated shampoos 1 449 1 721 1 809 2 134 2 237 0.4 194 1 431 476 136 326 D11AC03 selenium compounds1)1 449 1 721 1 809 2 134 2 237 0.4 194 1 431 476 136 326 D11AF Wart and anti-corn preparations1)2 333 2 701 2 853 2 884 3 214 0.6 1 388 1 222 454 150 599 D11AH Agents for dermatitis, excluding corticosteroids 13 169 14 358 16 457 17 758 19 667 3.7 2 568 9 022 6 390 1 687 31 540 D11AH01 tacrolimus 8 887 9 659 10 394 10 859 11 229 2.1 1 409 5 015 3 754 1 051 5 197 D11AH02 pimecrolimus 4 224 4 571 5 746 6 543 8 054 1.5 1 249 3 942 2 272 591 3 825 D11AH04 alitretinoin 317 364 733 853 967 0.2 0 360 531 76 22 518 D11AX Other dermatologicals 2 771 4 777 6 704 10 323 14 238 2.7 40 6 012 6 306 1 880 10 120 D11AX01 minoxidil1)292 325 358 397 469 0.1 <5 271 146 50 244 D11AX10 finasteride 583 582 540 515 519 0.1 0 362 152 5 2 713 D11AX16 eflornithine 380 560 685 790 934 0.2 5 538 323 68 736 D11AX18 diclofenac 465 339 249 368 406 0.1 <5 6 152 247 442 D11AX21 brimonidine 0 1 572 2 489 1 954 1 805 0.3 <5 770 851 181 1 241 D11AX22 ivermectin 0 0 840 4 655 8 311 1.6 23 3 020 4 136 1 132 3 757 D11AX24 deoxycholic acid 0 0 0 0 <5 - 0 0 <5 0 10 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 814 970 835 075 859 359 876 600 166.1 3 888 447 213 278 099 147 400 1 164 181 G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 35 989 37 665 38 581 40 070 42 519 8.1 137 31 028 9 477 1 877 9 955 G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS 35 989 37 665 38 581 40 070 42 519 8.1 137 31 028 9 477 1 877 9 955 G01AA Antibiotics 22 040 22 764 23 982 24 308 23 450 4.4 54 17 324 5 236 836 5 591 G01AA10 clindamycin 22 040 22 764 23 982 24 308 23 450 4.4 54 17 324 5 236 836 5 591 G01AC Quinoline derivatives 0 0 11 1 928 6 558 1.2 <5 4 841 1 565 148 1 543 G01AC05 dequalinium 0 0 11 1 928 6 558 1.2 <5 4 841 1 565 148 1 543 G01AD Organic acids 7 11 15 12 10 0.0 <5 <5 6 <5 14 G01AD02 acetic acid 7 11 15 12 10 0.0 <5 <5 6 <5 14 G01AF Imidazole derivatives 15 467 16 475 16 264 15 785 15 115 2.9 80 10 882 3 172 981 2 786 G01AF01 metronidazole 7 569 7 559 7 376 6 968 6 303 1.2 9 4 518 1 526 250 877 G01AF02 clotrimazole1)6 873 7 953 8 020 7 976 7 989 1.5 59 5 811 1 480 639 1 692 G01AF05 econazole1)1 322 1 268 1 168 1 127 1 127 0.2 14 785 220 108 216 G01AX Other antiinfectives and antiseptics 9 8 9 10 8 0.0 0 <5 5 <5 21 G01AX03 policresulen 9 8 9 10 8 0.0 0 <5 5 <5 21 G02 OTHER GYNECOLOGICALS 47 703 48 836 49 294 50 823 52 144 9.9 12 44 713 7 181 238 65 087 G02A UTEROTONICS 6 9 10 7 11 0.0 0 10 <5 0 2 G02AB Ergot alkaloids 5 9 10 7 11 0.0 0 10 <5 0 2 G02AB01 methylergometrine 5 9 10 7 11 0.0 0 10 <5 0 2 G02AD Prostaglandins <5 0 0 0 0 0.0 0 0 0 0 0 G02AD02 dinoprostone <5 0 0 0 0 0.0 0 0 0 0 0 G02B CONTRACEPTIVES FOR TOPICAL USE 45 532 46 545 46 912 48 551 49 912 9.5 10 43 451 6 447 <5 62 103 G02BA Intrauterine contraceptives 25 540 27 849 28 970 31 358 34 139 6.5 8 28 333 5 794 <5 44 299 G02BA03 plastic IUD with progestogen 25 540 27 849 28 970 31 358 34 139 6.5 8 28 333 5 794 <5 44 299 G02BB Intravaginal contraceptives 20 195 19 002 18 258 17 547 16 170 3.1 <5 15 502 666 0 17 804 G02BB01 vaginal ring with progestogen and estrogen 20 195 19 002 18 258 17 547 16 170 3.1 <5 15 502 666 0 17 804 G02C OTHER GYNECOLOGICALS 2 270 2 374 2 440 2 331 2 296 0.4 <5 1 321 739 234 2 982 G02CB Prolactine inhibitors 2 270 2 310 2 279 2 315 2 293 0.4 <5 1 321 736 234 2 981 998 463 G02CB03 cabergoline 1 104 1 196 1 320 1 424 1 503 0.3 <5 835 511 156 1 855 G02CB04 quinagolide 224 215 200 206 175 0.0 0 64 94 17 664 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.9 ATC group G - Genito urinary system and sex hormones ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 0 <5 0 1 G02CX04 Cimicifugae rhizoma1)0 64 161 16 <5 - 0 0 <5 0 1 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 558 156 575 031 583 888 593 953 594 870 112.7 2 955 376 231 162 836 52 848 529 962 G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 336 365 344 874 350 587 353 941 351 197 66.6 1 642 330 427 19 118 10 186 651 G03AA Progestogens and estrogens, fixed combinations 233 755 237 366 238 563 236 034 230 419 43.7 1 211 222 771 6 432 5 117 156 G03AA07 levonorgestrel and ethinylestradiol 125 595 138 553 145 945 150 143 152 705 28.9 975 148 705 3 021 <5 54 112 G03AA09 desogestrel and ethinylestradiol 51 914 45 974 41 677 37 097 31 982 6.1 101 30 545 1 336 0 13 889 G03AA12 drospirenone and ethinylestradiol 56 408 51 713 48 901 46 233 43 520 8.3 167 41 635 1 718 0 41 847 G03AA13 norelgestromin and ethinylestradiol 8 904 9 061 8 751 8 394 7 926 1.5 14 7 562 350 0 6 239 G03AA14 nomegestrol and estradiol 1 194 1 140 1 152 1 095 1 068 0.2 <5 1 G03AB Progestogens and estrogens, sequential preparations 13 478 12 601 11 539 10 426 9 293 1.8 23 8 344 925 <5 4 361 G03AB04 norethisterone and ethinylestradiol 11 584 10 762 9 765 8 750 7 727 1.5 14 6 961 751 <5 2 622 G03AB08 dienogest and estradiol 1 921 1 860 1 796 1 694 1 577 0.3 9 1 394 174 0 1 739 G03AC Progestogens 105 909 112 335 119 624 128 200 132 116 25.0 506 119 562 12 044 <5 65 095 G03AC01 norethisterone 5 776 5 326 4 908 4 625 4 256 0.8 7 3 462 787 0 1 040 G03AC06 medroxyprogesterone 18 870 18 607 18 083 17 296 16 340 3.1 36 12 204 4 097 <5 4 174 G03AC08 etonogestrel 6 642 8 044 12 689 19 677 23 778 4.5 118 23 301 359 0 27 265 G03AC09 desogestrel 77 052 83 077 87 454 90 935 92 421 17.5 361 85 157 6 902 <5 32 616 G03AD Emergency contraceptives 241 1 091 285 151 141 0.0 8 125 8 0 39 G03AD01 levonorgestrel1)113 131 71 64 56 0.0 <5 51 <5 0 13 G03AD02 ulipristal1)129 962 216 88 85 0.0 6 74 5 0 26 G03B ANDROGENS 8 752 10 714 12 260 14 554 15 427 2.9 33 3 932 9 162 2 300 63 799 G03BA 3-oxoandrosten (4) derivatives 8 741 10 706 12 256 14 550 15 422 2.9 33 3 928 9 161 2 300 63 719 G03BA03 testosterone 8 741 10 706 12 256 14 550 15 422 2.9 33 3 928 9 161 2 300 63 719 G03BB 5-androstanon (3) derivatives 11 11 5 8 9 0.0 0 8 <5 0 80 G03BB01 mesterolone 11 11 5 8 9 0.0 0 8 <5 0 80 G03C ESTROGENS 126 359 134 122 138 248 144 129 150 015 28.4 158 6 946 96 318 46 593 117 546 G03CA Natural and semisynthetic estrogens, plain 119 654 127 204 131 606 137 669 143 976 27.3 157 6 814 91 344 45 661 108 497 G03CA01 ethinylestradiol 48 35 22 13 17 0.0 7 <5 5 <5 272 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group G ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales estradiol 109 118 044 123 113 129 932 136 672 25.9 30 6 541 89 053 41 048 104 600 G03CA04 estriol1)11 302 10 657 9 956 9 242 8 853 1.7 120 308 3 030 5 395 3 622 G03CA57 conjugated estrogens <5 6 5 <5 <5 <5 2 G03CX Other estrogens 7 534 7 896 7 503 7 301 6 897 1.3 <5 177 5 682 1 036 9 049 G03CX01 tibolone 7 534 7 896 7 503 7 301 6 897 1.3 <5 177 5 682 1 036 9 049 G03D PROGESTOGENS 41 850 40 263 38 820 38 079 39 183 7.4 1 137 28 178 9 682 186 25 078 G03DA Pregnen (4) derivatives 14 386 15 007 15 505 15 875 16 568 3.1 27 11 774 4 593 174 22 407 G03DA02 medroxyprogesterone 6 590 6 557 6 510 6 469 6 869 1.3 27 3 747 2 998 97 1 315 G03DA04 progesterone 7 929 8 612 9 172 9 584 9 934 1.9 0 8 223 1 634 77 21 091 G03DB Pregnadien derivatives 159 169 172 191 241 0.1 <5 208 32 0 583 G03DB01 dydrogesterone 0 0 0 0 64 0.0 0 63 <5 0 66 G03DB06 chlormadinone 0 0 <5 <5 0 0.0 0 0 0 0 0 G03DB08 dienogest 159 169 171 190 177 0.0 <5 145 31 0 517 G03DC Estren derivatives 28 086 25 847 23 943 22 767 23 274 4.4 1 113 16 957 5 191 13 2 089 G03DC02 norethisterone 28 086 25 847 23 943 22 767 23 274 4.4 1 113 16 957 5 191 13 2 089 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 41 341 43 978 42 973 42 769 41 514 7.9 <5 2 661 34 800 4 051 35 946 G03FA Progestogens and estrogens, fixed combinations 32 658 34 657 33 672 33 661 32 749 6.2 <5 752 28 104 3 891 29 870 G03FA01 norethisterone and estrogen 31 956 33 829 32 779 32 742 31 823 6.0 <5 693 773 G03FA12 medroxyprogesterone and estrogen 801 954 997 1 014 1 027 0.2 0 61 893 73 1 097 G03FB Progestogens and estrogens, sequential preparations 671 10 426 10 358 10 196 9 801 1.9 0 1 978 7 659 164 6 076 G03FB05 norethisterone and estrogen 9 671 10 426 10 358 10 196 9 801 1.9 0 1 978 7 659 164 6 076 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 10 334 10 411 10 672 10 733 9 047 1.7 0 8 604 430 13 83 490 G03GA Gonadotropins 6 317 6 475 6 933 7 143 7 587 1.4 0 7 310 271 6 82 138 G03GA01 chorionic gonadotrophin 1 143 990 655 639 736 0.1 0 560 170 6 428 G03GA02 human menopausal gonadotrophin 2 101 2 220 2 494 2 832 2 849 0.5 0 2 789 60 0 27 629 G03GA04 urofollitropin 268 461 81 5 <5 - 0 <5 0 0 8 G03GA05 follitropin alfa 1 926 2 004 2 628 2 812 3 532 0.7 0 3 478 54 0 34 456 G03GA06 follitropin beta 2 335 2 039 2 000 2 086 1 324 0.3 0 1 311 13 0 9 985 G03GA07 lutropin alfa 9 8 <5 0 0 0.0 0 0 0 0 0 G03GA08 choriogonadotropin alfa 5 007 5 308 6 007 6 240 6 467 1.2 0 6 375 92 0 3 698 G03GA09 corifollitropin alfa 323 289 313 352 486 0.1 0 473 13 0 3 756 G03GA10 follitropin delta 0 0 0 0 98 0.0 0 98 0 0 978 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group G ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 92G03GA30 combinations 8 28 69 34 96 0.0 0 95 <5 0 1 200 G03GB Ovulation stimulants, synthetic 5 048 4 883 4 732 4 489 1 935 0.4 0 1 739 189 7 1 351 G03GB02 clomifene 5 048 4 883 4 732 4 489 1 935 0.4 0 1 739 189 7 1 351 G03H ANTIANDROGENS 17 481 15 961 15 321 14 968 14 553 2.8 101 13 936 453 63 6 585 G03HA Antiandrogens, plain 175 160 199 221 255 0.1 0 146 47 62 640 G03HA01 cyproterone 175 160 199 221 255 0.1 0 146 47 62 640 G03HB Antiandrogens and estrogens 17 309 15 802 15 127 14 749 14 301 2.7 101 13 793 406 <5 5 945 G03HB01 cyproterone and estrogen 17 309 15 802 15 127 14 749 14 301 2.7 101 13 793 406 <5 5 945 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 767 838 1 346 1 903 2 062 0.4 <5 738 1 124 199 10 866 G03XA Antigonadotropins and similar agents 53 57 42 46 46 0.0 <5 14 21 10 199 G03XA01 danazol 53 57 42 46 46 0.0 <5 14 21 10 199 G03XB Progesterone receptor modulators 15 255 965 1 559 1 766 0.3 0 724 1 041 <5 9 962 G03XB01 mifepristone 0 0 0 0 0 1 G03XB02 ulipristal 15 255 961 1 557 1 765 0.3 0 724 1 040 <5 9 961 G03XC Selective estrogen receptor modulators 699 526 339 298 250 0.1 0 0 62 188 706 G03XC01 raloxifene 699 526 339 298 250 0.1 0 0 62 188 706 G04 UROLOGICALS 185 262 198 294 210 558 224 501 239 837 45.5 806 24 678 113 260 101 093 559 177 G04B UROLOGICALS 128 788 136 885 144 559 154 260 165 502 31.4 806 21 338 87 899 Drugs for urinary frequency and incontinence 52 117 56 111 59 253 62 109 65 824 12.5 757 6 007 25 301 33 759 206 057 G04BD04 oxybutynin 1 468 1 624 1 881 2 364 2 839 0.5 161 1 536 736 406 14 080 G04BD07 tolterodine 11 304 9 815 8 622 7 939 7 389 1.4 374 397 2 368 4 250 15 597 G04BD08 solifenacin 20 910 18 606 17 575 17 047 16 400 3.1 242 1 089 6 368 8 701 46 797 G04BD10 darifenacin 3 475 2 862 2 453 2 187 2 011 0.4 <5 87 713 1 207 6 067 G04BD11 fesoterodine 13 441 11 256 10 029 9 437 8 942 1.7 <5 541 3 616 4 783 28 156 G04BD12 mirabegron 6 735 17 823 24 298 28 867 34 219 6.5 25 2 813 13 822 17 559 95 359 G04BE Drugs used in erectile dysfunction 78 488 82 779 87 397 94 327 101 982 19.3 42 15 320 63 843 22 777 240 653 G04BE01 alprostadil 2 893 3 165 3 134 3 169 3 091 0.6 0 144 1 748 1 199 5 866 G04BE03 sildenafil 35 222 36 589 39 748 44 279 49 803 9.4 42 7 559 30 694 11 508 68 644 G04BE04 yohimbine 11 11 <5 0 0 0.0 0 0 0 0 0 G04BE08 tadalafil 40 063 43 262 45 286 48 390 50 838 9.6 0 8 033 32 599 10 206 150 526 G04BE09 vardenafil 8 785 8 321 8 096 8 256 8 188 1.6 0 990 5 246 1 952 13 773ATC group G ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales avanafil 0 0 0 0 286 0.1 0 39 193 54 149 G04BE30 combinations 293 326 333 403 636 0.1 0 27 412 197 1 695 G04BX Other urologicals 23 37 55 169 317 0.1 <5 207 97 9 285 G04BX01 magnesium hydroxide 19 20 14 23 <5 0 18 G04BX14 dapoxetine 0 13 37 139 294 0.1 0 <5 180 DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 66 317 72 725 78 573 83 917 89 368 16.9 0 3 627 31 637 54 104 112 132 G04CA Alpha-adrenoreceptor antagonists 53 898 60 216 66 020 71 252 76 632 14.5 0 1 849 29 016 45 767 93 176 G04CA01 alfuzosin 48 16 27 28 23 0.0 0 0 9 14 52 G04CA02 tamsulosin 45 144 47 791 50 318 52 615 55 027 10.4 0 1 746 22 424 30 857 41 283 G04CA03 terazosin 601 547 502 509 421 0.1 0 47 168 206 387 G04CA52 tamsulosin and dutasteride 10 799 14 946 18 363 21 617 24 463 4.6 0 47 7 628 16 788 49 623 G04CA53 tamsulosin and solifenacin 0 0 25 348 703 0.1 0 21 311 371 1 830 G04CB Testosterone-5-alpha reductase inhibitors 18 209 17 815 17 547 17 492 17 414 3.3 0 1 788 3 752 11 874 18 956 G04CB01 finasteride 17 016 16 774 16 639 16 687 16 763 3.2 0 1 752 3 625 11 386 17 137 G04CB02 dutasteride 1 258 1 098 962 846 686 0.1 0 47 134 505 1 819ATC group G ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales EXCL. SEX HORMONES AND INSULINS 422 537 437 511 445 510 452 531 463 794 87.9 17 922 114 393 196 870 134 609 512 630 H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 25 586 26 356 26 936 26 687 27 881 5.3 9 853 14 462 2 027 1 539 289 967 H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 1 975 2 027 2 079 2 091 2 133 0.4 1 151 606 320 88 H01AB Thyrotropin 16 0 0 <5 0 0.0 0 0 0 0 0 H01AB01 thyrotropin alfa 16 0 0 <5 0 0.0 0 0 0 0 0 H01AC Somatropin and somatropin agonists 1 928 1 995 2 042 2 048 2 087 0.4 1 148 595 294 50 75 244 H01AC01 somatropin 1 928 1 995 2 042 2 046 2 083 0.4 1 147 592 294 50 74 861 H01AC03 mecasermin 0 0 0 <5 6 0.0 383 H01AX Other anterior pituitary lobe hormones and analogues 30 32 35 40 42 0.0 0 10 26 6 12 832 H01AX01 pegvisomant 30 32 35 40 42 0.0 0 10 26 6 12 832 H01B POSTERIOR PITUITARY LOBE HORMONES 19 133 18 980 18 918 18 399 19 303 3.7 8 741 8 236 1 216 1 110 49 014 H01BA Vasopressin and analogues 11 257 11 736 11 854 11 662 11 983 2.3 8 688 1 041 1 148 1 106 47 371 H01BA02 desmopressin 11 257 11 736 11 854 11 662 11 982 2.3 8 688 1 041 1 148 1 105 47 344 H01BA04 terlipressin 0 0 0 0 <5 - 0 0 0 <5 27 H01BB Oxytocin and analogues 7 878 7 249 7 066 6 737 7 320 1.4 53 7 195 68 <5 1 643 H01BB02 oxytocin 7 878 7 249 7 066 6 737 7 320 1.4 53 7 195 68 <5 1 643 H01C HYPOTHALAMIC HORMONES 4 737 5 608 6 197 6 487 6 745 1.3 10 5 775 576 384 152 856 H01CA Gonadotropin-releasing hormones 2 337 2 833 3 031 2 954 2 632 0.5 <5 2 603 28 0 5 993 H01CA02 nafarelin 2 337 2 833 3 031 2 954 2 632 0.5 <5 2 603 28 0 5 993 H01CB Somatostatin and analogues 751 830 895 927 944 0.2 9 61 490 384 134 860 H01CB02 octreotide 569 603 638 616 <5 44 320 252 74 817 H01CB03 lanreotide 204 248 291 329 351 0.1 9 17 180 145 56 861 H01CB05 pasireotide <5 <5 5 5 11 0.0 0 <5 7 <5 3 181 H01CC Anti-gonadotropin-releasing hormones 1 934 2 304 2 686 3 082 3 650 0.7 0 3 586 64 0 12 004 H01CC01 ganirelix 1 504 2 075 2 608 3 011 3 071 0.6 0 3 014 57 0 9 730 H01CC02 cetrorelix 451 286 109 143 753 0.1 0 743 10 0 2 274 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 216 737 227 420 231 199 233 848 240 224 45.5 5 835 62 161 100 628 71 600 78 8163.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales PLAIN 216 497 227 187 230 961 233 616 240 195 45.5 5 835 62 158 100 609 71 593 78 802 H02AA Mineralocorticoids 1 367 1 403 1 442 1 490 1 546 0.3 93 457 654 342 455 H02AA02 fludrocortisone 1 367 1 403 1 442 1 490 1 546 0.3 93 457 654 342 455 H02AB Glucocorticoids 216 331 227 005 230 772 233 414 239 986 45.5 5 828 62 121 100 549 71 488 78 347 H02AB01 betamethasone 1 988 2 307 2 651 2 982 3 476 0.7 1 987 514 739 236 833 H02AB02 dexamethasone 3 485 5 508 7 265 8 837 10 446 2.0 323 991 5 243 3 889 15 319 H02AB04 methylprednisolone 11 015 10 306 9 767 9 093 7 919 1.5 32 1 641 3 873 2 373 2 884 H02AB06 prednisolone 168 968 174 044 177 337 181 260 187 335 35.5 3 020 41 433 78 998 63 884 33 691 H02AB07 prednisone 347 330 303 294 268 0.1 0 37 98 133 821 H02AB08 triamcinolone 34 019 38 537 37 520 35 086 34 710 6.6 356 18 117 13 656 2 581 5 340 H02AB09 hydrocortisone 637 683 700 827 948 0.2 89 340 432 87 12 526 H02AB10 cortisone 2 820 2 905 3 006 3 130 3 254 0.6 107 808 1 501 838 6 610 H02AB13 deflazacort 26 36 45 51 55 0.0 29 16 5 5 324 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS 386 416 418 402 107 0.0 0 11 59 37 15 H02BX Corticosteroids for systemic use, combinations 386 416 418 402 107 0.0 0 11 59 37 15 H02BX01 methylprednisolone, combinations 386 416 418 402 107 0.0 0 11 59 37 15 H03 THYROID THERAPY 197 795 202 576 207 060 212 089 216 620 41.1 1 359 40 237 103 533 71 491 92 629 H03A THYROID PREPARATIONS 193 254 197 828 202 208 207 170 211 335 40.1 1 325 38 702 101 212 70 096 85 431 H03AA Thyroid hormones 193 254 197 828 202 208 207 170 211 335 40.1 1 325 38 702 101 212 70 096 85 431 H03AA01 levothyroxine sodium 192 528 196 793 200 932 205 630 209 382 39.7 1 318 38 096 99 994 69 974 65 230 H03AA02 liothyronine sodium 4 750 5 361 6 206 7 273 8 412 1.6 19 2 457 5 066 870 6 116 H03AA03 combinations of levothyroxine gland preparations 1 196 1 828 2 656 3 407 4 144 0.8 <5 1 325 2 596 219 14 080 H03B ANTITHYROID PREPARATIONS 6 398 6 713 6 923 7 103 7 525 1.4 61 2 384 3 399 1 681 7 194 H03BA Thiouracils 581 733 629 557 581 733 629 58 609 H03BB Sulfur-containing imidazole derivatives 6 039 6 239 6 483 6 729 7 157 1.4 59 2 228 3 234 1 636 6 586 H03BB01 carbimazole 6 039 6 239 6 483 6 729 7 157 1.4 59 2 228 3 234 1 636 6 586 H03C IODINE THERAPY <5 6 12 7 <5 - 0 <5 0 <5 3 H03CA Iodine therapy <5 6 12 <5 - 0 <5 0 <5 3 H04 PANCREATIC HORMONES 5 688 5 495 5 398 5 588 5 427 1.0 1 185 2 358 1 479 405 2 208ATC group H ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 495 5 398 5 588 5 427 1.0 1 185 2 358 1 479 405 2 208 H04AA Glycogenolytic hormones 5 688 5 495 5 398 5 588 5 427 1.0 1 185 2 358 1 479 405 2 208 H04AA01 glucagon 5 688 5 495 5 398 5 588 5 427 1.0 1 185 2 358 1 479 405 2 208 H05 CALCIUM HOMEOSTASIS 1 224 1 375 1 559 1 827 2 096 0.4 0 160 990 946 49 007 H05A PARATHYROID HORMONES AND ANALOGUES 468 608 720 931 1 151 0.2 0 78 623 450 36 179 H05AA Parathyroid hormones and analogues 468 608 720 931 1 151 0.2 0 78 623 450 36 179 H05AA02 teriparatide 467 608 720 931 1 151 0.2 0 78 623 450 35 700 H05AA03 parathyroid hormone <5 0 0 0 <5 - 0 0 <5 0 479 H05B ANTI-PARATHYROID AGENTS 756 767 839 896 945 0.2 0 82 367 496 12 828 H05BA Calcitonin preparations 21 16 8 7 8 0.0 0 0 <5 <5 80 H05BA01 calcitonin (salmon synthetic) 21 16 8 7 8 0.0 0 0 <5 <5 80 H05BX Other anti-parathyroid agents 735 751 831 0.2 0 82 363 492 12 748 H05BX01 cinacalcet 525 520 569 615 674 0.1 0 45 242 387 8 605 H05BX02 paricalcitol 284 289 309 341 333 0.1 0 47 156 130 4 143ATC group H ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales ANTIINFECTIVES FOR SYSTEMIC USE 1 288 914 1 252 912 1 239 437 1 209 403 1 177 724 223.2 127 743 457 401 381 958 210 622 1 501 250 J01 ANTIBACTERIALS FOR SYSTEMIC USE 1 195 320 1 172 061 1 151 022 1 109 722 1 063 315 201.5 121 674 405 823 342 861 192 957 298 886 J01A TETRACYCLINES 187 918 179 821 181 376 168 809 159 385 30.2 2 429 81 634 51 481 23 841 31 885 J01AA Tetracyclines 187 918 179 821 181 376 168 809 159 385 30.2 2 429 81 634 51 481 23 841 31 885 J01AA02 doxycycline 145 943 138 206 141 612 131 272 122 266 23.2 1 210 54 889 43 818 22 349 19 022 J01AA04 lymecycline 23 686 24 963 24 562 23 337 24 396 4.6 852 18 258 4 539 747 9 108 J01AA06 oxytetracycline 10 32 21 30 26 0.0 <5 9 16 0 9 J01AA07 tetracycline 20 959 19 709 18 062 16 804 15 267 2.9 412 10 244 3 754 857 3 710 J01AA08 minocycline 240 95 56 35 28 0.0 0 8 6 36 J01AA12 tigecycline <5 <5 <5 <5 0 0.0 0 0 0 J01B AMPHENICOLS 0 0 0 <5 0 0.0 0 0 0 0 0 J01BA Amphenicols 0 0 0 <5 0 0.0 0 0 0 0 0 J01BA01 chloramphenicol 0 0 0 <5 0 0.0 0 0 0 0 0 J01C BETA-LACTAM ANTI- BACTERIALS, PENICILLINS 774 820 774 578 769 300 750 891 730 187 138.4 91 513 271 347 231 051 136 276 134 989 J01CA Penicillins with extended spectrum 321 225 323 045 319 427 311 008 298 397 56.6 23 937 92 647 100 180 81 633 57 128 J01CA01 ampicillin 57 46 49 62 54 0.0 <5 6 20 27 68 J01CA04 amoxicillin 134 844 133 023 132 453 125 992 119 990 22.7 19 930 27 151 41 750 31 159 18 257 J01CA08 pivmecillinam 200 464 203 727 200 845 198 004 190 781 36.2 4 248 67 899 62 699 55 935 38 764 J01CA11 mecillinam 8 11 10 16 18 0.0 <5 <5 10 6 39 J01CE Beta-lactamase sensitive penicillins 438 658 421 779 417 056 404 417 394 483 74.8 67 896 158 497 116 722 51 368 53 769 J01CE01 benzylpenicillin 103 127 120 149 166 0.0 <5 61 88 196 J01CE02 phenoxymethylpenicillin 438 344 74.7 67 893 158 463 116 667 51 321 53 291 J01CE08 benzathine benzylpenicillin 112 82 87 60 57 0.0 <5 32 18 <5 282 J01CF Beta-lactamase resistant penicillins 87 628 104 462 105 979 105 128 103 589 19.6 5 369 42 368 35 887 19 965 22 566 J01CF01 dicloxacillin 81 161 101 196 104 231 103 820 103 272 19.6 5 265 42 296 35 815 19 896 22 068 J01CF02 cloxacillin 8 105 3 964 2 210 1 624 379 0.1 61 97 123 98 302 J01CF05 flucloxacillin 28 22 29 47 66 0.0 62 <5 0 <5 195 J01CR Combinations of penicillins, 434 770 1 017 1 0.3 868 164 1 amoxicillin beta- J01CR05 piperacillin and beta- lactamase inhibitor 53 53 79 104 66 0.0 <5 11 23 31 264 J01D OTHER BETA-LACTAM ANTIBACTERIALS 22 070 19 475 17 367 14 827 13 449 2.6 2 040 4 818 4 366 2 225 6 5313.11 ATC group J - Antiinfectives for systemic use ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 18 026 16 071 13 968 12 546 2.4 1 969 4 480 4 083 2 014 1 966 J01DB01 cefalexin 20 940 18 012 16 055 13 951 12 529 2.4 1 969 4 473 4 080 2 007 1 949 J01DB03 cefalotin 9 15 16 19 17 0.0 0 7 <5 7 18 J01DC Second-generation cephalosporins 98 78 93 97 72 0.0 <5 <5 22 45 61 J01DC02 cefuroxime 98 78 93 97 72 0.0 <5 <5 22 45 61 J01DD Third-generation cephalosporins 1 010 1 373 1 172 740 785 0.2 71 323 240 151 2 366 J01DD01 cefotaxime 703 1 054 790 363 305 0.1 <5 110 125 67 652 J01DD02 ceftazidime 73 77 69 68 75 0.0 11 30 19 15 524 J01DD04 ceftriaxone 238 244 313 312 412 0.1 57 186 99 70 1 190 J01DF Monobactams 10 13 14 13 16 0.0 <5 9 <5 <5 801 J01DF01 aztreonam <5 <5 801 J01DH Carbapenems 85 65 86 73 86 0.0 <5 25 25 34 1 143 J01DH02 meropenem 62 49 49 58 63 0.0 <5 20 18 24 674 J01DH03 ertapenem 17 16 32 10 21 0.0 0 5 6 10 352 J01DH51 imipenem and cilastatin 0 0 0 <5 - 0 0 0 194 J01DI54 ceftolozane and beta- lactamase inhibitor 0 0 0 0 0 0 194 J01E SULFONAMIDES AND TRIMETHOPRIM 116 722 121 251 121 068 121 722 121 434 23.0 12 527 30 180 41 081 37 646 13 786 J01EA Trimethoprim and derivatives 78 689 76 472 72 142 69 823 68 123 12.9 7 299 18 100 21 375 21 349 5 935 J01EA01 trimethoprim 78 689 76 472 72 142 69 823 68 123 12.9 7 299 18 100 21 375 21 349 5 935 J01EC Intermediate-acting sulfonamides 0 0 0 <5 9 0.0 0 <5 <5 15 J01EC02 sulfadiazine 0 0 0 <5 9 6 15 J01EE sulfon- amides and trimethoprim, incl. derivatives 42 790 49 930 54 153 57 183 58 807 11.1 5 697 12 966 21 394 18 750 7 836 J01EE01 sulfamethoxazole and trimethoprim 42 790 49 930 54 153 57 183 58 807 11.1 5 697 12 966 21 394 18 750 7 836 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 296 217 006 187 736 35.6 26 987 77 748 61 776 21 225 32 767 J01FA Macrolides 238 975 212 200 190 231 168 977 145 999 27.7 23 084 61 743 46 570 14 602 23 337 J01FA01 erythromycin 120 963 110 826 101 160 92 247 82 929 15.7 19 363 30 200 24 745 8 621 12 671 J01FA02 spiramycin 2 018 1 863 1 652 1 307 1 065 0.2 18 356 515 176 174 J01FA06 roxithromycin <5 5 <5 <5 3 J01FA09 clarithromycin 34 941 29 173 24 069 18 856 15 730 3.0 1 504 5 882 6 058 2 286 2 994ATC group J 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 77 639 69 386 61 238 49 933 9.5 2 589 26 896 16 575 3 873 7 496 J01FA15 telithromycin 6 <5 <5 0 0 0.0 0 0 0 0 0 J01FF Lincosamides 66 378 63 250 59 149 53 932 46 587 8.8 4 415 18 046 16 911 7 215 9 430 J01FF01 clindamycin 66 378 63 250 59 149 53 932 46 587 8.8 4 415 18 046 16 911 7 215 9 430 J01G AMINOGLYCOSIDE ANTIBACTERIALS 242 258 214 216 222 0.0 48 100 49 25 9 034 J01GA Streptomycins <5 <5 0 <5 0 J01GA01 streptomycin <5 <5 0 <5 0 0.0 0 0 0 0 0 J01GB Other aminoglycosides 241 257 214 215 222 0.0 48 100 49 25 9 034 J01GB01 tobramycin 211 213 177 168 172 0.0 42 82 29 19 6 427 J01GB03 gentamicin 21 34 24 32 32 0.0 5 8 13 6 1 234 J01GB06 amikacin 9 11 13 15 20 0.0 <5 11 7 0 1 373 J01M QUINOLONE ANTIBACTERIALS 68 203 65 117 58 858 53 197 45 649 8.7 384 11 168 18 479 15 618 12 009 J01MA Fluoroquinolones 68 203 65 117 58 858 53 197 45 649 8.7 384 11 168 18 479 15 618 12 009 J01MA01 ofloxacin 1 647 1 496 1 312 1 083 941 0.2 <5 243 414 283 308 J01MA02 ciprofloxacin 66 556 63 320 56 847 51 047 43 221 8.2 381 9 430 18 041 15 369 10 125 J01MA12 levofloxacin 18 29 21 24 60 0.0 <5 27 24 8 306 J01MA14 moxifloxacin 290 547 939 1 247 1 600 0.3 <5 1 519 70 10 1 269 J01X OTHER ANTIBACTERIALS 61 581 63 139 64 278 65 539 66 806 12.7 1 153 11 691 23 001 30 961 57 885 J01XA Glycopeptide antibacterials 29 31 44 47 43 0.0 8 8 15 12 349 J01XA01 vancomycin 28 30 44 47 42 0.0 8 7 15 12 340 J01XA02 teicoplanin <5 <5 0 0 <5 - 0 <5 0 0 9 J01XB Polymyxins 79 88 94 111 111 0.0 6 60 34 11 3 812 J01XB01 colistin 79 88 94 111 111 0.0 6 60 34 11 3 812 J01XC Steroid antibacterials 646 481 411 346 326 0.1 18 107 112 89 272 J01XC01 fusidic acid 646 481 411 346 326 0.1 18 107 112 89 272 J01XD Imidazole derivatives 28 30 34 30 27 0.0 0 <5 16 9 75 J01XD01 metronidazole 28 30 34 30 27 0.0 0 <5 16 9 75 J01XE Nitrofuran derivatives 36 821 36 895 36 527 36 830 37 003 7.0 1 025 8 426 13 012 14 540 4 333 J01XE01 nitrofurantoin 36 821 36 895 36 527 36 830 37 003 7.0 1 025 8 426 13 012 14 540 4 333 J01XX Other antibacterials 29 569 31 554 33 306 34 356 35 522 6.7 134 3 844 11 909 19 635 49 044 J01XX01 fosfomycin 6 7 19 19 30 0.0 0 10 7 13 143 J01XX05 methenamine 29 300 31 313 33 030 34 039 35 183 6.7 134 3 791 11 765 19 493 41 481 J01XX08 linezolid 273 250 275 305 314 0.1 0 137 135 4 751 J01XX09 daptomycin <5 0 <5 0 0 0.0 0 0 0 0 0 J01XX11 tedizolid 0 0 0 9 18 0.0 0 <5 11 5 2 669ATC group J ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales USE 48 187 48 649 47 203 43 725 41 387 7.8 442 25 356 12 071 3 518 31 208 J02A ANTIMYCOTICS FOR SYSTEMIC USE 48 187 48 649 47 203 43 725 41 387 7.8 442 25 356 12 071 3 <5 199 J02AB Imidazole derivatives 1 716 0 25 11 8 0.0 0 5 <5 0 281 J02AB02 ketoconazole 1 716 0 25 11 8 0.0 0 5 <5 0 281 J02AC Triazole derivatives 46 571 48 646 47 180 43 708 41 371 7.8 441 25 350 12 067 3 513 29 559 J02AC01 fluconazole1)46 203 48 145 46 746 43 304 41 008 7.8 433 25 184 11 925 3 466 17 323 J02AC02 itraconazole 576 703 526 401 365 0.1 <5 218 116 30 697 J02AC03 voriconazole 87 85 103 105 97 0.0 <5 22 45 26 3 987 J02AC04 posaconazole 63 85 101 120 106 0.0 8 28 61 9 7 322 J02AC05 isavuconazole 0 0 0 0 <5 - 0 <5 <5 <5 230 J02AX Other antimycotics for systemic use 7 5 8 10 10 0.0 0 <5 <5 <5 639 J04 ANTIMYCOBACTERIALS 1 980 2 105 1 792 1 971 1 998 0.4 183 778 637 400 8 008 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 1 524 1 636 1 347 1 496 1 517 0.3 171 674 404 268 7 607 J04AA Aminosalicylic acid and derivatives 0 0 <5 <5 0 0.0 0 0 0 0 0 J04AA01 4-aminosalicylic acid 0 0 <5 <5 0 0.0 0 0 0 0 0 J04AB Antibiotics 563 656 636 940 1 031 0.2 156 366 278 231 4 402 J04AB01 cycloserine 0 0 12 13 12 0.0 0 8 <5 0 903 J04AB02 rifampicin 555 644 583 651 696 0.1 82 160 226 228 1 245 J04AB04 rifabutin 9 12 5 6 11 0.0 0 <5 6 <5 274 J04AB05 rifapentine 0 0 36 272 319 0.1 78 195 44 <5 1 980 J04AB30 capreomycin 0 0 0 <5 0 0.0 0 0 0 0 0 J04AC Hydrazides 95 78 115 336 378 0.1 84 219 64 11 361 J04AC01 isoniazid 95 78 115 336 378 0.1 84 219 64 11 361 J04AD Thiocarbamide derivatives 0 0 6 6 11 0.0 0 8 <5 0 153 J04AD01 protionamide 0 0 6 6 11 0.0 0 8 <5 0 153 J04AK Other drugs for treatment of tuberculosis 318 291 233 204 177 0.0 12 81 45 39 995 J04AK01 pyrazinamide 68 58 41 46 40 0.0 11 22 <5 5 81 J04AK02 ethambutol 304 273 219 181 162 0.0 6 74 45 37 672ATC group J ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales in 1000 NOK<15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2018:2 Folkehelseinstituttet 101J04AK05 bedaquiline 0 <5 0 0 <5 0 242 J04AM Combinations of drugs for treatment of tuberculosis 917 976 678 529 471 0.1 17 307 114 33 1 694 J04AM02 rifampicin and isoniazid 856 915 636 466 420 0.1 15 270 107 28 1 134 J04AM05 rifampicin, pyrazinamide and isoniazid 225 178 129 126 95 <5 64 21 8 208 J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid 14 53 68 101 128 0.0 5 86 28 9 352 J04B DRUGS FOR TREATMENT OF LEPRA 457 470 448 475 485 0.1 12 106 235 132 401 J04BA Drugs for treatment of lepra 457 470 448 475 485 0.1 12 106 235 132 401 J04BA01 clofazimine 0 0 <5 5 9 0.0 <5 <5 <5 0 44 J04BA02 dapsone 457 470 445 470 476 0.1 10 102 232 132 357 J05 ANTIVIRALS FOR YSTEMIC USE 39 342 39 587 43 664 48 150 53 194 10.1 816 26 089 19 800 6 489 1 013 184 J05A DIRECT ACTING ANTIVIRALS 39 342 39 587 43 664 48 150 53 194 10.1 816 26 089 19 800 6 489 1 013 184 J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 31 271 33 914 37 004 40 201 43 852 8.3 721 21 843 15 366 5 922 45 447 J05AB01 aciclovir 12 598 12 720 13 191 13 449 13 519 2.6 480 7 168 4 470 1 5 valaciclovir 18 985 21 583 24 257 27 263 30 907 5.9 243 15 175 10 976 4 513 27 681 J05AB14 valganciclovir 365 379 371 377 439 0.1 18 103 241 77 11 877 J05AD Phosphonic acid derivatives <5 <5 <5 0 0 0 0 0 J05AD01 foscarnet <5 <5 <5 0 0 0.0 0 0 0 0 0 J05AE Protease inhibitors 1 307 1 339 1 064 772 508 0.1 <5 250 243 13 22 505 J05AE01 saquinavir 7 5 <5 63 J05AE03 ritonavir 963 1 004 811 605 399 0.1 <5 203 183 11 1 511 J05AE07 fosamprenavir <5 0 0 0 0 0.0 0 0 0 0 0 J05AE08 atazanavir 1 140 1 121 850 573 353 0.1 <5 173 172 6 14 616 J05AE10 darunavir 177 228 218 200 148 0.0 0 74 67 7 6 316 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 587 663 778 21 494 539 41 30 829 J05AF01 zidovudine 36 21 15 14 19 0.0 8 <5 9 0 79 J05AF02 didanosine 15 11 5 0 0 0.0 0 0 0 0 0 J05AF05 lamivudine 100 89 94 84 75 0.0 13 14 41 7 806 J05AF06 abacavir 66 58 67 67 58 0.0 13 12 29 <5 1 651 J05AF07 tenofovir disoproxil 297 355 421 13 8 099 J05AF08 adefovir dipivoxil 10 10 9 6 5 0.0 0 <5 <5 0 272ATC group J 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 0 <5 0 50 J05AF10 entecavir 175 210 271 343 410 0.1 0 168 223 19 16 495 J05AF11 telbivudine <5 <5 <5 <5 0 0 J05AF13 tenofovir alafenamide 0 0 0 0 121 0.0 0 60 56 5 3 376 J05AG Non-nucleoside reverse transcriptase inhibitors 398 346 307 246 197 0.0 6 58 120 13 4 994 J05AG01 nevirapine 164 158 147 126 99 0.0 <5 34 56 7 2 365 J05AG03 efavirenz 192 147 119 76 46 0.0 <5 9 28 5 1 081 J05AG04 etravirine 35 31 29 28 24 0.0 0 8 16 0 823 J05AG05 rilpivirine 12 15 14 19 31 0.0 0 7 23 <5 724 J05AH Neuraminidase inhibitors 3 993 1 098 1 528 2 153 1 923 0.4 64 717 759 383 495 J05AH01 zanamivir 85 18 52 25 0 0.0 0 0 0 0 0 J05AH02 oseltamivir 3 911 1 080 1 477 2 129 1 923 0.4 64 717 759 383 495 J05AP Antivirals for treatment of HCV infections 790 799 1 037 1 175 1 955 0.4 <5 753 1 178 23 477 516 J05AP01 ribavirin 785 696 561 754 <5 3 963 J05AP02 telaprevir 85 25 0 0 0 0.0 0 0 0 0 0 J05AP03 boceprevir 161 61 <5 0 0 0.0 0 0 0 0 0 J05AP05 simeprevir 0 94 69 5 <5 - 0 0 <5 0 533 J05AP07 daclatasvir 0 32 129 235 47 0.0 0 13 34 0 9 049 J05AP08 sofosbuvir 0 450 360 384 101 0.0 0 27 73 <5 36 788 J05AP09 dasabuvir 0 0 12 299 105 0.0 0 41 61 <5 1 244 J05AP51 sofosbuvir and ledipasvir 0 0 534 312 29 0.0 0 6 22 <5 11 073 J05AP53 ombitasvir, paritaprevir and ritonavir 0 0 13 312 107 0.0 0 41 63 <5 14 296 J05AP54 elbasvir and grazoprevir 0 0 0 0 1 152 0.2 0 488 651 13 125 115 J05AP55 sofosbuvir and velpatasvir 0 0 0 51 504 0.1 0 135 366 <5 274 685 J05AP56 sofosbuvir, velpatasvir and voxilaprevir 0 0 0 0 <5 0 0 0 <5 606 J05AP57 glecaprevir and pibrentasvir 0 0 0 0 <5 - 0 0 0 <5 162 J05AR Antivirals for treatment of HIV infections, combinations 3 043 3 369 3 638 4 082 4 821 0.9 17 2 2 208 140 398 594 J05AR01 zidovudine and lamivudine 249 181 130 21 38 <5 1 873 J05AR02 lamivudine and abacavir 376 424 307 195 131 0.0 5 52 68 6 4 349 J05AR03 tenofovir disoproxil and emtricitabine 1 526 1 589 1 536 1 454 1 627 0.3 <5 1 109 498 18 45 444 J05AR04 zidovudine, lamivudine and abacavir 17 12 11 295 789 732 649 467 0.1 0 188 265 14 36 107ATC group J ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 576 600 324 0.1 0 165 151 8 21 467 J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat 33 135 265 259 104 0.0 0 47 55 <5 8 074 J05AR10 lopinavir and ritonavir 401 298 212 145 89 0.0 5 34 46 <5 3 068 J05AR13 lamivudine, abacavir and dolutegravir 0 91 610 968 1 200 0.2 5 497 643 55 121 498 J05AR14 darunavir and cobicistat 0 0 17 48 83 0.0 0 36 46 <5 3 555 J05AR15 atazanavir and cobicistat 0 0 <5 7 <5 0 247 J05AR17 emtricitabine and tenofovir alafenamide 0 0 0 95 329 0.1 0 116 195 18 15 806 J05AR18 emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat 0 0 0 482 891 0.2 <5 404 457 28 91 716 J05AR19 emtricitabine, tenofovir alafenamide and rilpivirine 0 0 0 0 244 289 15 45 095 J05AX Other antivirals 379 601 743 836 839 0.2 9 475 336 19 32 806 J05AX05 inosine pranobex 45 40 25 18 13 0.0 <5 5 6 <5 78 J05AX08 raltegravir 333 470 580 638 583 0.1 8 373 189 13 17 417 J05AX09 maraviroc 8 8 8 7 6 0.0 0 <5 <5 0 458 J05AX12 dolutegravir 0 105 143 194 246 0.1 <5 96 144 5 14 852ATC group J ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales AGENTS 90 729 95 220 99 426 104 942 111 469 21.1 1 512 25 218 51 335 33 404 4 028 825 L02 ENDOCRINE THERAPY 26 900 26 977 27 821 28 869 31 639 6.0 184 5 507 10 615 15 333 394 631 L02A HORMONES AND RELATED AGENTS 11 171 10 472 10 398 10 452 10 640 2.0 182 1 687 1 855 6 916 102 980 L02AA Estrogens <5 0 <5 <5 0 0.0 0 0 L02AA02 polyestradiol phosphate <5 0 <5 <5 0 0.0 0 0 0 0 0 L02AB Progestogens 154 142 138 138 130 0.0 0 6 45 79 324 L02AB01 megestrol 154 142 138 138 130 0.0 0 6 45 79 324 L02AE Gonadotropin releasing hormone analogues 11 019 10 335 10 260 10 315 10 513 2.0 182 1 682 1 810 6 839 102 656 L02AE01 buserelin 1 355 724 495 387 335 0.1 0 325 10 0 499 L02AE02 leuprorelin 3 736 3 477 3 139 2 786 2 467 0.5 182 506 262 1 517 22 721 L02AE03 goserelin 6 028 6 218 6 599 7 001 7 312 1.4 <5 434 1 524 5 353 79 124 L02AE04 triptorelin 13 23 131 241 479 0.1 0 455 24 0 312 L02AE05 histrelin 20 6 0 0 0 0.0 0 0 0 0 0 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 19 816 20 708 21 821 22 834 25 548 4.8 <5 4 156 9 825 11 565 291 651 L02BA Anti-estrogens 4 250 4 417 4 609 4 958 5 439 1.0 <5 882 3 487 1 068 22 770 L02BA01 tamoxifen 4 036 4 181 4 338 4 612 4 963 0.9 <5 864 3 231 866 4 664 L02BA03 fulvestrant 246 263 292 376 522 0.1 0 20 273 229 18 106 L02BB Anti-androgens 6 964 7 078 7 081 6 985 7 007 1.3 0 <5 1 288 5 718 158 408 L02BB01 flutamide 202 136 108 85 82 0.0 0 0 5 77 603 L02BB03 bicalutamide 6 720 6 480 6 313 6 116 6 041 1.1 0 <5 1 076 4 964 22 400 L02BB04 enzalutamide 85 517 826 938 1 093 0.2 0 0 247 846 135 405 L02BG Aromatase inhibitors 8 322 8 902 9 813 10 626 12 995 2.5 0 3 325 5 316 4 354 36 966 L02BG03 anastrozole 1 537 1 280 1 028 843 757 0.1 0 40 369 348 3 013 L02BG04 letrozole 6 155 6 999 8 128 9 079 11 537 2.2 0 3 267 4 589 3 681 29 994 L02BG06 exemestane 901 910 983 1 015 974 0.2 0 26 508 440 3 959 L02BX Other hormone antagonists and related agents 1 182 1 380 1 415 1 401 1 273 0.2 0 0 288 985 73 507 L02BX02 degarelix 487 642 806 872 837 0.2 0 0 217 620 9 494 L02BX03 abiraterone 762 804 660 581 473 0.1 0 0 85 388 64 013 L03 IMMUNOSTIMULANTS 6 747 6 485 6 306 6 819 6 431 1.2 49 1 287 3 814 1 281 174 966 L03A IMMUNOSTIMULANTS 6 747 6 485 6 306 6 819 6 431 1.2 49 1 287 3 814 1 281 174 966 L03AA Colony stimulating factors 2 831 3 313 4 159 4 909 4 775 0.9 45 683 2 859 1 188 63 437 L03AA02 filgrastim 623 611 593 583 588 0.1 39 132 295 122 8 051 L03AA13 pegfilgrastim 2 353 2 734 3 138 3 605 3 947 0.8 6 535 2 431 975 50 977 L03AA14 lipegfilgrastim 0 109 676 956 370 0.1 <5 36 224 109 4 4093.12 ATC group L - Antineoplastic and immunomodulating agents 2014 2015 2016 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 1 375 1 210 952 0.2 <5 335 538 75 62 451 L03AB01 interferon alfa natural 14 8 8 0 0 0.0 0 0 0 0 0 L03AB03 interferon gamma 10 11 10 13 10 0.0 <5 8 0 0 2 223 L03AB04 interferon alfa-2a 25 19 19 19 21 0.0 0 0 6 15 687 L03AB05 interferon alfa-2b 40 47 34 36 40 0.0 0 <5 18 18 974 L03AB07 interferon beta-1a 1 159 872 592 461 372 0.1 <5 103 256 12 32 220 L03AB08 interferon beta-1b 611 489 321 211 134 0.0 0 46 84 <5 7 320 L03AB10 peginterferon alfa-2b 260 171 71 51 50 0.0 <5 12 31 6 1 716 L03AB11 peginterferon alfa-2a 651 550 319 315 214 0.0 0 98 91 25 8 216 L03AB13 peginterferon beta-1a 0 <5 11 149 135 0.0 0 73 62 0 9 096 L03AX Other immunostimulants 1 322 1 058 789 723 722 0.1 0 278 426 18 49 078 L03AX03 BCG vaccine 12 13 14 13 5 0.0 0 0 <5 <5 33 L03AX13 glatiramer acetate 1 310 1 045 775 710 717 0.1 0 278 423 16 49 044 L04 IMMUNOSUPPRESSANTS 52 031 56 456 60 044 63 829 67 111 12.7 1 188 17 889 34 418 13 616 2 647 667 L04A IMMUNOSUPPRESSANTS 52 031 56 456 60 044 63 829 67 111 12.7 1 188 17 889 34 418 13 616 2 647 667 L04AA Selective immunosuppressants 7 280 8 528 9 551 10 333 10 851 2.1 136 2 833 6 161 1 721 570 456 L04AA06 mycophenolic acid 4 207 4 425 4 668 4 925 5 164 1.0 113 1 160 2 914 977 46 384 L04AA10 sirolimus 189 215 242 272 295 0.1 16 38 184 57 7 675 L04AA13 leflunomide 1 785 2 006 2 142 2 225 2 256 0.4 0 251 1 407 598 12 863 L04AA18 everolimus 449 474 484 487 481 0.1 8 70 276 127 36 185 L04AA23 natalizumab 0 0 0 0 <5 - 0 0 <5 0 18 L04AA24 abatacept 72 144 222 258 283 0.1 0 47 171 65 17 773 L04AA25 eculizumab 10 11 17 18 18 0.0 0 9 8 <5 79 665 L04AA27 fingolimod 896 1 110 1 238 1 329 1 411 0.3 <5 715 692 <5 250 837 L04AA28 belatacept 0 0 0 <5 0 0.0 0 0 0 0 0 L04AA29 tofacitinib 0 0 0 0 87 0.0 0 26 49 12 2 097 L04AA31 teriflunomide 140 638 1 069 1 362 1 427 0.3 0 617 793 17 113 762 L04AA32 apremilast 0 0 9 35 27 0.0 0 10 15 <5 1 817 L04AA33 vedolizumab 0 <5 <5 0 0 0.0 0 0 0 0 0 L04AA37 baricitinib 0 0 0 0 28 0.0 0 <5 19 5 1 381 L04AB Tumor necrosis factor alpha (TNF-) inhibitors 13 980 15 154 15 163 15 647 16 505 3.1 251 5 808 8 633 1 813 1 225 106 L04AB01 etanercept 6 521 5 968 5 551 5 737 7 350 1.4 140 2 238 3 970 1 002 318 565 L04AB02 infliximab <5 0 <5 <5 0 4 L04AB04 adalimumab 4 962 5 075 4 699 4 448 4 376 0.8 118 1 766 2 107 385 481 451 L04AB05 certolizumab pegol 1 232 3 024 3 506 4 262 3 646 0.7 0 1 372 1 920 354 250 314ATC group L ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales golimumab 2 145 2 086 2 040 1 848 1 684 0.3 <5 663 898 122 174 772 L04AC Interleukin inhibitors 436 820 1 407 1 848 2 673 0.5 25 925 1 475 248 230 602 L04AC01 daclizumab 0 0 0 0 14 0.0 0 7 7 0 1 675 L04AC03 anakinra 125 148 170 189 197 0.0 8 90 77 22 14 049 L04AC05 ustekinumab 304 555 764 830 814 0.2 5 47 76 753 L04AC07 tocilizumab <5 112 454 521 608 0.1 <5 177 308 122 39 872 L04AC08 canakinumab 6 11 13 23 24 0.0 11 6 5 <5 29 544 L04AC10 secukinumab 0 0 22 371 1 0.2 <5 381 662 58 68 709 L04AD Calcineurin inhibitors 5 524 5 733 5 979 6 203 6 274 1.2 191 1 590 3 413 1 080 139 798 L04AD01 ciclosporin 3 199 3 156 3 156 3 130 2 954 0.6 82 683 1 554 635 47 555 L04AD02 tacrolimus 2 381 2 644 2 889 3 132 3 383 0.6 109 926 1 895 453 92 244 L04AX Other immunosuppressants 35 841 38 141 40 202 42 349 44 324 8.4 885 10 353 22 329 10 757 481 704 L04AX01 azathioprine 7 362 7 650 7 894 8 280 8 280 1.6 229 3 916 3 296 839 7 509 L04AX02 thalidomide 295 246 238 200 90 0.0 <5 5 33 49 2 587 L04AX03 methotrexate 28 059 30 026 31 706 33 357 35 139 6.7 663 6 478 18 672 9 326 98 416 L04AX04 lenalidomide 257 308 434 612 810 0.2 0 13 332 465 270 309 L04AX05 pirfenidone 50 58 65 69 78 0.0 0 0 36 42 16 433 L04AX06 pomalidomide 0 74 95 130 178 0.0 0 <5 75 99 86 448ATC group L ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales MUSCULO-SKELETAL SYSTEM 925 319 928 438 942 067 946 467 963 353 182.6 15 305 325 959 446 233 175 856 491 216 M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC 714 834 679 158.2 13 361 313 430 333 274 104 M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS 158.2 108 328 273 709 M01AB Acetic acid derivatives and related substances 439 563 391 876 376 875 349 105 341 369 64.7 4 782 144 664 159 725 32 198 44 728 M01AB01 indometacin 1 129 1 232 1 178 1 220 1 282 0.2 11 464 654 153 1 187 M01AB02 sulindac 0 0 <5 5 5 0.0 0 0 <5 <5 11 M01AB05 diclofenac1)417 775 372 039 357 601 330 952 323 120 61.2 4 742 140 530 149 878 27 970 35 523 M01AB15 ketorolac 12 27 20 18 25 0.0 0 12 13 0 12 M01AB16 aceclofenac 0 0 0 <5 <5 - 0 0 <5 0 4 M01AB55 diclofenac, combinations 25 182 22 213 21 482 19 774 19 896 3.8 32 4 610 10 811 4 443 7 991 M01AC Oxicams 52 902 48 308 40 894 35 293 31 649 6.0 134 9 422 17 570 4 523 9 993 M01AC01 piroxicam 39 641 36 954 32 480 28 375 25 189 4.8 115 8 047 14 116 2 911 8 122 M01AC06 meloxicam 13 527 11 551 8 736 7 051 6 577 1.3 19 1 414 3 524 1 620 1 871 M01AE Propionic acid derivatives 343 199 373 687 398 840 429 125 448 361 85.0 8 612 167 342 215 905 56 502 132 171 M01AE01 ibuprofen1)217 264 224 042 222 338 222 755 230 829 43.7 7 154 96 932 104 867 21 876 35 895 M01AE02 naproxen1)72 012 86 217 95 355 105 672 99 739 18.9 1 356 39 783 45 285 13 315 23 812 M01AE03 ketoprofen 5 438 4 975 4 492 4 252 3 766 0.7 11 748 2 163 844 2 290 M01AE14 dexibuprofen 637 539 200 30 24 0.0 0 7 14 <5 30 M01AE17 dexketoprofen <5 11 9 9 17 0.0 0 7 8 <5 2 M01AE52 naproxen and esomeprazole 64 416 77 488 99 704 123 511 142 741 27.1 171 40 197 78 892 23 481 70 142 M01AG Fenamates 337 366 417 454 494 0.1 <5 292 189 9 378 M01AG02 tolfenamic acid 337 366 417 454 494 0.1 <5 292 189 9 378 M01AH Coxibs 72 688 92 056 97 948 96 791 101 372 19.2 106 30 128 54 623 16 515 69 792 M01AH01 celecoxib 16 437 15 175 14 874 14 296 14 719 2.8 21 4 095 7 622 M01AH04 M01AH05 etoricoxib 57 270 77 854 84 190 83 452 87 661 16.6 85 26 302 47 590 13 684 55 869 M01AX Other antiinflammatory and antirheumatic agents, non-steroids 34 782 32 661 32 460 31 596 30 244 5.7 <5 1 530 15 664 13 046 16 646 M01AX01 nabumetone 3 773 3 177 2 886 2 427 2 175 0.4 <5 386 1 166 621 1 145 M01AX05 glucosamine1)30 393 28 822 28 914 28 405 27 221 5.2 <5 1 089 14 085 12 045 13 609 M01C SPECIFIC ANTIRHEUMATIC AGENTS 99 77 66 64 49 0.0 0 <5 31 15 395 M01CB Gold preparations 71 61 61 59 42 0.0 0 <5 26 15 348 M01CB01 sodium aurothiomalate 19 17 19 24 13 0.0 0 0 5 8 65 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.13 ATC group M - Musculo-skeletal system ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 29 0.0 0 <5 21 7 283 M01CC Penicillamine and similar agents 12 9 5 5 7 0.0 0 <5 5 0 47 M01CC01 penicillamine 12 9 5 5 7 0.0 0 <5 5 0 47 M01CX Other specific antirheumatic agents 16 7 0 0 0 0.0 0 0 0 0 0 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 60 159 64 758 72 625 73 834 77 616 14.7 2 255 21 823 32 703 20 835 14 441 M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 60 157 64 751 72 617 73 830 77 611 14.7 2 255 21 822 32 700 20 834 14 440 M02AA Antiinflammatory preparations, non-steroids for topical use 60 050 64 683 72 605 73 826 77 607 14.7 2 255 21 822 32 700 20 830 14 439 M02AA10 ketoprofen 51 649 51 400 50 448 48 193 46 996 8.9 1 380 13 645 20 062 11 909 5 859 M02AA13 ibuprofen1)5 818 5 790 4 996 4 420 3 930 0.7 228 1 150 1 364 1 188 801 M02AA15 diclofenac1)2 890 8 030 17 986 22 059 27 659 5.2 655 7 212 11 658 8 134 7 779 M02AB Capsaicin and similar agents 5 <5 <5 <5 0 0.0 0 0 0 0 0 M02AB01 capsaicin 5 <5 <5 <5 0 0.0 0 0 0 0 0 M02AC Preparations with salicylic acid derivatives 119 73 0 0 0 0.0 0 0 0 0 0 M02AX Other topical products for joint and muscular pain 8 5 8 <5 5 0.0 0 0 0 5 1 M02AX10 various 8 5 8 <5 5 0.0 0 0 0 5 1 M03 MUSCLE RELAXANTS 6 104 6 869 7 501 8 272 8 991 1.7 154 2 886 4 779 1 172 51 378 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 5 630 5 779 5 749 5 868 5 883 1.1 148 1 341 3 357 1 037 9 762 M03BA Carbamic acid esters 745 635 588 495 421 0.1 0 54 323 44 1 484 M03BA02 carisoprodol 745 635 588 495 421 0.1 0 54 323 44 1 484 M03BB Oxazol, thiazine, and tria - zine derivatives <5 20 21 41 44 0.0 0 17 21 6 80 M03BB03 chlorzoxazone <5 20 21 41 44 0.0 0 17 21 6 80 M03BX Other centrally acting agents 4 901 5 146 5 159 5 347 5 430 1.0 148 1 271 3 023 988 8 198 M03BX01 baclofen 4 850 5 080 5 075 5 269 5 357 1.0 148 1 242 2 986 981 7 707 M03BX02 tizanidine 78 93 107 105 103 0.0 0 39 56 8 491 M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS 0 0 0 0 <5 - <5 0 0 0 1 M03CA Dantrolene and derivatives 0 0 0 0 <5 - <5 0 0 0 1 M03CA01 dantrolene 0 0 0 0 <5 - <5 0 0 0 1 M04 ANTIGOUT PREPARATIONS 47 763 50 836 53 500 56 374 59 343 11.3 30 3 885 24 547 30 881 47 537 M04A ANTIGOUT PREPARATIONS 47 763 50 836 53 500 56 374 59 343 11.3 30 3 885 24 547 30 881 47 537 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group M ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales Preparations inhibiting uric acid production 43 558 46 073 48 334 50 525 53 155 10.1 10 3 147 21 980 28 018 37 444 M04AA01 allopurinol 43 473 45 944 48 142 50 261 52 795 10.0 10 3 108 21 831 27 846 19 800 M04AA03 febuxostat 105 148 218 300 438 0.1 0 50 190 198 17 644 M04AB Preparations increasing uric acid excretion 1 970 1 942 1 924 1 878 1 788 0.3 <5 105 733 949 2 637 M04AB01 probenecid 1 970 1 942 1 924 1 878 1 788 0.3 <5 105 733 949 2 637 M04AC Preparations with no effect on uric acid metabolism 5 085 6 207 7 054 8 293 9 200 1.7 19 1 065 4 062 4 054 7 456 M04AC01 colchicine 5 085 6 207 7 054 8 293 9 200 1.7 19 1 065 4 062 4 054 7 456 M05 DRUGS FOR TREATMENT OF BONE DISEASES 61 037 61 688 62 020 63 305 64 868 12.3 <5 674 24 137 40 056 83 385 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 61 037 61 688 62 020 63 305 64 868 12.3 <5 674 24 137 40 056 83 385 M05BA Bisphosphonates 58 056 57 770 57 318 57 490 57 746 10.9 <5 630 22 935 34 180 47 549 M05BA01 etidronic acid 22 0 0 0 0 0.0 0 0 0 0 0 M05BA02 clodronic acid 34 13 10 7 <5 - 0 0 0 <5 21 M05BA03 pamidronic acid 18 16 17 9 5 0.0 0 0 <5 <5 26 M05BA04 alendronic acid 53 858 53 144 52 362 52 152 51 864 9.8 <5 496 20 160 31 207 26 507 M05BA06 ibandronic acid 664 658 659 618 597 0.1 0 6 241 350 1 818 M05BA07 risedronic acid 639 481 403 327 309 0.1 0 <5 105 202 765 M05BA08 zoledronic acid 3 378 3 965 4 344 4 921 5 613 1.1 0 135 2 756 2 722 18 413 M05BB Bisphosphonates, combinations 668 <5 0 0 0 0.0 0 0 0 0 0 M05BB01 etidronic acid and calcium, sequential 668 <5 0 0 0 0.0 0 0 0 0 0 M05BX Other drugs affecting bone structure and mineralization 3 212 4 412 5 198 6 410 7 906 1.5 0 47 1 367 6 492 35 836 M05BX04 denosumab 3 212 4 412 5 198 6 410 7 906 1.5 0 47 1 367 6 492 35 836 M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM 76 40 60 166 295 0.1 <5 25 236 33 20 371 M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM 76 40 60 166 295 0.1 <5 25 236 33 20 371 M09AB Enzymes 76 40 58 164 292 0.1 0 24 235 33 6 313 M09AB02 collagenase clostridium histolyticum 76 40 58 164 292 0.1 0 24 235 33 6 313 M09AX Other drugs for disorders of the musculo-skeletal system 0 0 <5 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 110N NERVOUS SYSTEM 1 327 510 1 354 299 1 380 890 1 412 242 1 450 941 275.0 32 190 459 701 620 719 338 331 3 245 094 N02 ANALGESICS 790 759 818 063 847 861 876 882 913 160 173.1 8 235 282 394 406 783 215 748 815 862 N02A OPIOIDS 528 299 538 389 550 458 559 406 563 551 106.8 1 735 181 075 251 733 129 008 493 945 N02AA Natural opium alkaloids 33 494 37 640 42 019 48 789 57 193 10.8 121 9 921 24 911 22 240 113 509 N02AA01 morphine 6 852 7 145 7 565 7 951 8 200 1.6 66 847 3 600 3 687 22 062 N02AA03 hydromorphone 95 130 127 137 123 0.0 0 28 64 31 8 434 N02AA05 oxycodone 26 884 30 548 34 406 40 730 48 755 9.2 58 9 030 21 531 18 136 61 132 N02AA08 dihydrocodeine 53 45 35 42 37 0.0 0 7 28 <5 260 N02AA51 morphine, combinations 0 0 0 0 <5 - 0 0 <5 0 17 N02AA55 oxycodone and naloxone 4 069 5 037 5 713 6 521 7 246 1.4 <5 776 2 731 3 738 21 605 N02AB Phenylpiperidine derivatives 12 148 12 610 12 729 12 920 12 405 2.4 14 1 848 5 259 5 284 56 922 N02AB01 ketobemidone 4 143 4 342 4 252 4 146 3 604 0.7 <5 1 037 1 895 669 2 935 N02AB02 pethidine 1 281 1 247 1 177 1 112 948 0.2 0 251 551 146 4 066 N02AB03 fentanyl 7 173 7 490 7 753 8 058 8 180 1.6 11 634 2 998 4 537 49 921 N02AC Diphenylpropylamine derivatives 12 7 12 0 0 0.0 0 0 0 0 0 N02AC04 dextropropoxyphene 12 7 12 0 0 0.0 0 0 0 0 0 N02AD Benzomorphan derivatives 24 24 20 15 10 0.0 0 <5 6 <5 562 N02AD01 pentazocine 24 24 20 15 10 0.0 0 <5 6 <5 562 N02AE Oripavine derivatives 15 863 16 731 17 813 18 354 18 403 3.5 6 1 414 4 864 12 119 71 497 N02AE01 buprenorphine 15 863 16 731 17 813 18 354 18 403 3.5 6 1 414 4 864 12 119 71 497 N02AG Opioids in combination with antispasmodics 1 895 1 812 1 766 1 719 1 688 0.3 0 583 835 270 1 889 N02AG01 morphine and antispasmodics 314 134 <5 0 0 0.0 0 0 0 0 0 N02AG02 ketobemidone and antispasmodics 1 586 1 681 1 765 1 719 1 688 0.3 0 583 835 270 1 889 N02AJ Opioids in combination with non-opioid analgesics 383 926 378 124 374 905 369 279 356 278 67.5 1 268 123 967 159 033 72 010 149 353 N02AJ06 codeine and paracetamol 383 911 373 346 367 448 361 371 351 291 66.6 1 251 122 320 156 881 70 839 147 130 N02AJ07 codeine and acetylsalicylic acid 18 20 23 20 18 0.0 0 5 8 5 42 N02AJ13 tramadol and paracetamol 0 6 826 10 499 10 761 6 698 1.3 20 2 240 2 897 1 541 2 182 N02AX Other opioids 172 547 188 983 204 517 217 509 228 155 43.2 408 70 731 105 501 51 515 100 213 N02AX02 tramadol 172 161 188 470 203 288 215 712 225 070 42.7 406 70 103 103 902 50 659 85 903 N02AX06 tapentadol 615 851 2 006 2 822 4 613 0.9 <5 1 021 2 350 1 239 14 310 N02B OTHER ANALGESICS AND ANTIPYRETICS 386 153 416 641 446 685 481 088 527 266 99.9 4 760 122 158 239 086 161 262 122 712 N02BA Salicylic acid and derivatives 936 1 019 1 073 1 086 1 261 0.2 248 481 376 156 613 N02BA01 acetylsalicylic acid1)931 1 017 0.2 248 481 373 155 5713.14 ATC group N - Nervous system level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales in 1000 NOK<15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for 0 0 0 N02BB Pyrazolones 1 051 1 031 1 144 1 318 1 550 0.3 9 777 519 245 473 N02BB02 metamizole sodium 18 41 41 49 65 0.0 0 7 32 26 116 N02BB51 phenazone, combinations excl. psycholeptics 1 033 990 1 103 1 269 1 485 0.3 9 770 487 219 358 N02BE Anilides 384 456 414 896 444 973 479 273 525 156 99.5 4 510 121 235 238 383 161 028 113 253 N02BE01 paracetamol1)384 388 414 754 444 756 479 030 524 901 99.5 4 508 121 094 238 307 160 992 113 173 N02BE51 paracetamol, combinations excl. psycholeptics1)134 240 322 355 392 0.1 <5 191 137 60 79 N02BG Other analgesics and antipyretics 404 366 344 326 472 0.1 <5 298 62 8 373 N02BG07 flupirtine <5 <5 <5 0 0 0 0 N02BG10 cannabinoids 402 365 340 326 472 0.1 <5 109 298 62 8 373 N02C ANTIMIGRAINE PREPARATIONS 97 251 101 231 105 199 107 882 115 514 21.9 2 397 55 603 52 205 N02CA Ergot alkaloids 877 454 371 292 0.1 0 23 136 87 292 N02CA04 methysergide <5 0 0 0 0 0.0 0 0 0 0 0 N02CA52 ergotamine, combinations excl. psycholeptics 21 8 9 7 7 0.0 0 0 <5 5 9 N02CA72 ergotamine, combinations with psycholeptics 856 446 364 287 240 0.1 0 23 134 83 283 N02CC Selective serotonin (5HT1) agonists 93 214 97 102 101 024 103 715 111 321 21.1 2 343 54 596 49 431 4 951 195 531 N02CC01 sumatriptan 47 946 50 676 52 589 51 695 58 093 11.0 1 886 31 438 22 482 2 287 86 428 N02CC02 naratriptan 1 707 1 941 2 109 2 242 2 485 0.5 13 1 142 1 208 122 6 728 N02CC03 zolmitriptan 15 150 15 840 16 228 20 268 19 321 3.7 425 8 745 9 252 899 42 653 N02CC04 rizatriptan 25 269 26 829 27 935 30 355 31 217 5.9 268 15 778 13 932 1 239 31 375 N02CC05 almotriptan 2 988 3 056 2 889 2 916 2 934 0.6 7 1 305 1 489 133 6 513 N02CC06 eletriptan 11 735 11 871 12 331 12 796 13 275 2.5 41 5 708 6 947 579 21 534 N02CC07 frovatriptan 8 20 180 223 192 0.0 <5 103 86 <5 301 N02CX Other antimigraine preparations 4 271 4 524 4 622 4 762 4 844 0.9 56 1 287 3 068 433 3 381 N02CX01 pizotifen 72 62 58 50 45 0.0 0 16 23 6 158 N02CX02 clonidine 4 199 4 463 4 567 4 714 4 802 0.9 56 1 272 3 047 427 3 223 N03 ANTIEPILEPTICS 116 903 118 788 122 547 127 262 131 955 25.0 3 618 38 248 61 115 28 974 462 919 N03A ANTIEPILEPTICS 116 903 118 788 122 547 127 262 131 955 25.0 3 618 38 248 61 115 28 974 462 919 N03AA Barbiturates and derivatives 2 361 2 246 2 174 2 087 2 006 0.4 67 197 1 002 740 3 957 N03AA02 phenobarbital 2 064 1 920 1 829 1 744 1 630 0.3 66 151 847 566 3 129 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales <5 46 157 181 829 N03AB Hydantoin derivatives 1 704 1 541 1 436 1 281 1 118 0.2 17 122 577 402 2 198 N03AB02 phenytoin 1 704 1 541 1 436 1 281 1 118 0.2 17 122 577 402 2 198 N03AB05 fosphenytoin 0 <5 <5 0 0 0.0 0 0 0 0 0 N03AD Succinimide derivatives 206 227 224 266 289 0.1 147 117 21 <5 2 352 N03AD01 ethosuximide 206 227 224 266 289 0.1 147 117 21 <5 2 352 N03AE Benzodiazepine derivatives 11 748 10 909 9 856 8 702 7 198 1.4 143 1 570 3 692 1 793 3 874 N03AE01 clonazepam 11 748 10 909 9 856 8 702 7 198 1.4 143 1 570 3 692 1 793 3 874 N03AF Carboxamide derivatives 16 961 16 205 15 668 15 310 14 894 2.8 723 3 734 7 382 3 055 38 934 N03AF01 carbamazepine 14 205 13 396 12 720 12 256 11 495 2.2 154 2 482 6 242 2 617 11 795 N03AF02 oxcarbazepine 2 526 2 518 2 635 2 703 2 968 0.6 551 968 1 019 430 11 449 N03AF03 rufinamide 100 98 96 94 90 0.0 23 55 11 <5 1 970 N03AF04 eslicarbazepine 294 332 383 461 <5 319 221 47 13 719 N03AG Fatty acid derivatives 15 127 15 285 15 209 15 249 15 197 2.9 1 529 5 696 6 312 1 660 46 677 N03AG01 valproic acid 15 047 15 200 15 135 15 167 15 118 2.9 1 499 5 679 6 284 1 656 45 755 N03AG03 aminobutyric acid 16 20 8 16 14 0.0 0 6 8 0 16 N03AG04 vigabatrin 94 90 85 85 87 0.0 47 16 20 <5 610 N03AG06 tiagabine 10 9 9 9 9 0.0 0 <5 5 <5 296 N03AX Other antiepileptics 82 517 85 807 91 235 97 526 104 042 19.7 2 086 31 233 47 625 23 098 364 927 N03AX03 sultiame 206 239 238 277 323 0.1 252 69 <5 0 2 520 N03AX09 lamotrigine 27 013 27 569 28 530 29 235 30 145 5.7 870 14 009 11 999 3 267 106 689 N03AX10 felbamate 20 17 22 18 19 0.0 <5 13 <5 0 380 N03AX11 topiramate 3 230 3 649 3 954 4 174 4 617 0.9 229 2 396 1 786 206 12 580 N03AX12 gabapentin 30 998 32 203 35 533 39 417 42 711 8.1 97 8 595 21 685 12 334 65 309 N03AX14 levetiracetam 7 307 7 934 8 528 9 244 9 761 1.9 841 3 233 3 418 2 269 49 698 N03AX15 zonisamide 611 633 638 639 52 335 186 50 9 096 N03AX16 pregabalin 19 654 20 230 20 711 21 852 23 571 4.5 11 5 229 11 953 6 378 96 730 N03AX17 stiripentol 21 25 27 30 33 0.0 18 15 0 0 2 859 N03AX18 lacosamide 445 500 555 625 703 0.1 44 350 244 65 10 220 N03AX21 retigabine 103 36 20 17 <5 - 0 <5 <5 0 64 N03AX22 perampanel 149 220 254 303 360 0.1 34 188 114 24 5 143 N03AX23 brivaracetam 0 0 0 89 201 0.0 13 125 51 12 3 640 N04 ANTI-PARKINSON DRUGS 19 088 20 072 20 744 21 511 22 269 4.2 36 1 697 9 116 11 420 148 127 N04A ANTICHOLINERGIC AGENTS 2 481 2 348 2 252 2 119 2 071 0.4 22 445 1 287 317 1 578 N04AA Tertiary amines 2 448 2 322 2 236 2 103 2 055 0.4 22 444 1 274 315 1 547 N04AA01 trihexyphenidyl 27 41 44 52 54 0.0 22 16 14 <5 319 N04AA02 biperiden 2 418 2 279 2 189 2 049 2 000 0.4 0 428 1 259 313 1 226ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales Ethers chemically close to antihistamines 34 32 17 17 17 0.0 0 <5 14 <5 32 N04AB02 orphenadrine (chloride) 34 32 17 17 0.0 0 <5 14 <5 32 N04B DOPAMINERGIC AGENTS 16 673 17 785 18 545 19 443 20 262 3.8 15 1 255 7 863 11 129 146 549 N04BA Dopa and dopa derivatives 8 579 9 033 9 332 9 663 10 093 1.9 15 133 2 849 7 096 89 776 N04BA02 levodopa and decarboxylase inhibitor 7 860 8 339 8 702 9 055 9 513 1.8 15 128 2 658 6 712 75 999 N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor 1 399 1 391 1 350 1 392 1 387 0.3 0 8 526 853 13 777 N04BB Adamantane derivatives 161 158 162 191 207 0.0 0 44 126 37 814 N04BB01 amantadine 161 158 162 191 207 0.0 0 44 126 37 814 N04BC Dopamine agonists 10 874 11 676 12 154 12 849 13 281 2.5 0 1 116 6 304 5 861 39 042 N04BC01 bromocriptine 13 N04BC04 ropinirole 2 729 2 869 2 930 2 957 2 923 0.6 0 150 1 451 1 322 13 997 N04BC05 pramipexole 7 750 8 469 8 906 9 577 10 013 1.9 0 950 4 733 4 330 14 939 N04BC06 cabergoline 121 109 88 91 80 0.0 0 8 37 35 197 N04BC07 apomorphine 18 26 30 45 62 0.0 0 <5 32 28 3 706 N04BC09 rotigotine 573 560 533 537 552 240 278 6 190 N04BD Monoamine oxidase B inhibitors 3 652 3 868 4 011 4 134 4 304 0.8 0 48 1 933 2 323 15 559 N04BD01 selegiline 2 183 2 257 2 318 2 400 2 439 0.5 0 29 1 124 1 286 4 325 N04BD02 rasagiline 1 530 1 648 1 739 1 778 1 887 0.4 0 20 831 1 036 10 306 N04BD03 safinamide 0 0 0 10 101 0.0 0 0 41 60 928 N04BX Other dopaminergic agents 119 111 105 127 142 0.0 0 0 55 87 1 358 N04BX01 tolcapone 8 6 8 9 8 0.0 0 0 5 <5 398 N04BX02 entacapone 111 105 98 118 134 0.0 0 0 50 84 960 N05 PSYCHOLEPTICS 619 567 630 363 631 239 638 090 645 060 122.2 13 291 155 567 276 674 199 528 662 525 N05A ANTIPSYCHOTICS 106 651 109 198 113 424 118 840 124 611 23.6 1 034 46 527 54 827 22 223 311 449 N05AA Phenothiazines with aliphatic side-chain 20 118 18 907 17 572 16 472 15 331 2.9 9 3 747 8 062 3 513 5 863 N05AA01 chlorpromazine 222 201 167 168 202 0.0 0 117 59 26 569 N05AA02 levomepromazine 19 912 18 724 17 418 16 313 15 135 2.9 9 3 631 8 007 3 488 5 294 N05AB Phenothiazines with piperazine structure 13 470 11 104 10 512 9 382 9 108 1.7 15 1 980 3 798 3 315 7 585 N05AB02 fluphenazine 14 17 17 14 9 0.0 0 0 <5 5 39 N05AB03 perphenazine 3 506 1 758 1 706 1 659 1 577 0.3 0 268 991 318 6 040 N05AB04 prochlorperazine 10 061 9 346 8 802 7 715 7 529 1.4 15 1 714 2 807 2 1 505 N05AB06 trifluoperazine <5 <5 0 <5 2014 2015 2016 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 54 46 44 38 35 0.0 0 <5 13 99 N05AC01 3 N05AC02 thioridazine 49 43 41 36 33 0.0 0 90 N05AC04 6 N05AD Butyrophenone derivatives 3 966 4 030 3 877 3 998 3 835 0.7 <5 274 1 391 2 167 1 314 N05AD01 haloperidol 3 959 4 023 3 870 3 987 3 822 0.7 <5 270 1 387 2 162 1 296 N05AD03 melperone 7 6 7 Indole derivatives 902 870 963 1 013 1 006 0.2 0 501 440 65 8 393 N05AE03 sertindole 125 100 110 96 79 0.0 0 30 44 5 887 N05AE04 ziprasidone 778 766 677 639 586 0.1 0 224 313 49 4 233 N05AE05 lurasidone 0 5 189 291 347 0.1 0 250 86 11 3 273 N05AF Thioxanthene derivatives 22 303 21 600 20 895 20 308 19 329 3.7 13 6 429 9 570 3 317 12 189 N05AF01 flupentixol 4 351 4 185 3 902 3 744 3 486 0.7 0 867 1 715 904 1 786 N05AF03 chlorprothixene 15 541 15 115 14 813 14 499 13 822 2.6 12 5 148 6 614 2 048 7 389 N05AF05 zuclopenthixol 3 044 2 914 2 729 2 561 2 470 0.5 <5 573 1 490 406 3 014 N05AG Diphenylbutylpiperidine derivatives 117 114 112 112 104 0.0 0 51 42 11 347 N05AG01 fluspirilene 0 0 <5 <5 <5 - 0 0 <5 0 4 N05AG02 pimozide 115 114 111 109 101 0.0 0 51 39 11 314 N05AG03 penfluridol <5 0 0 N05AH Diazepines, thiazepines and oxepines 44 837 50 380 56 867 64 650 72 723 13.8 126 32 686 31 341 8 570 144 639 N05AH01 loxapine 0 0 <5 0 0 0.0 0 0 0 0 0 N05AH02 clozapine 2 533 2 571 2 576 2 610 2 651 0.5 0 1 101 1 426 124 9 778 N05AH03 olanzapine 16 385 16 701 16 920 16 990 17 421 3.3 40 6 546 8 087 2 748 52 947 N05AH04 quetiapine 28 125 33 528 39 942 47 818 55 638 10.5 90 26 568 23 031 5 949 81 576 N05AH05 asenapine 87 50 28 29 29 0.0 0 17 12 0 338 N05AL Benzamides 569 600 657 608 629 0.1 0 292 315 22 4 156 N05AL01 sulpiride 0 0 0 0 <5 - 0 0 0 1 N05AL03 650 0.1 0 289 313 22 4 128 N05AN Lithium 7 682 7 559 7 579 7 570 7 628 1.5 <5 2 237 4 049 1 341 17 231 N05AN01 lithium 7 682 7 559 7 579 7 570 7 628 1.5 <5 2 237 4 049 1 341 17 231 N05AX Other antipsychotics 13 752 14 019 14 344 14 612 14 943 2.8 924 6 559 5 299 0 N05AX08 risperidone 8 392 8 329 8 263 8 305 8 141 1.5 793 2 709 2 810 1 829 28 006 N05AX12 aripiprazole 5 143 5 399 5 731 5 910 6 375 1.2 177 3 640 2 249 309 43 977ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 510 391 35 37 649 N05B ANXIOLYTICS 270 647 267 746 262 533 258 101 252 789 47.9 2 506 58 752 113 975 77 556 105 920 N05BA Benzodiazepine derivatives 245 061 241 318 236 274 233 577 229 065 43.4 2 170 49 688 104 631 72 576 93 576 N05BA01 diazepam 120 562 116 561 109 997 105 594 100 854 19.1 1 863 22 204 46 405 30 382 40 562 N05BA02 chlordiazepoxide <5 0 N05BA04 oxazepam 134 612 134 599 135 729 137 340 136 950 26.0 79 29 731 62 306 44 834 47 107 N05BA06 lorazepam 48 54 70 98 142 0.0 6 50 64 22 398 N05BA08 bromazepam 8 6 7 7 23 N05BA09 clobazam 710 752 779 10 2 449 N05BA12 alprazolam 3 851 3 535 3 206 2 895 2 587 0.5 <5 951 1 283 352 3 035 N05BB Diphenylmethane deriva - tives 33 868 34 711 34 043 31 107 29 716 5.6 342 10 741 12 164 6 469 8 418 N05BB01 hydroxyzine 33 868 34 711 34 043 31 107 29 716 5.6 342 10 741 12 164 6 469 8 418 N05BC Carbamates <5 0 0 0 0 0.0 0 0 0 0 0 N05BC01 meprobamate <5 0 0 0 0 0.0 0 0 0 0 0 N05BE Azaspirodecanedione derivatives 2 403 2 230 2 273 2 248 2 119 0.4 <5 818 937 363 3 926 N05BE01 buspirone 2 403 2 230 2 273 2 248 2 119 0.4 <5 818 937 363 3 926 N05C HYPNOTICS AND SEDATIVES 410 808 423 732 424 579 431 014 435 943 82.6 10 946 89 251 184 199 151 547 245 157 N05CA Barbiturates, plain 0 <5 0 0 0 0.0 0 0 0 0 0 N05CA04 barbital 0 <5 0 0 0 0.0 0 0 0 0 0 N05CC Aldehydes and derivatives 5 6 9 7 13 0.0 8 <5 <5 0 56 N05CC01 chloral hydrate 5 6 9 13 0.0 8 <5 <5 0 56 N05CD Benzodiazepine derivatives 28 367 28 276 27 274 26 877 26 433 5.0 2 553 5 382 9 738 8 760 27 345 N05CD01 flurazepam 16 17 15 11 9 0.0 0 0 <5 7 36 N05CD02 nitrazepam 24 446 23 303 21 519 20 328 19 139 3.6 289 3 333 8 205 7 312 10 196 N05CD03 flunitrazepam 1 185 1 119 959 790 645 0.1 0 131 324 190 1 616 N05CD05 triazolam 91 74 67 62 49 0.0 0 8 18 23 97 N05CD08 midazolam 3 117 4 255 5 213 6 217 7 125 1.4 2 471 2 090 1 265 1 299 15 400 N05CF Benzodiazepine related drugs 355 049 358 302 354 743 355 844 350 093 66.4 50 53 935 158 181 137 927 136 110 N05CF01 zopiclone 303 992 304 071 298 574 296 755 290 210 55.0 37 40 607 129 787 119 779 111 886 N05CF02 zolpidem 62 261 65 751 67 381 70 628 70 841 13.4 14 15 879 33 175 21 773 24 224 N05CH Melatonin receptor agonists 56 177 68 793 75 769 82 748 94 753 18.0 8 770 39 235 32 754 13 994 78 745 N05CH01 melatonin 56 177 68 793 75 769 82 748 94 753 18.0 8 770 39 235 32 754 13 994 78 745 N05CM Other hypnotics and sedatives 2 087 2 150 2 145 2 122 1 961 0.4 0 143 500 1 318 2 900 N05CM02 clomethiazole 1 986 1 939 1 971 1 945 1 835 0.4 0 118 445 1 272 2 742ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales scopolamine 65 110 61 65 41 0.0 0 0 8 33 70 N05CM06 propiomazine 38 100 108 105 77 0.0 0 24 44 9 86 N05CM09 Valerianae radix1)<5 5 5 9 9 0.0 0 2 N06 PSYCHOANALEPTICS 353 980 359 882 367 494 376 408 382 158 72.4 12 105 131 655 155 473 82 925 710 549 N06A ANTIDEPRESSANTS 313 336 317 158 322 928 329 608 332 397 63.0 624 108 435 150 315 73 023 299 109 N06AA Non-selective monoamine reuptake inhibitors 65 888 67 286 68 349 69 403 70 267 13.3 83 18 473 36 859 14 852 29 232 N06AA02 imipramine 21 16 16 16 13 0.0 <5 <5 6 <5 38 N06AA04 clomipramine 2 602 2 488 2 342 2 216 2 122 0.4 5 352 1 120 645 1 731 N06AA05 opipramol 5 9 7 8 7 0.0 0 <5 <5 <5 10 N06AA06 trimipramine 9 890 9 406 8 837 8 128 7 521 1.4 <5 1 333 3 565 2 622 5 358 N06AA07 lofepramine 9 6 6 5 0.0 0 <5 <5 <5 34 N06AA09 amitriptyline 49 857 51 933 53 890 55 869 57 811 11.0 71 16 319 31 087 10 334 19 723 N06AA10 nortriptyline 1 996 2 178 2 192 2 251 2 143 0.4 5 614 986 538 1 254 N06AA12 doxepin 2 280 2 016 1 846 1 641 1 454 0.3 <5 89 490 874 1 085 N06AA21 maprotiline 0 <5 0 0 0 0.0 0 0 0 0 0 N06AB Selective serotonin reuptake inhibitors 185 672 185 867 186 016 186 321 183 597 34.8 511 66 975 78 415 37 696 127 612 N06AB03 fluoxetine 10 750 11 117 12 141 12 232 12 055 2.3 150 7 097 4 046 762 16 929 N06AB04 citalopram 25 200 23 517 22 310 20 210 18 571 3.5 <5 3 769 9 345 5 456 10 530 N06AB05 paroxetine 14 828 14 246 13 797 13 122 12 510 2.4 0 2 328 6 660 3 522 11 103 N06AB06 sertraline 29 740 30 840 30 094 32 444 34 076 6.5 355 14 911 13 005 5 805 33 581 N06AB08 fluvoxamine 559 543 554 542 505 0.1 0 189 246 70 946 N06AB10 escitalopram 109 896 110 767 113 697 112 762 110 559 21.0 26 40 940 46 721 22 872 54 523 N06AF Monoamine oxidase inhibitors, non-selective 97 89 88 89 93 0.0 0 21 47 25 1 121 N06AF01 isocarboxazid 0 0 <5 <5 <5 - 0 0 <5 0 20 N06AF03 phenelzine 91 83 83 85 88 0.0 0 20 43 25 626 N06AF04 tranylcypromine 6 7 6 <5 8 0.0 0 5 <5 0 476 N06AG Monoamine oxidase A inhibitors 738 707 721 668 634 0.1 0 165 304 165 1 517 N06AG02 moclobemide 738 707 721 668 634 0.1 0 165 304 165 1 517 N06AX Other antidepressants 101 299 103 291 107 774 112 616 115 819 22.0 40 34 714 51 824 29 241 139 627 N06AX01 oxitriptan 276 280 203 95 90 0.0 <5 36 45 7 174 N06AX02 tryptophan 8 18 9 32 17 0.0 0 8 8 <5 20 N06AX03 mianserin 27 133 26 388 25 418 24 219 23 176 4.4 6 4 771 10 890 7 509 11 235 N06AX05 trazodone 12 17 19 18 24 0.0 <5 9 14 0 48 N06AX06 nefazodone 30 30 31 28 26 0.0 0 <5 23 <5 414 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales mirtazapine 36 953 38 608 40 914 43 265 45 123 8.6 16 11 438 17 894 15 775 37 940 N06AX12 bupropion 11 330 11 691 12 121 12 100 11 958 2.3 <5 5 627 5 343 986 26 259 N06AX14 tianeptine <5 0 7 6 9 0.0 0 7 <5 0 137 N06AX16 venlafaxine 31 108 31 307 32 625 32 903 32 906 6.2 11 11 044 15 953 5 898 28 017 N06AX18 reboxetine 383 338 329 286 263 0.1 0 105 140 18 570 N06AX21 duloxetine 3 503 3 958 4 663 5 361 6 119 1.2 0 1 882 3 299 938 14 542 N06AX22 agomelatine 18 17 12 19 16 0.0 0 5 9 <5 156 N06AX26 vortioxetine 0 25 1 381 5 041 7 126 1.4 <5 3 223 3 187 714 20 117 N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS 34 763 37 098 39 626 42 365 45 899 8.7 11 627 28 122 5 932 218 362 393 N06BA Centrally acting sympathomimetics 34 369 36 710 39 231 41 988 45 520 8.6 11 620 27 948 5 796 156 353 324 N06BA01 amfetamine 402 419 378 315 348 0.1 <5 213 119 14 14 578 N06BA02 dexamfetamine 1 691 1 886 2 008 2 282 2 589 0.5 117 1 681 761 30 48 560 N06BA04 methylphenidate 30 397 32 335 34 062 35 618 37 698 7.1 10 202 23 045 4 367 84 194 804 N06BA07 modafinil 436 486 548 582 678 0.1 10 434 207 27 7 244 N06BA09 atomoxetine 3 282 3 635 3 630 3 669 3 707 0.7 1 301 2 119 285 <5 34 357 N06BA12 lisdexamfetamine 26 388 2 115 3 908 5 884 1.1 1 824 3 412 643 5 53 781 N06BC Xanthine derivatives 309 311 320 304 300 0.1 <5 138 113 48 226 N06BC01 caffeine 309 311 320 304 300 0.1 <5 138 113 48 226 N06BX Other psychostimulants and nootropics 95 89 93 92 98 0.0 6 50 28 14 8 843 N06BX03 piracetam 84 73 72 75 81 0.0 <5 39 27 14 299 N06BX13 idebenone 11 16 21 17 17 0.0 5 11 <5 0 8 544 N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION 0 0 0 <5 0 0.0 0 0 0 0 0 N06CA Antidepressants in combination with psycholeptics 0 0 0 <5 0 0.0 0 0 0 0 0 N06CA02 melitracen and psycholeptics 0 0 0 <5 0 0.0 0 0 0 0 0 N06D ANTI-DEMENTIA DRUGS 15 483 15 427 15 167 15 233 15 281 2.9 0 15 1 582 13 684 49 047 N06DA Anticholinesterases 12 995 12 805 12 594 12 572 12 630 2.4 0 5 1 358 11 267 38 994 N06DA02 donepezil 7 960 7 701 7 476 7 360 7 449 1.4 0 <5 800 6 647 19 264 N06DA03 rivastigmine 5 146 5 212 5 239 5 344 5 380 1.0 0 <5 596 4 781 18 443 N06DA04 galantamine 301 257 224 193 172 0.0 0 0 19 153 1 287 N06DX Other anti-dementia drugs 3 682 3 729 3 646 3 821 3 818 0.7 0 11 468 3 339 10 053 N06DX01 memantine 3 645 3 729 3 646 3 821 3 818 0.7 0 11 468 3 339 10 053 N06DX02 Ginkgo folium1)37 0 0 0 0 0.0 0 0 0 0 0 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 50 686 45 836 42 973 41 387 39 788 7.5 41 12 020 24 162 3 565 428 694 N07A PARASYMPATHOMIMETICS 747 784 781 837 874 0.2 6 158 360 350 4 439 N07AA Anticholinesterases 591 619 621 692 737 0.1 6 151 281 299 2 903 N07AA01 neostigmine <5 0 0 0 <5 - 0 0 10 N07AA02 pyridostigmine 588 617 620 688 733 <5 0 <5 0 N07AB Choline esters 29 32 21 9 0 0.0 0 0 0 0 0 N07AB01 carbachol 29 32 21 9 0 0.0 0 0 0 0 0 N07AX Other parasympathomimetics 131 134 140 139 137 0.0 0 7 79 51 1 537 N07AX01 pilocarpine 131 134 140 135 130 0.0 0 7 74 49 952 N07AX03 cevimeline 0 0 0 <5 7 0.0 0 0 5 <5 585 N07B DRUGS USED IN ADDICTIVE DISORDERS 47 793 41 853 38 600 36 830 35 133 6.7 15 10 891 21 622 2 605 216 468 N07BA Drugs used in nicotine dependence 23 082 17 794 17 103 16 961 16 000 3.0 <5 3 774 10 643 1 582 27 069 N07BA01 nicotine1)928 931 993 1 191 1 168 0.2 <5 118 730 319 814 N07BA03 varenicline 22 201 16 911 16 174 15 833 14 902 2.8 0 3 664 9 963 1 275 26 255 N07BB Drugs used in alcohol dependence 17 479 16 397 13 683 12 143 11 498 2.2 14 3 573 6 969 942 12 898 N07BB01 disulfiram 4 315 4 233 4 226 4 247 4 146 0.8 0 1 256 2 578 312 2 826 N07BB03 acamprosate 580 469 465 472 435 0.1 0 118 294 23 727 N07BB04 naltrexone 11 314 10 488 8 189 6 840 6 483 1.2 14 2 054 3 845 570 8 562 N07BB05 nalmefene 1 722 1 615 1 162 921 695 0.1 0 234 413 48 783 N07BC Drugs used in opioid dependence 7 736 8 017 8 115 8 010 7 933 1.5 0 3 627 4 219 87 176 501 N07BC01 buprenorphine 2 650 2 894 3 037 3 168 3 321 0.6 0 1 786 1 528 7 59 788 N07BC02 methadone 3 718 3 604 3 545 3 424 3 346 0.6 0 1 103 2 165 78 83 487 N07BC05 levomethadone 0 <5 6 14 16 0.0 0 9 6 <5 925 N07BC51 buprenorphine, combinations 2 012 2 265 2 198 2 018 1 774 0.3 0 1 070 702 <5 32 302 N07C ANTIVERTIGO PREPARATIONS 555 682 708 0.1 <5 376 204 1 695 N07CA Antivertigo preparations 555 682 708 732 649 204 1 624 N07CA03 flunarizine 20 33 34 34 44 0.0 <5 22 19 0 71 N07CA52 cinnarizine, combinations 0 0 0 0 <5 - 0 0 <5 0 1 N07X OTHER NERVOUS SYSTEM DRUGS 2 114 3 055 3 338 3 377 3 389 0.6 18 879 2 049 443 206 092 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 119N07XX Other nervous system drugs 2 114 3 055 3 338 3 377 3 389 0.6 18 879 2 049 443 206 092 N07XX02 riluzole 285 290 301 336 353 0.1 0 18 200 135 4 221 N07XX04 sodium oxybate 84 96 103 116 142 0.0 14 95 29 <5 11 888 N07XX05 amifampridine <5 7 11 14 8 0.0 <5 <5 5 0 2 619 N07XX06 tetrabenazine 43 52 48 41 44 0.0 <5 6 21 15 772 N07XX07 fampridine 1 692 1 631 1 690 1 703 1 751 0.3 0 181 1 287 283 47 802 N07XX09 dimethyl fumarate 8 1 054 1 273 1 235 1 158 0.2 0 590 561 7 137 998 N07XX11 pitolisant 0 0 0 0 6 0.0 <5 <5 <5 0 230 N07XX59 dextromethorphan, combinations 0 0 0 0 8 0.0 0 <5 6 0 563 1) The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive this drug dispensed according to special arrangements in the health regions.ATC group N ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 581 94 698 93 310 93 329 17.7 4 347 40 992 35 652 12 338 28 124 P01 ANTIPROTOZOALS 92 720 92 914 89 211 87 278 86 800 16.5 2 528 37 585 34 650 12 037 24 019 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 58 337 59 261 57 466 55 655 53 658 10.2 634 21 468 22 212 9 344 6 327 P01AB Nitroimidazole derivatives 58 335 59 259 57 466 55 655 53 655 10.2 634 21 467 22 211 9 343 6 287 P01AB01 metronidazole 58 227 59 238 57 450 55 641 53 649 10.2 634 21 466 22 206 9 343 6 251 P01AB02 tinidazole 149 27 22 26 16 0.0 <5 8 7 0 9 P01AB03 ornidazole 0 0 <5 0 26 P01AC Dichloroacetamide derivatives 9 5 0 0 0 0.0 0 0 0 0 0 P01AC01 diloxanide 9 5 0 0 0 0.0 0 0 0 0 0 P01AX Other agents against amoebiasis and other protozoal diseases 0 0 0 0 <5 - 0 <5 <5 <5 41 P01AX05 0 <5 <5 0 28 P01AX06 atovaquone 0 0 0 0 <5 - 0 0 0 <5 13 P01B ANTIMALARIALS 35 069 34 230 32 307 32 165 33 624 6.4 1 898 16 335 12 648 2 743 17 659 P01BA Aminoquinolines 6 131 6 041 6 216 6 288 6 280 1.2 35 1 685 3 325 1 235 4 052 P01BA01 chloroquine 14 13 12 11 11 0.0 0 <5 6 <5 17 P01BA02 hydroxychloroquine 6 112 6 020 6 199 6 258 6 260 1.2 34 1 677 3 316 1 233 4 011 P01BA03 primaquine 6 9 11 22 10 0.0 <5 6 <5 0 24 P01BB Biguanides 24 803 25 262 23 468 23 563 25 145 4.8 1 592 13 712 8 577 1 264 12 543 P01BB01 proguanil <5 <5 <5 0 0 P01BB51 proguanil, combinations 24 799 25 260 23 466 23 563 25 144 4.8 1 591 13 712 8 577 1 264 12 542 P01BC Methanolquinolines 4 312 3 086 2 769 2 436 2 323 0.4 278 1 008 783 254 1 041 P01BC01 quinine 396 350 368 331 286 0.1 0 15 106 165 240 P01BC02 mefloquine 3 917 2 737 2 401 2 105 2 037 0.4 278 993 677 89 801 and derivatives, plain <5 0 <5 0 0 0.0 0 0 0 0 0 P01BE03 artesunate <5 0 <5 0 0 0.0 0 0 0 0 0 P01BF Artemisinin and derivatives, combinations <5 5 <5 6 13 0.0 0 9 <5 0 16 P01BF01 artemether and lumefantrine <5 5 <5 6 13 0.0 0 9 <5 0 163.15 ATC group P - Antiparasitic products, insecticides and repellents level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 000 Number of individuals per age groupSales - leishmaniasis and <5 0 32 P02 ANTHELMINTICS 2 388 2 775 2 957 3 066 3 231 0.6 1 463 1 189 462 117 1 634 P02B ANTITREMATODALS 55 52 66 65 56 0.0 <5 37 13 <5 130 P02BA Quinoline derivatives and related substances 55 52 66 65 56 0.0 <5 37 13 <5 130 P02BA01 praziquantel 55 52 66 65 56 0.0 <5 37 13 <5 130 P02C ANTINEMATODAL AGENTS 2 330 2 713 2 891 2 991 3 167 0.6 1 458 1 145 449 115 1 492 P02CA Benzimidazole derivatives 2 127 2 432 2 610 2 626 2 696 0.5 1 376 873 356 91 929 P02CA01 mebendazole1)1 993 2 272 2 276 2 261 2 294 0.4 1 189 718 304 83 519 P02CA03 albendazole 140 172 343 376 415 0.1 192 158 57 8 410 P02CF Avermectines 86 125 123 217 324 0.1 15 203 87 19 532 P02CF01 ivermectin 86 125 123 217 324 0.1 15 203 87 19 532 P02CX Other antinematodals 139 176 186 174 177 0.0 70 82 17 8 32 P02CX01 pyrvinium1)139 176 186 174 177 0.0 70 82 17 8 32 P02D ANTICESTODALS 16 20 10 22 22 0.0 <5 14 5 0 12 P02DA Salicylic acid derivatives 16 20 10 22 22 0.0 <5 14 5 0 12 P02DA01 niclosamide 16 20 10 22 22 0.0 <5 14 5 0 12 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS 1 688 2 157 2 779 3 211 3 561 0.7 377 2 387 INCL. SCABICIDES 2 157 2 3 211 3 561 0.7 377 2 387 603 194 2 471 P03AC Pyrethrines, incl. synthetic compounds 1 618 2 092 2 706 3 148 3 507 0.7 370 2 356 590 191 2 439 P03AC04 permethrin1)1 618 2 092 2 706 3 148 3 507 0.7 370 2 356 590 191 2 439 P03AX Other ectoparasiticides, incl. scabicides 80 72 87 69 71 0.0 10 42 15 <5 32 P03AX01 benzyl benzoate1)34 32 36 37 44 0.0 6 31 5 <5 24 P03AX03 malathion1)47 41 51 32 27 0.0 <5 11 10 <5 8 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group P ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 122R RESPIRATORY SYSTEM 1 220 112 1 259 843 1 296 928 1 330 147 1 374 981 260.6 162 413 500 922 498 654 212 992 1 718 210 R01 NASAL PREPARATIONS 376 766 405 387 416 908 428 436 460 559 87.3 37 162 210 293 167 730 45 374 148 477 R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE 316 889 349 590 357 036 366 599 395 123 74.9 35 770 176 160 141 864 41 329 133 732 R01AA Sympathomimetics, plain 3 520 3 606 3 691 3 702 3 300 0.6 914 1 267 778 341 304 R01AA05 oxymetazoline1)1 824 2 000 2 101 2 047 1 563 0.3 607 562 284 110 153 R01AA07 xylometazoline1)1 700 1 618 1 596 1 671 1 745 0.3 310 706 497 232 151 R01AB Sympathomimetics, combinations excl. corticosteroids 387 427 495 480 435 0.1 12 190 145 88 38 R01AB06 xylometazoline1)387 427 495 480 435 0.1 12 190 145 88 38 R01AC Antiallergic agents, excl. corticosteroids 38 277 47 317 42 319 42 169 46 164 8.8 12 481 20 738 10 707 2 238 12 530 R01AC01 cromoglicic acid1)7 646 8 651 7 724 7 457 7 607 1.4 1 813 3 132 2 202 460 1 988 R01AC02 levocabastine1)30 702 38 754 34 707 34 878 38 774 7.4 10 761 17 688 8 539 1 786 10 542 R01AC03 azelastine 132 214 101 0 0 0.0 0 0 0 0 0 R01AD Corticosteroids 279 941 305 163 316 591 325 942 351 612 66.6 23 718 157 088 132 001 38 805 119 747 R01AD04 flunisolide 10 12 12 12 12 0.0 0 0 8 <5 18 R01AD05 budesonide 28 699 28 577 26 320 25 023 25 004 4.7 1 005 8 450 11 715 3 834 8 976 R01AD08 fluticasone 21 129 21 841 21 422 21 199 21 209 4.0 1 012 6 986 9 959 3 252 11 039 R01AD09 mometasone1)152 995 160 714 160 158 161 114 171 090 32.4 10 734 72 855 66 696 20 805 41 228 R01AD11 triamcinolone1)6 924 6 975 6 357 6 023 5 719 1.1 170 2 009 2 690 850 2 423 R01AD12 fluticasone furoate 79 316 92 012 88 457 87 374 92 014 17.4 8 924 45 175 30 254 7 661 17 951 R01AD58 fluticasone, combinations 1 551 7 848 31 101 42 588 55 895 10.6 2 723 30 637 18 164 4 371 38 110 R01AX Other nasal preparations 1 000 1 224 1 312 1 482 1 923 0.4 158 738 543 484 1 114 R01AX03 ipratropium bromide 534 615 590 585 791 0.2 <5 121 272 396 705 R01AX06 mupirocin 466 609 722 899 1 134 0.2 156 617 273 88 409 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 89 209 84 739 92 553 97 245 105 358 20.0 1 984 55 018 41 846 6 510 14 746 R01BA Sympathomimetics 89 209 84 739 92 553 97 245 105 358 20.0 1 984 55 018 41 846 6 510 14 746 R01BA01 phenylpropanolamine 89 207 84 735 92 551 97 241 105 358 20.0 1 984 55 018 41 846 6 510 14 746 R01BA51 phenylpropanolamine, combinations 0 0 <5 <5 0 0.0 0 0 0 0 R01BA52 pseudoephedrine, combinations <5 <5 <5 0 0 0.0 0 0 0 0 0 R02 THROAT PREPARATIONS 0 231 601 860 959 0.2 59 538 245 117 94 R02A THROAT PREPARATIONS 0 231 601 860 959 0.2 59 538 245 117 94 R02AA Antiseptics 0 0 0 113 242 0.1 17 139 63 23 22 R02AA03 dichlorobenzyl alcohol 0 0 0 113 242 0.1 17 139 63 23 22 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.16 ATC group R - Respiratory system ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 0 231 601 748 721 0.1 42 400 185 94 72 R02AX01 flurbiprofen1)0 0 0 14 90 0.0 6 54 19 11 11 R02AX03 benzydamine1)0 231 601 735 639 0.1 36 350 170 83 61 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 418 306 430 210 437 217 448 102 457 872 86.8 70 871 115 358 171 948 99 695 1 180 526 R03A ADRENERGICS, INHALANTS 357 307 370 805 379 571 395 846 410 441 77.8 59 419 105 660 156 235 89 127 733 286 R03AA Alpha- and beta- adrenoreceptor agonists 201 157 122 68 52 0.0 35 13 <5 0 81 R03AA01 epinephrine 201 157 122 68 52 0.0 35 13 <5 0 81 R03AC Selective beta-2- adrenoreceptor agonists 266 976 278 642 283 524 297 047 308 927 58.5 57 346 84 358 109 693 57 530 144 821 R03AC02 salbutamol 219 571 231 841 239 799 255 957 270 499 51.3 56 621 74 567 92 434 46 877 89 282 R03AC03 terbutaline 29 979 29 663 28 384 27 455 25 686 4.9 720 8 676 11 512 4 778 9 415 R03AC04 fenoterol 14 17 16 11 11 0.0 0 <5 10 0 34 R03AC12 salmeterol 8 885 8 614 8 426 8 185 8 238 1.6 243 1 059 3 588 3 348 13 245 R03AC13 formoterol 13 601 12 919 12 162 11 282 10 731 2.0 150 1 921 5 059 3 601 17 147 R03AC18 indacaterol 9 343 9 391 7 525 6 114 5 163 1.0 0 67 2 267 2 829 13 713 R03AC19 olodaterol 0 131 817 927 1 029 0.2 0 29 498 502 1 985 R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 180 135 183 306 187 955 192 942 196 252 37.2 7 999 47 844 88 079 52 330 492 871 R03AK06 salmeterol and fluticasone 94 551 92 173 88 212 83 967 78 843 14.9 6 194 17 957 32 447 22 245 178 848 R03AK07 formoterol and budesonide 83 758 83 643 82 837 80 791 78 736 14.9 864 19 457 37 647 20 768 187 997 R03AK08 formoterol and beclometasone 4 443 5 526 8 761 13 249 17 061 3.2 121 4 343 8 255 4 342 43 209 R03AK10 vilanterol and fluticasone furoate 0 5 049 12 815 20 372 26 166 5.0 879 6 603 11 945 6 739 71 438 R03AK11 formoterol and fluticasone 2 239 3 733 3 673 4 045 4 482 0.9 160 1 441 2 020 861 11 379 R03AL Adrenergics in combinations with anticholinergics incl. triple combinations with corticosteroids 0 4 849 10 887 17 031 22 168 4.2 <5 270 9 935 11 962 95 514 R03AL02 salbutamol and ipratropium bromide 0 0 0 <5 0 0 1 R03AL03 vilanterol and umeclidinium bromide 0 137 2 442 4 546 6 634 1.3 0 79 3 017 3 538 28 160 R03AL04 indacaterol and glycopyrronium bromide 0 4 720 7 447 7 618 7 435 1.4 0 65 3 230 4 140 33 769 R03AL05 formoterol and aclidinium bromide 0 0 919 2 538 2 823 0.5 0 38 1 334 1 451 10 828 R03AL06 olodaterol and tiotropium bromide 0 0 440 3 086 5 969 1.1 <5 83 2 625 3 260 22 064 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 0 337 0.1 0 9 168 160 692 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 153 128 159 015 159 601 162 051 165 633 31.4 42 570 25 865 53 546 43 652 278 914 R03BA Glucocorticoids 91 993 96 580 97 203 99 473 103 028 19.5 42 122 21 961 26 782 12 163 88 708 R03BA01 beclometasone 3 713 3 822 3 692 3 652 3 817 0.7 777 951 1 359 730 2 836 R03BA02 budesonide 19 625 18 785 17 790 17 063 16 579 3.1 1 858 3 985 6 875 3 861 22 661 R03BA05 fluticasone 61 703 64 166 63 633 64 979 67 460 12.8 39 599 11 978 11 178 4 705 38 916 R03BA07 mometasone 703 578 431 392 348 0.1 10 115 157 66 502 R03BA08 ciclesonide 8 080 11 093 13 598 15 260 16 702 3.2 735 5 329 7 658 2 980 23 794 R03BB Anticholinergics 66 894 68 515 68 640 69 233 69 975 13.3 1 026 5 313 29 799 33 837 190 174 R03BB01 ipratropium bromide 28 751 28 642 29 165 30 118 30 696 5.8 1 018 4 436 12 565 12 677 26 708 R03BB04 tiotropium bromide 41 458 40 771 40 057 38 667 37 851 7.2 21 950 16 201 20 679 140 040 R03BB05 aclidinium bromide 1 518 2 631 2 976 3 048 2 929 0.6 0 45 1 341 1 543 8 352 R03BB06 glycopyrronium bromide 1 899 2 874 2 251 1 905 1 705 0.3 0 25 815 865 5 508 R03BB07 umeclidinium bromide 0 0 214 1 854 3 072 0.6 0 55 1 491 1 526 9 567 R03BC Antiallergic agents, excl. corticosteroids 345 364 <5 32 R03BC01 cromoglicic acid <5 <5 5 <5 32 R03C ADRENERGICS FOR SYSTEMIC USE 27 069 23 347 20 579 13 869 4 772 0.9 2 469 754 1 074 475 1 584 R03CA Alpha- and beta- adrenoreceptor agonists 12 615 8 918 7 536 4 389 3 636 0.7 2 039 632 729 236 1 029 R03CA02 ephedrine 12 615 8 918 7 536 4 389 3 636 0.7 2 039 632 729 236 1 029 R03CC Selective beta-2- adrenoreceptor agonists 14 953 14 831 13 286 9 634 1 161 0.2 445 127 350 239 555 R03CC02 salbutamol 3 497 3 141 2 693 3 741 483 0.1 391 33 36 23 138 R03CC03 terbutaline 11 371 11 582 10 520 6 105 536 0.1 54 80 248 154 250 R03CC12 bambuterol 206 218 172 145 150 0.0 <5 16 71 62 161 R03CC13 clenbuterol 0 0 <5 <5 <5 - 0 <5 0 0 6 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 41 450 40 854 39 980 39 686 39 924 7.6 5 908 9 834 16 574 608 742 R03DA Xanthines 2 677 2 316 2 017 0.4 <5 97 933 985 2 700 R03DA02 choline theophyllinate 7 6 5 0 0 0.0 0 0 0 0 0 R03DA04 theophylline 3 417 3 039 2 667 2 305 2 006 0.4 <5 94 925 985 2 617 R03DA05 aminophylline 17 12 13 15 16 0.0 0 <5 11 <5 83 R03DC Leukotriene receptor antagonists 37 874 37 473 36 608 36 321 36 373 6.9 5 872 9 155 15 120 6 226 29 372 R03DC01 zafirlukast 19 20 17 15 16 0.0 0 0 8 8 185ATC group R ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 36 591 36 306 36 357 6.9 5 872 9 155 15 112 6 218 29 187 R03DX Other systemic drugs for obstructive airway diseases 1 303 1 452 1 764 2 147 2 691 0.5 58 796 1 157 680 134 671 R03DX05 omalizumab 256 413 752 1 122 1 519 0.3 761 612 88 108 361 R03DX07 roflumilast 1 049 1 039 1 012 977 997 0.2 0 6 426 565 4 453 R03DX08 reslizumab 0 0 0 0 <5 - 0 0 <5 0 18 R03DX09 mepolizumab 0 0 0 61 197 0.0 0 34 136 27 21 838 R05 COUGH AND COLD PREPARATIONS 375 140 356 030 387 309 390 932 389 149 73.8 26 079 123 767 158 311 80 992 97 994 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 113 563 104 508 106 875 103 679 101 730 19.3 5 674 18 996 39 893 37 167 45 894 R05CA Expectorants 3 977 5 185 5 302 6 010 5 064 1.0 1 774 1 218 1 289 783 445 R05CA03 guaifenesin 0 0 0 <5 0 0.0 0 0 0 0 0 R05CA10 combinations1)3 977 5 185 5 302 6 007 5 064 1.0 1 774 1 218 1 289 783 445 R05CB Mucolytics 110 174 100 034 102 333 98 519 97 444 18.5 3 977 17 933 38 898 36 636 45 449 R05CB01 acetylcysteine1)106 696 96 331 98 792 94 871 93 303 17.7 1 747 17 271 38 180 36 105 36 489 R05CB02 bromhexine1)4 134 4 351 4 157 4 300 4 689 0.9 2 204 734 959 792 799 R05CB13 dornase alfa ( desoxyribonuclease) 129 145 155 156 165 0.0 54 94 14 <5 8 161 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 259 319 246 923 271 827 275 066 273 933 51.9 18 237 95 756 114 361 45 579 43 065 R05DA Opium alkaloids and derivatives 259 319 246 923 271 827 275 066 273 933 51.9 18 237 95 756 114 361 45 579 43 065 R05DA01 ethylmorphine 250 796 238 540 262 841 266 227 265 341 50.3 17 723 93 173 110 622 43 823 39 703 R05DA03 hydrocodone 514 441 493 395 364 0.1 <5 72 185 106 191 R05DA04 codeine 6 904 6 709 7 207 7 015 6 853 1.3 44 2 223 3 234 1 352 2 167 R05DA07 noscapine1)1 636 1 771 1 818 2 177 496 695 715 364 260 R05DA09 dextromethorphan <5 0 0 0 0 0.0 0 0 0 0 0 R05DA20 combinations 2 631 2 619 2 746 2 532 2 369 0.5 35 626 1 183 525 745 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 46 193 44 505 51 619 55 023 55 933 10.6 3 175 19 888 23 226 9 644 9 034 R05FA Opium derivatives and expectorants 46 193 44 505 51 619 55 023 55 933 10.6 3 175 19 888 23 226 9 644 9 034 R05FA02 opium derivatives and expectorants 46 193 44 505 51 619 55 023 55 933 10.6 3 175 19 888 23 226 9 644 9 034 R06 ANTIHISTAMINES FOR SYSTEMIC USE 555 485 615 581 618 356 642 752 683 165 129.5 84 659 280 533 241 279 76 694 228 904 R06A ANTIHISTAMINES FOR SYSTEMIC USE 555 485 615 581 618 356 642 752 683 165 129.5 84 659 280 533 241 279 76 694 228 904 R06AA Aminoalkyl ethers 29 44 50 2 581 8 784 1.7 8 3 885 3 764 1 127 3 375 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 7 <5 <5 6 R06AA04 clemastine 18 20 13 20 13 0.0 0 6 <5 <5 26 R06AA09 doxylamine 0 0 0 2 535 8 741 1.7 8 3 871 3 746 1 116 3 190 R06AA52 diphenhydramine, combinations 0 19 29 17 20 0.0 0 <5 13 6 154 R06AB Substituted alkylamines 19 417 18 231 11 520 5 868 5 347 1.0 1 245 1 640 1 647 815 5 211 R06AB02 dexchlorpheniramine 19 417 18 231 11 520 5 868 5 347 1.0 1 245 1 640 1 647 815 5 211 R06AD Phenothiazine derivatives 66 678 69 771 71 384 72 539 72 702 13.8 3 450 27 104 31 071 11 077 50 140 R06AD01 alimemazine 60 961 63 783 65 267 66 312 66 923 12.7 3 411 24 485 28 802 10 225 47 592 R06AD02 promethazine 6 242 6 509 6 681 6 799 6 324 1.2 42 2 888 2 495 899 2 547 R06AD03 thiethylperazine 6 5 6 <5 0 0.0 0 0 0 0 0 R06AE Piperazine derivatives 277 991 297 671 285 600 285 951 291 357 55.2 34 273 110 443 107 420 39 221 65 708 R06AE03 cyclizine1)774 837 947 1 076 1 098 0.2 36 258 515 289 964 R06AE05 meclozine1)2 613 2 983 3 202 3 378 3 838 0.7 120 3 047 437 234 511 R06AE07 cetirizine1)274 382 293 687 281 322 281 412 286 302 54.3 34 106 107 135 106 364 38 697 63 667 R06AE09 levocetirizine 572 619 597 600 612 0.1 22 251 271 68 566 R06AX Other antihistamines for systemic use 223 948 268 418 285 906 311 620 343 951 65.2 49 689 153 960 111 651 28 651 104 470 R06AX02 cyproheptadine 31 32 35 29 25 0.0 <5 6 10 6 58 R06AX13 loratadine1)61 729 62 810 57 892 55 508 54 389 10.3 1 551 22 965 22 420 7 453 15 851 R06AX17 ketotifen 10 7 7 11 11 0.0 0 <5 <5 <5 21 R06AX22 ebastine1)9 205 9 554 11 024 11 836 12 808 2.4 240 5 440 5 711 1 417 7 914 R06AX26 fexofenadine1)29 771 34 434 36 382 39 227 42 308 8.0 769 21 303 16 123 4 113 15 522 R06AX27 desloratadine 129 266 169 031 188 287 212 900 243 334 46.1 47 479 109 167 70 307 16 381 65 034 R06AX28 rupatadine 0 0 38 130 122 0.0 21 63 33 5 65 R06AX29 bilastine 0 <5 10 12 23 0.0 0 13 7 <5 6 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 12 15 18 39 49 0.0 11 32 <5 <5 62 214 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 12 15 18 39 49 0.0 11 32 <5 <5 62 214 R07AX Other respiratory system products 9 8 10 26 41 0.0 6 32 <5 0 62 117 R07AX02 ivacaftor 9 8 10 11 13 0.0 <5 6 <5 0 26 718 R07AX30 ivacaftor and lumacaftor 0 0 0 15 28 0.0 <5 26 0 0 35 400 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 107 039 192 919 213 636 155 156 401 363 S01 OPHTHALMOLOGICALS 540 362 578 242 569 991 572 678 596 365 113.0 93 301 169 350 187 981 145 733 385 563 S01A ANTIINFECTIVES 249 591 252 458 246 266 240 135 243 440 46.1 59 538 71 690 74 256 37 956 49 766 S01AA Antibiotics 246 579 249 383 243 182 236 834 239 976 45.5 59 405 70 533 72 855 37 183 48 138 S01AA01 chloramphenicol 185 720 193 008 190 237 187 623 193 942 36.8 42 466 59 466 61 566 30 444 42 488 S01AA02 chlortetracycline 0 6 <5 0 <5 <5 3 S01AA11 gentamicin 111 42 37 31 17 0.0 0 8 6 <5 3 S01AA12 tobramycin 1 783 1 0.3 391 444 285 126 S01AA13 fusidic acid 64 306 60 942 55 790 51 375 48 485 9.2 18 951 11 721 11 328 6 485 3 945 S01AA26 azithromycin 8 981 6 944 6 268 5 796 5 330 1.0 1 552 1 520 1 419 839 620 S01AA27 cefuroxime 0 0 <5 0 0 0.0 0 0 0 0 0 S01AA30 combinations of different antibiotics 4 797 5 579 5 758 6 263 6 446 1.2 284 1 298 2 564 2 300 951 S01AD Antivirals 3 230 3 287 2 908 3 300 3 375 0.6 115 898 1 358 1 004 842 S01AD02 trifluridine 0 0 0 0 <5 - 0 <5 0 0 6 S01AD03 aciclovir 3 230 3 287 2 908 3 300 3 374 0.6 115 897 1 358 1 004 836 S01AE Fluoroquinolones 2 613 2 669 2 844 2 926 3 082 0.6 120 1 130 1 274 558 750 S01AE03 ciprofloxacin 2 613 2 669 2 844 2 926 3 082 0.6 120 1 130 1 274 558 750 S01AX Other antiinfectives <5 8 8 0 1 S01B ANTIINFLAMMATORY AGENTS 51 179 53 602 59 747 62 824 67 149 12.7 2 436 11 329 23 152 30 232 24 711 S01BA Corticosteroids, plain 33 532 35 407 37 696 42 473 48 920 9.3 2 393 10 328 17 929 18 270 13 752 S01BA01 dexamethasone 20 553 21 838 23 154 29 392 36 013 6.8 790 6 168 13 648 15 407 10 742 S01BA02 hydrocortisone 0 0 0 0 60 0.0 <5 18 26 15 13 S01BA04 prednisolone 13 742 14 636 15 448 16 479 17 943 3.4 1 721 5 800 6 635 3 787 2 823 S01BA07 fluorometholone 7 9 9 25 17 0.0 0 <5 6 7 20 S01BA09 clobetasone 15 13 12 12 14 0.0 0 <5 7 <5 33 S01BA13 rimexolone 4 162 4 105 4 322 2 440 83 0.0 <5 19 40 21 121 S01BB Corticosteroids and mydriatics in combination <5 0 0 0 0 0.0 0 0 0 0 0 S01BB03 fluorometholone and mydriatics <5 0 0 0 0 0.0 0 0 0 0 0 S01BC Antiinflammatory agents, non-steroids 20 187 21 212 26 341 27 895 28 399 5.4 59 1 377 8 250 18 713 10 959 S01BC03 diclofenac 6 137 6 025 7 513 7 688 7 732 1.5 43 787 2 554 4 348 1 7893.17 ATC group S - Sensory organs ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 9 786 12 824 15 204 17 423 3.3 10 361 4 877 12 175 8 379 S01BC11 bromfenac 5 325 5 715 6 465 5 400 3 545 0.7 6 239 928 2 372 790 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION 57 314 58 553 55 152 49 893 43 762 8.3 937 7 315 15 543 19 967 8 080 S01CA Corticosteroids and antiinfectives in combination 57 314 58 553 55 152 49 893 43 762 8.3 937 7 315 15 543 19 967 8 080 S01CA01 dexamethasone and antiinfectives 57 314 58 553 55 152 49 893 43 762 8.3 937 7 315 15 543 19 967 8 080 S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS 72 192 72 872 73 674 74 978 76 099 14.4 290 2 407 21 434 51 968 150 401 S01EA Sympathomimetics in glaucoma therapy 4 920 5 140 5 385 4 901 4 787 0.9 10 189 1 238 3 350 4 395 S01EA01 epinephrine <5 0 0 0 0 0.0 0 0 0 0 0 S01EA03 apraclonidine 155 193 238 169 205 0.0 <5 25 80 99 89 S01EA05 brimonidine 4 805 4 998 5 195 4 772 4 633 0.9 9 167 1 173 3 284 4 306 S01EB Parasympathomimetics 1 012 955 907 917 910 0.2 5 50 269 586 1 197 S01EB01 pilocarpine 1 012 955 907 917 910 0.2 5 50 269 586 1 197 S01EB02 carbachol <5 0 0 0 0 0.0 0 0 0 0 0 S01EC Carbonic anhydrase inhibitors 10 892 11 093 11 510 12 539 13 374 2.5 165 833 3 301 9 075 18 732 S01EC01 acetazolamide 1 840 1 822 1 611 1 687 2 065 0.4 54 584 741 686 1 165 S01EC03 dorzolamide 2 357 2 430 2 567 2 840 3 152 0.6 19 100 778 2 255 4 775 S01EC04 brinzolamide 7 109 7 266 7 478 7 486 7 290 1.4 97 142 1 569 5 482 8 977 S01EC05 methazolamide 0 <5 0 0 0 0.0 0 0 0 0 0 S01EC54 brinzolamide, combinations 0 0 614 1 554 2 062 0.4 <5 44 530 1 487 3 815 S01ED Beta blocking agents 49 878 50 197 50 545 51 182 51 703 9.8 199 1 320 14 523 35 661 74 258 S01ED01 timolol 21 606 21 495 21 520 21 391 21 098 4.0 145 555 6 557 13 841 22 037 S01ED02 betaxolol 1 247 1 150 960 834 723 0.1 6 10 139 568 427 S01ED51 timolol, combinations 29 164 29 552 30 224 31 281 32 044 6.1 62 855 8 527 22 600 51 794 S01EE Prostaglandin analogues 37 446 37 948 38 604 38 866 38 665 7.3 47 748 10 174 27 696 51 820 S01EE01 latanoprost 23 338 23 693 24 167 24 533 24 257 4.6 32 441 6 189 17 595 24 020 S01EE03 bimatoprost 2 247 2 344 2 584 2 380 2 444 0.5 0 89 636 1 719 4 265 S01EE04 travoprost 7 095 6 454 5 844 5 206 4 520 0.9 <5 57 979 3 483 7 485 S01EE05 tafluprost 5 994 6 577 7 157 7 675 8 197 1.6 14 174 2 576 5 433 16 050 S01F MYDRIATICS AND CYCLOPLEGICS 5 318 5 397 5 201 5 556 4 995 1.0 352 1 340 2 168 1 135 1 028 S01FA Anticholinergics 5 311 5 384 5 194 5 540 4 976 0.9 352 1 336 2 154 1 134 1 018 S01FA01 atropine 2 185 2 033 1 850 1 553 1 336 0.3 267 311 490 268 282ATC group S ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 0 65 S01FA04 cyclopentolate 3 177 3 401 3 365 4 059 3 749 0.7 81 1 080 1 704 884 636 S01FA06 tropicamide 139 168 162 128 86 0.0 6 26 43 11 34 S01FA54 cyclopentolate, combinations antiglaucoma preparations 28 46 39 46 51 0.0 0 13 33 5 10 S01FB01 phenylephrine 28 46 39 46 51 0.0 0 13 33 5 10 S01G DECONGESTANTS AND ANTIALLERGICS 163 518 195 587 184 818 185 939 201 407 38.2 33 865 88 223 62 856 16 463 64 406 S01GA Sympathomimetics used as decongestants 19 136 21 906 20 453 19 535 20 161 3.8 1 944 8 922 7 437 1 858 5 990 S01GA01 naphazoline1)0 0 0 5 <5 6 <5 2 S01GA52 tetryzoline, combinations1)19 136 21 906 20 453 19 530 20 152 3.8 1 943 8 920 7 434 1 855 5 988 S01GX Other antiallergics 147 512 177 610 167 905 169 762 185 118 35.1 32 593 81 024 56 644 14 857 58 416 S01GX01 cromoglicic acid1)21 636 25 240 23 575 23 034 23 718 4.5 3 520 9 358 8 508 2 332 8 593 S01GX02 levocabastine1)75 061 91 780 86 161 87 921 97 537 18.5 18 262 43 356 28 748 7 171 24 960 S01GX04 nedocromil 1 395 1 168 0 0 0 0.0 0 0 0 0 0 S01GX06 emedastine 345 384 380 398 413 0.1 82 164 120 47 138 S01GX07 azelastine 508 615 118 0 0 0.0 0 0 0 0 0 S01GX08 ketotifen1)17 238 21 010 20 747 21 391 23 557 4.5 4 038 10 145 7 379 1 995 9 397 S01GX09 olopatadine 35 267 43 210 41 899 41 694 45 550 8.6 8 110 20 163 13 509 3 768 15 328 S01X OTHER OPHTHALMOLOGICALS 45 774 52 953 61 068 69 031 79 804 15.1 662 8 113 31 769 39 260 86 882 S01XA Other ophthalmologicals 45 774 52 953 61 068 69 031 79 804 15.1 662 8 113 39 260 86 882 S01XA03 sodium chloride, hypertonic 15 21 22 29 35 0.0 0 <5 9 24 50 S01XA08 acetylcysteine 0 0 0 0 <5 - 0 0 <5 0 10 S01XA18 ciclosporin 474 601 784 1 823 2 697 0.5 44 457 1 344 852 19 791 S01XA20 artificial tears and other indifferent preparations1)45 650 52 768 60 851 68 604 79 216 15.0 628 7 985 31 503 39 100 65 976 S01XA21 mercaptamine 0 0 0 0 6 0.0 <5 <5 0 0 815 S02 OTOLOGICALS 20 091 23 042 24 528 22 510 20 226 3.8 4 237 6 232 6 786 2 971 3 726 S02A ANTIINFECTIVES 8 282 7 549 6 437 5 536 5 224 1.0 1 715 1 555 1 353 601 906 S02AA Antiinfectives 8 282 7 549 6 437 5 536 5 224 1.0 1 715 1 555 1 353 601 906 S02AA01 chloramphenicol 11 11 13 11 0 0.0 0 0 0 0 0 S02AA03 boric acid 7 <5 <5 8 20 0.0 0 7 11 <5 11 S02AA15 ciprofloxacin 8 264 7 537 6 423 5 520 5 204 1.0 1 715 1 548 1 342 599 895 S02B CORTICOSTEROIDS 10 784 10 853 12 168 7 855 1 355 0.3 16 284 679 376 250 S02BA Corticosteroids 10 784 10 853 12 168 7 855 1 355 0.3 16 284 679 376 250 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group S ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales betamethasone 10 784 10 853 12 168 7 855 1 355 0.3 16 284 679 376 250 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 1 764 5 664 7 031 10 163 14 369 2.7 2 644 4 587 5 015 2 123 2 570 S02CA Corticosteroids and antiinfectives in combination 1 764 5 664 7 031 10 163 14 369 2.7 2 644 4 587 5 015 2 123 2 570 S02CA02 flumetasone and antiinfectives 64 101 74 62 59 0.0 <5 9 34 13 24 S02CA05 fluocinolone acetonide and antiinfectives 1 702 5 565 6 965 10 104 14 314 2.7 2 641 4 578 4 984 2 111 2 547 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 73 853 75 987 72 119 74 436 74 488 14.1 13 272 22 825 26 810 11 581 12 074 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 73 853 75 987 72 119 74 436 74 488 14.1 13 272 22 825 26 810 11 581 12 074 S03CA Corticosteroids and antiinfectives in combination 73 853 75 987 72 119 74 436 74 488 14.1 13 272 22 825 26 810 11 581 12 074 S03CA01 dexamethasone and antiinfectives 12 789 12 881 10 738 10 956 10 854 2.1 856 2 868 4 800 2 330 1 439 S03CA04 hydrocortisone and antiinfectives 63 093 65 069 63 014 65 134 65 319 12.4 12 552 20 469 22 737 9 561 10 635ATC group S ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 70 Legemiddelstatistikk 2018:2 Folkehelseinstituttet 131V VARIOUS 23 985 27 789 30 050 32 701 35 380 6.7 4 807 11 601 11 429 7 543 193 097 V01 ALLERGENS 9 462 10 346 11 619 12 876 14 582 2.8 2 606 9 304 2 581 91 104 542 V01A ALLERGENS 9 462 10 346 11 619 12 876 14 582 2.8 2 606 9 304 2 581 91 104 542 V01AA Allergen extracts 9 462 10 346 11 619 12 876 14 582 2.8 2 606 9 304 2 581 91 104 542 V01AA02 grass pollen 6 829 7 480 8 644 9 845 11 002 2.1 1 870 7 334 1 761 37 67 830 V01AA03 house dust mites 539 552 556 514 933 0.2 117 630 176 10 6 157 V01AA05 tree pollen 4 896 5 287 5 535 5 791 6 259 1.2 1 204 3 751 1 263 41 25 369 V01AA07 insects 160 148 165 149 144 0.0 17 39 74 14 962 V01AA10 flowers 149 120 96 43 <5 - 0 0 <5 <5 9 V01AA11 animals 494 526 569 555 513 0.1 89 316 104 <5 4 215 V03 ALL OTHER THERAPEUTIC PRODUCTS 2 655 3 018 3 300 3 537 3 876 0.7 86 455 1 567 1 768 78 947 V03A ALL OTHER THERAPEUTIC PRODUCTS 2 655 3 018 3 300 3 537 3 876 0.7 86 455 1 567 1 768 78 947 V03AB Antidotes 105 108 100 120 82 0.0 <5 32 46 <5 326 V03AB01 ipecacuanha 7 8 <5 2 V03AB03 edetates 0 0 0 <5 0 0.0 0 0 V03AB06 thiosulfate <5 <5 <5 <5 0 0.0 0 0 0 0 0 V03AB09 dimercaprol 9 8 12 6 6 0.0 0 <5 <5 0 61 V03AB14 protamine 0 0 0 <5 0 0.0 0 0 0 0 0 V03AB15 naloxone 14 14 12 20 11 0.0 0 5 6 0 6 V03AB16 ethanol <5 <5 <5 0 chloride 0 0 0 0 2 V03AB19 physostigmine 0 <5 0 0 <5 - <5 amyl nitrite 0 0 0 0 2 V03AB32 glutathione 67 61 63 72 34 0.0 0 10 22 <5 129 V03AB33 hydroxocobalamin 0 0 <5 0 0 0.0 0 0 0 0 0 V03AC Iron chelating agents 112 127 122 139 144 0.0 30 38 36 40 16 945 V03AC01 deferoxamine 38 36 31 30 31 0.0 15 11 <5 <5 737 V03AC02 deferiprone 19 26 23 22 21 0.0 <5 5 7 5 920 V03AC03 deferasirox 73 83 82 105 109 0.0 18 29 26 36 15 288 V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia 2 241 2 486 2 699 2 813 2 965 0.6 <5 263 1 214 1 484 29 471 V03AE01 polystyrene sulfonate1)600 727 846 881 951 0.2 <5 77 385 486 2 043 V03AE02 sevelamer 1 551 1 746 1 790 1 862 1 987 0.4 <5 192 850 944 17 251 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.3.18 ATC-group V - Various ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales 473 603 644 562 0.1 0 53 258 251 8 999 V03AE04 calcium acetate and magnesium carbonate 98 96 95 19 12 0.0 0 <5 5 6 65 V03AE05 sucroferric oxyhydroxide 0 0 0 63 122 0.0 0 14 63 45 1 101 V03AE07 calcium acetate 18 0 0 0 0 0.0 0 0 0 0 0 V03AE09 patiromer calcium 0 0 0 0 <5 - 0 0 <5 0 12 V03AF Detoxifying agents for antineoplastic treatment 70 66 57 61 61 0.0 11 16 21 13 463 V03AF01 mesna 8 7 <5 9 10 0.0 0 <5 8 0 8 V03AF03 calcium folinate 52 59 55 52 51 0.0 11 14 13 13 454 V03AG Drugs for treatment of hypercalcemia 99 163 279 371 579 0.1 29 99 228 223 666 V03AH Drugs for treatment of hypoglycemia 17 20 28 24 28 0.0 10 <5 10 <5 2 167 V03AH01 diazoxide 17 20 28 24 28 0.0 10 <5 10 <5 2 167 V03AX Other therapeutic products <5 7 22 13 24 0.0 <5 <5 14 5 28 904 ATC group V ATC level2013 2014 2015 2016 2017 2017 2017 2017 Number of individuals Prevalence per 1 individuals per age groupSales Antibiotics ARB for Anatomical (classification medicines) ASA Acetylsalisylsyre ASA Acetylsalisylic acid DDD Definert d\u00f8gndose klassifikasjon av sykdommer versjon 10ICD 10 ICPC Internasjonal klassifikasjon av sykdommer for prim\u00e6rhelsetjenestenICPC Marketing Authorisation NIPH Norwegian Institute of Public Health NOK Norske kroner NOK Norwegian kroner Anti-Inflammatory Drug OTC Reseptfritt OTC Over The Counter, non prescription drugs RTI Respiratory tract infections SPC Preparatomtale SPC Summary of Product Characteristics SSB 2013-2017 (per 1. juli) Population in Norway 2013-2017 (as of 1st July) Year 2013 2014 2015 2016 2017 Population 5 080 148 5 137 321 5 189 984 5 236 624 5 276 847 Folkemengde etter alder i 2017 (per 1. juli) Population by age in 2017 (as of 1st July) Age groups <15 15-44 45-69 70 Population 907 264 2 i det definerte befolkningsutvalget. Definitions Prevalence Users (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample. Incidence (new users) Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population per 31.12.2017 List of publications based on data from the Norwegian Prescription Database (NorPD) as of 31.12.2017 2017: Antonazzo IC, Berge LI, Engeland A, Bernt Fasmer O, et al. Diabetes is associated with decreased migraine risk: A nationwide cohort study. Cephalalgia 2017:333102417748573. Baftiu A, Feet SA, Larsson PG, Burns ML, Henning O, Saetre E, et al. Utilisa - tion and polypharmacy aspects of antiepileptic drugs in elderly versus younger patients with epilepsy: A pharmacoepidemiological study of CNS- active drugs \u00d6verland S, et al. General practice consultations and use of prescription drugs after changes to school absence policy. Tidsskr Nor Laegeforen 2017;137(16):1178-84. Beisland C, Johannesen TB, Klepp O, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population- based study. S, et al. Does progestin-only contraceptive use after pregnancy affect recovery from pelvic girdle pain? A prospective population study. PLoS One 2017;12(9):14. Blandhol M, Tysland T, Blix HS, Hoye S. Antibiotic switch during treatment with antibiotics against respiratory tract infections in ambulatory care in Norway. Infect Dis (Lond) 2017;49(11-12):854-8. Brakedal B, Flones I, Reiter C, Assmus J, et al. Glitazone Use Associated With Reduced Risk of Parkinson's Disease. Mov Disord 2017;32(11):1594-9. But A, De Bruin ML, MT, Hjellvik M, Auvinen A, Starup- Linde F, Karlstad \u00d8, Ekstr\u00f8m, N, Haukka J. Cancer Risk among insulin users: comparing analogues with human insulin in the CARING Length in Users Acetylcholinesterase Dement Cogn Daltveit AK, Vikse BE, Haugen M. Low Calcium Intake in Midpregnancy Is Associated with Hypertension Develop - ment within 10 Years after Pregnancy: The Norwegian Mother and Child Cohort Study. Journal of Nutrition 2017;147(9):1757-63. Engeland A, Bjorge T, Klungsoyr K, Skurtveit S, Furu K. Preterm births and use of medication in early adulthood: a population-based registry study. Pharma- coepidemiology and , Schwarze PE, et al. Road traffic noise and registry based use of sleep medication. Environ Health 2017;16:12. Ezat B, Pihlstrom L, Aasly J, Tysnes OB, Egge A, Dietrichs E. Use of advanced therapies for Parkinson's disease in Norway. Tidsskr Nor Laegeforen 2017;137(9):619-23. Fadnes LT, Diaz E. Primary healthcare usage and use of medications among immigrant children according to age of arrival to Norway: a population-based study. of analgesics during complete disease trajectories in patients who are diagnosed with and die from cancer within the five-year period 2005-2009. European Journal of Pain 2017;21(3):530-40. Fredheim OMS, Skurtveit S, Borchgrevink PC. Provision of analgesics to children before and after the new recommendations on Tidsskr of Stimulants and Atomoxetine for Attention-Deficit/Hyperac- tivity Disorder among 5.4 million Children Using Population-based Longitu Data. agent quetiapine is increasingly not used as such: dispensed in Norway 2004-2015. Eur J Clin Pharmacol Graner D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy, and the risk of adverse neonatal outcomes and congenital malformations-A population based European 2017. Mar 1;356:j629. http://www.bmj.com/content/356/bmj.j629.long Grinde B, Engdahl B. Prescription database analyses indicates that the asthma medicine montelukast might protect against dementia: a hypothesis to be verified. Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years. JAMA Intern Med 2017;177(12):1774-80. Halvorsen S, C, Falck P , Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J-Cardiovasc Pharmacother 2017;3(1):28-36. Hoff M, Meyer HE, Skurtveit AJ, Syversen U, et al. Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. despite easy access to contraception and L, Reichborn-Kjennerud E, et al. Hypnotics use in children 0-18 months: moderate agreement between mother-reported survey data and prescription registry data. J 2017;10:28. Johannsdottir Karlstad O, Loge Skurtveit S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A PA. Fecal carriage of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae after urinary tract infection - A three year prospective cohort study. PLoS One 2017;12(3):16. and Treatment in Relation to Children's Birth Month: Nationwide Study from Norway. Scand J Public Health. 2017 Jun;45:343-9. Kaspersen F, Ose SO, JH. Employees' drug purchases before and after organizational downsizing: a natural experiment on the Norwegian working population (2004-2012). Scand J Work Environ Health 2017;43(4):307-15. Kjerpeseth Selmer R, Ariansen I, Furu K, Skovlund E. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, to Kravdal \u00d8, of antidepres- sant medication in late mid-life: a register-based analysis of Norwegian women and men. Aging Ment Health. 2017 May;21(5):477-486. doi: 10.1080/13607863.2015.1118010. Epub Gemzell-Danielsson K, Heikinheimo O, Hognert H, Milsom I, et al. Contraceptive use O. Incidence of and factors associated with anticholinergic drug use among Norwegian women with urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2017;04:04. Milenkovic M, Haavik S. Recording of pharmaceutical interventions of potential clinical importance in Norwegian pharmacies. Norsk Farmaceutisk Tidsskrift M, Forsmo S, et al. Psoriasis, fracture risk and bone mineral density: the HUNT Study, Norway. Br J Naldi L, Saunes M. The association between the clinical diversity of psoriasis and depres- sive symptoms: the 2017;31(12):2062-8. M\u00e5rild K, Blix HS, St\u00f6rdal K. Use of antibiotics in children during the period 2005 - 16. Tidsskr Nor Laegeforen 2017;137(18):1414-9. Nakken O, Lindstrom JC, Tysnes OB, Holmoy T. Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers. Amyotrophic Lateral sclerosis & Frontotemporal Degeneration 2017:1-8. Odsbu I, Selmer R, Lundborg CS, Blix HS. Increased prescribing of systemic tetracyclines and PM, et al. Maternal Folate Intake during Pregnancy and Childhood Asthma in a Population-based Cohort. Am J Respir Norwegian dentists: a survey over 25 years (1990- 2015). Eur J Oral Sci 2017;125(4):280-7. Raknes G, Smabrekke L. Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental PLoS and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database. Pharmacoepidemiology and Drug Safety 2017;26(6):685-93. Raknes G, Smabrekke L. A sudden and unprecedented increase in low dose naltrexone (LDN) prescribing in Norway. Patient and prescriber characteris- tics, and dispense patterns. A drug utilization cohort study. Pharmacoepide - miology and Drug Safety 2017;26(2):136-42. Rebnord, Midttun, \u00d8. et al. The kynurenine: tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia AK, Robsahm TE, et al. Cancer Risk in Women Treated with Fertility Drugs According to Parity Status-A Registry-based Cohort Study. Cancer Epidemiology Biomarkers & Prevention 2017;26(6):953-62. Sakshaug S, Handal M, Hjellvik V, Berg C, Ripel A, Gustavsen I, et al. Long- term Use of Z-Hypnotics and with Benzodiazepines J, Baz-Lomba JA, Bramness JG. Assessing prescription drug abuse using functional principal component analysis (FPCA) of waste - water data. Pharmacoepidemiology and Drug Safety 2017;26(3):320-6. Samuelsen PJ, Nielsen CS, Wilsgaard T, Stubhaug A, Svendsen K, Eggen AE. Pain sensitivity Jason LA, Kirkevold M. From good health to illness with post- infectious fatigue syndrome: a qualitative study of adults' experiences of the illness trajectory. BMC family practice 2017;18(1):49. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non-refu- gees from War-Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. Journal of Immigrant and Minority Health 2017;19(3):582-9. Svendsen K, Halvorsen KH, Vorren S, Samdal H, Garcia B. Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports? Eur J Clin Pharmacol 2017;18:18. Svendsen T, A, Burns Johannessen SI, Landmark CJ. Therapeutic Drug Monitoring of Lacosamide in Norway: Focus on - acetate-A national approach to the evalu - ation of therapeutic drug monitoring data and clinical outcome. Epilepsy Research 2017;129:125-31. Svendsen T, Brodtkorb E, Reimers A, variability, efficacy and tolerability of eslicarbazepine acetate-A national approach to the evaluation of therapeutic drug moni - toring data and clinical outcome. Epilepsy Res 2017;129:125-31. Efjestad A, Ihle-Hansen H, Hjellvik V, Blix HS. Length in Users Acetylcholinesterase Dement Cogn Seim A, Krokstad S, Helvik AS. Use of alcohol and drugs with addiction potential among older women and men in a population-based study. The Nord-Trondelag Health Study and users and disability pension: an eight-year nationwide observational follow-up study. Scand J Prim Health Care 2017;35(3):240-6. Urbaniak AM, Strom BO, Krontveit R, Svanqvist KH. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database. Drugs Aging 2017;34(8):635-45. Vie TL, Hufthammer KO, Holmen TL, Meland E, Breidablik HJ. Is self-rated health in adolescence a predictor of prescribed medication in adulthood? Findings from the Nord Tr\u00f8ndelag Health Study and the D\u00edez-Domingo Ziv-Baran T, Kim SK. Anti- biotic Use in Children - A Cross-National Analysis of 6 Countries. J Pediatr 2017;182:239-44. L. Psycho social factors are strongly associated with insomnia in users and nonusers of prescribed sleep medication: Evidence from the HUNT3 study. J Multidisci - 2016;9:547-55. SI, Larsson PG. Changes in of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological Dorum LM, et al. Aspirin as secondary prevention in patients with colorectal cancer: An S. Antipsychotic Drugs and Risk of Hip Fracture in People Aged 60 and Older in Norway. J Am Geriatr Soc AH, al. Prescription trajectories and effect of total hip arthroplasty on the use of analgesics, hypnotics, antidepressants, and anxiolytics: Results from a popu total hip N, et al. Opioids for outpatients with cancer in their last year of life: A nation - wide pharmacoepidemiological study. Journal of Opioid Management 2016;12(1):25-36. Charlton RA, Klungs\u00f8yr K, Neville AJ, Jordan S, Pierini A, de Jong-van den Berg LTW, et al. Prescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European Regions. PLoS One 2016; 18;11(5): e0155737. doi: 10.1371/journal.pone.0155737. Charlton RA, A, Klungs\u00f8yr K, Neville AJ, Jordan S, de Jong-van den Berg LT, et al. Asthma medication prescribing before, during and after pregnancy: a study in seven European regions. BMJ Open 2016 Jan 19;6(1):e009237. leiner HF, Bjoro T, Midthjell K, Grill V, Asvold BO. Prevalence of thyroid dysfunction in autoimmune and type 2 diabetes: The population-based hunt study in Norway. S, Lund IO, Handal M. A Unique Opportunity to Study Short and Long Term Consequences in Children Prenatally Exposed to Illicit Drugs and Opioid Maintenance Treat - ment Using Czech and Scandinavian Registers. Cent Eur J Public Health 2016;24(3):248-51. Garne E, Vinkel Hansen A, Morris J, Jordan S, Klungs\u00f8yr K, Engeland A, et al. Risk of congenital anomalies after exposure to asthma medica- tion in the first trimester of pregnancy - a cohort linkage study. BJOG 2016;123(10):1609-18. Gimeno-Feliu LA, Calderon-Larranaga A, Prados-Torres A, Revilla-Lopez C, Diaz E. Patterns of pharmaceutical use for immigrants to Spain and Norway: a comparative study of prescription databases in two European countries. International Journal for Equity in Health 2016;15. Halvorsen S, Jortveit J, Hasvold P , Thuresson M, \u00d8ie E. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial Nesv\u00e5g R, Handal M. Antidepressant drug use among adolescents during drug use among 0-17 year olds during 2004-2014: a nationwide prescription database S. of Antidepressants to Survivors of Cancer in Childhood, Adoles - cence, and Young Adulthood: A Population-Based Study. J Adolesc Young Adult Oncol 2016;14:14. Jordan S, Morris JK, Davies GI, Tucker D, Thayer DS, Luteijn JM, Linked Databases in Wales, Martikainen Kieler H, et al. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries. Eur J Clin Pharmacol 2016;72(12):1507-14. Kaspersen SL, Pape K, Ose Unemployment and initiation of psychotropic medication: a case-crossover study of 2 348 Occup Environ Med 2016;73(11):719-26. Kjaerulff TM, Ersboll AK, Green A, Emneus M, Pukkala E, Bolin K, et al. Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study. Scand J Urol 2016;50(3):220-7. KM, Engeland A, Gilhus AM, Owe JF. Does the choice of antiepileptic drug patients? J Neurooncol 2016;129(3):461-9. Kravdal \u00d8, Grundy E. Health effects of parental deaths among adults in Norway: Purchases of prescription medicine before and after bereavement. SSM - Population Nystad W. Prenatal and infant paracetamol exposure and development of asthma: The Norwegian Mother and Child Cohort Study. Int J 2016;45(2):512- al. Maternal plasma total neopterin and kynurenine/tryptophan levels during pregnancy in relation to asthma development in the offspring. J Allergy Clin Immunol 2016;138(5):1319-25.e4. M, M, Schreuder P , Tambs K, Vold L, Stoltenberg C. Cohort Profile Update: The Norwegian Mother and Child Cohort Study (MoBa). Int J Epidemiol. 2016;45(2):382-8. Mellbye A, Borchgrevink OMS. The duration and course of opioid therapy in patients with chronic non-malig JW, Dalgard O. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. Hjellvik V, Handal M, Skurtveit S. Mental disorder diagnoses among children and adolescents who use antipsychotic drugs. Eur Neuropsychopharmacol 2016;26:1412-8. Olah KS, Kim TH, Lee HH, Kim JM. Re: Use of hormonal contraceptives among immigrant and native women in Norway: data from the Norwe- gian Prescription Database The contraceptive situation in Korea. BJOG 2016;123(5):840. Roman M, Graff-Iversen S, Weiderpass E, Vangen S, Sakshaug S, Hofvind S, et al. Postmenopausal hormone therapy and breast cancer prognostic char - acteristics: A linkage between nationwide registries. Cancer Epidemiology Biomarkers and Prevention 2016;25(11):1464-73. Roman M, Sakshaug S, Graff-Iversen S, Vangen S, Weiderpass E, Ursin G, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway. Int J Cancer 2016;138(3):584-93. Samuelsen PJ, Svendsen K, Wilsgaard T, Stubhaug A, Nielsen CS, Eggen AE. Persistent analgesic use and the association with chronic pain and other risk factors in the population-a longitudinal study from the Tromso Study and the Norwegian Prescription Database. Eur J Clin Pharmacol 2016;72:977-85. Selmer R, Haglund B, Furu K, Andersen M, Norgaard M, Zoega H, et al. Individual-based versus aggregate meta-analysis in multi-database studies of pregnancy outcomes: the Nordic example of selective serotonin reuptake inhibitors and venlafaxine in pregnancy. Pharmacoepidemiol Drug Saf 2016;25(10):1160-9. Skipenes VP , Skjeldestad FE. Prevalence of combined Acta Obstet Gynecol Scand 2016;95(9):1027-33. S\u00f8rensen M, Arneberg F, Line TM, Berg TJ. Cost of diabetes in Norway 2011. Diabetes Res Clin Pract 2016;122:124-32. Straiton ML, Reneflot A, Diaz E. Mental Health of Refugees and Non-refugees from War-Conflict Countries: Data from Primary Healthcare Services and the Norwegian Prescription Database. J Immigr Minor Health 2016;21:21. Tjagvad C, Skurtveit S, Bramness JG, Gjersing L, Gossop M, Clausen T. Misuse of prescription drugs and overdose deaths. Journal of Substance Use 2016;21(5):515-20. Tvete IF, Bj\u00f8rner T, Skomedal T. A 5-year follow-up study of users of benzodiazepine: Starting with diazepam versus oxazepam. Br J Gen Pract 2016;66(645):e241-e7. \u00d8vre-Eide V, Skjeldestad FE. Use pattern Acta Gynecol Handal M. Reduced Prescribing M. prescriptions and cycles of Mycoplasma pneumoniae infections in Norway: can a nationwide prescription register be used for surveil- lance? Epidemiology and Infection. Skurtveit S, Clausen T, Kun\u00f8e N. The Norwegian Offender Mental Health and Addiction Study - Design and Implementation of a National Survey and Prospective Cohort Study. Subst Abuse. 2015;9(Suppl 2):59-66. doi: 10.4137/SaRt.S23546. eCol R, Garne E, Wang H, Klungs\u00f8yr K, Jordan S, Neville A, Pierini A, Hansen A, Engeland A et al. Antiepileptic drug prescribing before, during and after pregnancy: a study in seven European regions. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1144-54. doi: 10.1002/pds.3847. Dale Romundstad P , Skurtveit S. Prevalence of use of non-prescription analgesics in the Norwegian HUNT3 population: Impact of gender, age, exercise and prescription of opioids. BMC Public Health. 2015;15:461. doi: 10.1186/s12889-015-1774-6 Gini R, Jordan SE, Klungsoyr K, Loane M, et al. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. European Journal of Epidemiology. 2015;30(6):501-8. doi: Fredheim T. Risk factors for excessive benzodiazepine use in a working age population: a nationwide 5-year survey in Norway. Scand J Prim Care. 10.3109/02813432.2015. Furu M, H, N\u00f8rgaard M. Serotonin-Reuptake Inhibitors and Venlafaxine in early pregnancy and risk of birth defects - a population based cohort study and sibling design. BMJ 2015. Moger TA. Socio-economic inequality in the use of procedures and mortality among AMI patients: Quantifying the effects along different J Chron Obstruct Pulmon Dis 2015;10:1695-702. doi: 10.2147/COPD.S83107 Hansen Borchgrevink PC, Dale O, Romundstad PR, Mahic M, et al. Consumption of and satisfaction with health care among opioid users with of Mela - tonin - A Register Linkage Study between the Norwegian Prescription Data- base and of Selec - tive Serotonin Reuptake Inhibitors in Elderly Monitoring. doi: 10.1097/FTD.0000000000000169. Hoff M, Skurtveit S, Meyer HE, Langhammer S\u00f8gaard AJ, Syversen U, et al. Use of anti-osteoporotic drugs in central Norway after a forearm fracture. Archives of Osteoporosis. 2015;10:30. doi: 10.1007/s11657-015-0235-2. H\u00f8iseth G, Middelkoop G, M\u00f8rland Has Previous Abuse of Fluni - trazepam Been Replaced by Clonazepam? European Addiction GS, Espehaug B, Midthjell K, Graue M, et al. Anxiety, depression and timing of insulin treatment among people with type 2 diabetes: Nine-year follow-up of the Nord-Tr\u00f8ndelag Health Study, Norway. Journal of Psychosomatic Research. 2015;79(4):309-15. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Vejrup K, et al. Hormonal contraceptive use before and after conception in relation to preterm birth and small for gestational age: An observational cohort study. BJOG 2015;122(10):1349-61. DOI: 10.1111/1471-0528.13114 C, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88-91. doi:10.1016/j.seizure.2015.02.017 Kann IC, Lundqvist C, Lur\u00e5s H. Polypharmacy Among the Elderly in a List-Patient System. Drugs - Real World Outcomes. 2015;2(3):193-8. doi: 10.1007/s40801-015-0036-3 Kelly E, Lu CY , Albertini S, Vitry A. Longitudinal trends in utilization of endocrine therapies for breast cancer: an international comparison. Journal of Clinical Pharmacy and K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG-an International and use of anti- depressant medication in late mid-life: a register-based analysis of Norwegian women and men. Aging & mental health. 2015:1-10. doi: 10.1080/13607863.2015.1118010 Lund IO, Skurtveit S, Handal M. Commentary on Raitasalo et al: the great potential in nation-wide registers to study prescription drug use and abuse. Addiction (Abingdon, England). 2015;110(4):644-5. DOI: 10.1111/add.12856 Lund IO, Bukten Handal M, Nordfjaern T, Brunborg GS, Rossow I. A Cohort Study on Long-Term Adverse Effects of Parental Drinking: Background and Study Design. Subst Abuse. 2015 Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2015 Sep;19(8):1095-100. doi: Nystad W. Grandmother's smoking when pregnant with the mother and asthma in the grandchild: the Norwegian Mother and Child Cohort Study. Thorax. 10.1136/thoraxjnl-2014-206438. Neutel 10.1007/s00228-015-1841-z. Rossow I, Bramness JG. The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study. LB, Engeland A. Risk of hip fracture among older people using antihypertensive drugs: a Bramness JG. Incident Users of Antipsychotic Agents and Future Use of Cholesterol-Lowering Drugs: An Observational, Pharmacoepidemiologic Study. Journal 10.4088/JCP .14m08996. Suhrke P , Zahl PH. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: A register-based cohort study. Cancer Medicine. 2015;4(8):1303-8. doi: 10.1002/cam4.474 Tvete IF, Bj\u00f8rner T, Skomedal T. Risk factors for excessive benzodiaz - epine use in a working age population: a nationwide 5-year survey in Norway. Scand J Prescription patterns of inhaled corticosteroids for preschool children - A Norwegian register study. Pediatric Allergy and Immunology. 2015;26(7):655-61. L, al. of SSRI and SNRI Antidepressants during Pregnancy: A Population-Based Study from epide drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. S, Ruths S. Risk of hip fracture among older people using anxiolytic and hypnotic drugs: a nationwide prospective cohort study. Eur Clin Berg-Hansen P , Moen S, Harbo H, Celius E. High prevalence and no latitude gradient of multiple sclerosis in Norway. Mult Scler 2014;20:1780-1782 Ferrer P , Rafaniello C, Sabate E, Coma A, Zara C, et al. Cross- national comparison of antiepileptic drug use: Catalonia, Denmark and Norway, 2007-2011. Epidemiology Public Health. 2014;11:e9405-1. Fredheim OM, Skurtveit S, Dale O, Romundstad P , Borchgrevink PC. Chronic pain and use of opioids: a population based pharmacoepidemio - logical study from the Norwegian prescription database and the Nord-Tr\u00f8n - delag health study (HUNT). Pain 2014;155:1213-1221 Gjelsvik B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self-poisoning: a multilevel approach. of b-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. European Urology 2014;65:635-641. Halvorsen T, Martinussen PE. The geography of chronic obstructive pulmonary disease: A population-based study of Norway. Soc Sci Med 2014;21:25-34. Jensen ET, Daniels JL, Sturmer T, Robinson WR, Williams CJ, Moster D, et al. Maternal hormonal contraceptive use and offspring overweight or obesity. Int J Obes. 2014;38:1275-81. Kalseth J, Cross-country comparisons of health-care costs: The case of cancer treatment in the Nordic countries. Health Policy 2014:115;172-179. Kann IC, Lundqvist C, Luras H. Prescription of addictive and non-addictive drugs to home-dwelling elderly. Drugs Aging. 2014 Jun;31(6):453-9. Karlstad \u00d8, Furu K, Skurtveit S, Selmer R. Drugs for Attention- Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59-65. Kieler H, Malm H, Artama M, Engeland A, Furu K, Gissler M, et al. Use of antidepressants and association with elective termination of pregnancy: population based case-control study. BJOG. 2014 Nov KB, Amundsen EJ, Dalgard O. HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984. Scand J Gastroenterol. 2014 Dec;49(12):1465-72. Langballe H, Ballard C, Aarsland D, Selbaek G. Short- and Long-Term Mortality Risk Associated with the Use of Antipsy - chotics Among 26,940 Dementia Outpatients: A Mahic M, Fredheim OM, Borchgrevink PC, Skurtveit S. Use of prescribed opioids by children and adolescents: Differences between Denmark, Norway and Sweden. Eur J Pain. 2014 Nov 20;[Epub ahead of print]: doi 10.1002/ Co-morbidity in persistent opioid users with chronic non-malignant pain in Norway. Eur J Pain. 2014;18:1083-1093 Neutel CI, Skurtveit S, Berg C, Sakshaug S. Trends in prescription of strong opioids for 41-80 year old Norwegians, 2005-2010. Eur J R. demographic, lifestyle and psychological predictors of benzodiazepine and z-hypnotic use patterns. Nord J Psychiatry Norum J, Olsen AI, Nohr FI, Heyd A, Totth A. Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study. Glob J Health Sci. 2014 Jul;6(4):155-62. Omland G, Ruths S, Diaz E. Use of hormonal contraceptives among immi - grants and native women in Norway: data from the Norwegian Prescription Database. BJOG 2014;121:1221-1228 Riska BS, Skurtveit S, Furu Dispensing of benzodi - azepines and benzodiazepine-related drugs to pregnant women: a popula - cohort Stene LC, Drivvoll AK, Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Child - hood Diabetes Registry. Diabetologia 2014;57:57-62. Skurtveit S, Selmer R, Odsbu I, Handal M. Self-reported data on medicine use in the Norwegian mother and child cohort study compared to data from the Norwegian prescription database. Norsk Epidemiologi. 2014;24(1-2). Str\u00f8m H, Selmer R, Birkeland KI, Schirmer H, Berg TJ, Jenum AK, et al. No increase in new users of blood glucose-lowering drugs in Norway 2006-2011: a nationwide prescription database study. BMC Public Health. 2014;14:520. K, Fredheim PA. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infec S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013;42:514-20. Berge LI, Riise T, KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? Epidemiology 2013;24:129-34. Bjorner T, Tvete IF, Aursnes I, Skomedal T. [Dispensing benzodiazepines and S, et al. Antidepressants to cancer patients during the last year of life--a population- based study. Psychooncology A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int T, Daltveit AK, Skurtveit Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug exposure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. British Journal of Gjelstad S, Dalen KJ. Are children carrying the burden of broad-spectrum antibiotics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infec - tions in Norway. Open 2013;3:e002285. M, Skurtveit S. A pharmacoepi - demiological cohort study of subjects starting strong opioids for nonma - lignant pain: a study from the Norwegian Prescription Database. Pain 201;154:2487-93. Hold\u00f8 I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013;98:732-6. Hoye S, Gjelstad S, Lindbaek M. Effects on antibiotic dispensing rates of interventions to promote delayed prescribing for respiratory tract infections in primary care. Br J GenPract. 2013;63:e777-86. Jonasson C, Tvete IF, Hatlebakk JG. Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Gastroenterol 2013;48:1010-7.Klovstad H, Natas O, Tverdal . Systematic screening with infor - mation and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:30. Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medicine 2013;81:42-52. Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. J Vet Pharmacol Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013;111:221-32. Lillefjell M, Haugan T, Martinussen P , Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. Journal of Musculoskeletal Pain 2013;21:311-319. Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. Eur J Clin Pharmacol Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. Addic - tion 2013;108:367-76. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overactive bladder in women: data from Norwegian Obstet 2013;92:1208-1215. prescribers in older safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69. Nordeng H, Lupattelli A, Rom\u00f8ren M, Koren G. Neonatal outcomes after gestational exposure to nitrofurantoin. Obstetrics and Gynecology 2013;121:306-13. Nordfjaern T, Bjerkeset O, Moylan Berk M, Grawe RW. Clusters of person - ality traits and psychological symptoms associated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013;38:2575-80. Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psychological health among the elderly. Hum Psychopharmacol 2013;28:248-57. Persheim Tidsskrift for den Fetveit A, Dalen I, Straand J. Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Tornhage CJ, Lokk J. a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc tive prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67-73. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug expo - sure: inclusion of dispensed drugs before pregnancy may lead to underesti- mation of risk associations. J GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. Journal of Women's Health 2013;22:250-8. Stephansson O, Kieler H, Haglund B, Artama Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48-54. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013;99:1755-60. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose congeners to iden -Legemiddelstatistikk 2018:2 Folkehelseinstituttet 140tify doctors more rationale prescribing. BMJ Open 2013;3:e003296. Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved Laegeforen 2013;133:615-6. Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. Diabet Med May]. Tidsskr Nor legemidler 1975-2010. [Patterns in - 2010] Tidsskr Bramness JG, Furu Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Therap 2012;91:438-41. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. Addiction 2012;107:967-72. Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in inci - dent users in Norway. Pharmacoepidemiol Drug Saf 2012;21:297-304. Devold HM, S\u00f8gaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225-33. Fasmer OB, methadone: pharmacoepidemiological Opoid switching to methadone: a pharmacoepidemiological study from a national prescription database. Palliat Med 2012;26;804-812. Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. Pharmacoepidemiol Drug Saf 2012;21:881-5. Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. J Clin Psychiatry. 2012;73:e548-54. M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nationwide prescription database study. Scandinavian Journal of Public Health 2012;40:704-11. Hjellvik V, Mahic M, Tverdal A. Utdanning in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2012;21:1045-52. Kieler H, Artama M, Engeland A, Ericsson O, Furu Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson H, Haglund B. Selec - tive serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hypertension of the newborn: population based cohort study from the five Nordic countries BMJ 2012;344:d8012. Kjome RL, Roraas T, Granas AG, Sandberg glucometer and Laegeforen 2012;132:1453-7. Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68:311-9. Holmen J. The HUNT study: Participation is associated with survival and depends on socioeco- nomic status, diseases and symptoms. BMC Medical K, Borchgrevink S, Fredheim OMS. Concomitant medication among persistent opioid users chronic malignant pain. Acta Anaesthesiologica Scandinavica 2012;56:1267-76. Neutel CI, Skurtveit the point of guidelines? Benzo- diazepine and z-hypnotic use by an elderly population. Sleep Medicine 2012;13:893-7. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medica- tion in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206 Neutel CI, Skurtveit S, C. Benzodiazepine and transdermal buprenorphine - long-term use drugs. Acta Anaesthesiol Scand. 2012;56:88-94. Nordfj\u00e6rn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiazepine and z-hypnotic users. Addic - tive Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical Pharmacology 2012;68:1085-94. Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Fredheim Lindbaek H. Pregnancy outcome after gestational exposure to erythromycin - a population-based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053-62. R\u00f8nning PA, Helseth E, Meling TR, population-based study on the effect temozolomide in the treatment of glioblastoma multiforme. Neuro-Oncology 2012;14:1178-84. Selmer R, Blix HS, Landmark K, Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up Hartz I. Mental distress and subsequent use of psychotropic drugs among adolescents - a prospective register linkage study. J Adolescent Health 2012;50:578-87 Steffenak AKM, Wilde-Larsson B, Nordstrom G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225-31. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Apr 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medi - cation for bipolar disorder and diabetes mellitus: A nationwide population- based study with focus on gender differences. BMC Medicine 2012;10:148. Svendsen K, Skurtveit S, Romundstad Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359-69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196-201. Von Soest T, Bramness JG, Pedersen W, Wichstr\u00f8m L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87-95. \u00c5svold BO, Vatten LJ, Midthjell within the refer - ence range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the 2012;97:93-9. M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159-67. Bramness JG, Sexton JA. The Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. BMC Public Health. 2011;11:144. Dalen DM, Furu K, Locatelli M, Str\u00f8m S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49-59. Engeland A, Bj\u00f8rge S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry- based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157-63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243-8. Fasmer OB, Riise opioid High validity of mother-reported use of antiasthmatics among children: a comparison with a prescription 2011;64:878-84. [Chlamydia South Tr\u00f8ndelag follow-up]. Tidsskr Nor Laegeforen Godman B, Sakshaug Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reim- bursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121-9. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi R, Kalaba J, Dalen H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother 2011;66:2425-33. Hancock P , Nystad W, London SJ. Oral contraceptive pill use before pregnancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528-36. Handal M, Engeland A, of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953-60 Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. Environ Sci Technol. 2011;45:5676-82. Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance - H. Boiled coffee intake and sub sequent risk for Type 2 Diabetes. Epidemiology 2011;22:418-21. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway -explained by hormone therapy or mammographic screening? International Journal S, Nafstad P , Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepide - miol Drug Saf 2011;20:370-7 Kjosavik SR, Hunskaar S. Initial prescription of anti- psychotics and antidepressants in general practice and Acta Scand Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51-9. Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant use of anti- dementia drugs with psychotropic drugs in Norway--a population-based study. Pharmacoepidemiol Drug Saf. Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population-based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90-8. Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. Scand J Pain 2011;2:36-44. Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005-2009. Phar - macoepidemiol 2011;20:457-63. Neubert A, Hsia , de Jong-van den Berg Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Pharmacol. 2011;72:969-77. , Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the J Clin Psychopharmacol. \u00d8degaard pharmaco-epidemiological study of migraine and antidepressant medica- tions: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198-204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. Pharm World Sci. 2010;32:752-8. Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiol Saf 2010;19:273-9. A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur J Neurol 2010;17:1445-50. Berg A, Furu analgetika [Use of for pain-relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463-6. Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and Bramness Engeland A, Skurtveit S. pregabalin (Lyrica) help patients reduce their use of benzodiazepines? A comparison with gaba- pentin using the Norwegian Devold HE, Falch JA, S\u00f8gaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306. Fredheim OM, Skurtveit . Increasing use of opoids from 2004 to 2007 - Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-294. Fredheim OM, Log T, Olsen adolescents; a study from a national prescrip- tion database in Norway. Pediatric Anesthesia Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as of Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodiazepines users. Soc Sci Med 2010;70:921-5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465-73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235-42. Hunskaar S, E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751-64 K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol M, CJ. Psychiatric comorbidity in patients Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nation - wide cohort. Diabetes Technol Ther 2010;12:701-5. Korn\u00f8r H, Pedersen W, Selmer Tverdal A. Benzodiazepines predict use of opioids- a follow-up study of 17 074 men and women. Pain Med 2010;11:805-14. Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol drugs: use and co-treatment with potentially interacting medications Eur S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or i Sogn og Fjordane [Use of lithium in the Norwegian counties and og Fjordane]. The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study. J Affect Disord 2009; Bramness JG, Skurtveit S, Neutel I, M\u00f8rland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharma - coepidemiol Drug Saf 2009;18:492-6. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224-8. Devold H, Molden of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234-41. Engeland Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Prescription of codeine for non-malignant pain in Norway- a pharmacoepidemio - logical study from The Norwegian Scand 2009;53:627-33. Gjerden P , Bramness and potential abuse of anticholin - ergic antiparkinson drugs in , L, the use of anticho - linergic antiparkinson drugs and safety and receptor drug-binding of Eur antipsychotic and anticholin - ergic antiparkinson drugs in Norway after withdrawal orphenadrine. J Clin Pharmacol 2009;68:238-42. Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320-6. Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nationwide administrative register. Nor J Epidemiol 2009;19:169-172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addic - tive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209-218. Hauge Aavitsland P . Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Bramness Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572-8. Landmark CJ, Larsson P , Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population-based study of prescriptions. Epilepsy Res 2009; 87: 31-9. Selmer Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355-62. Skurtveit S, Furu K, Kaasa Introduction of low dose trans- dermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 2009;13:949-53. Skurtveit Skrivarhaug T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study Pharmacoepidemiol Drug Saf medika- Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185-90. Berg A, Furu Skurtveit S. The role of pharmaco epidemiological studies in the market withdrawal of carisoprodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167-72. Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074-5. Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescriptions of antidepressants. J T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care 2008;26:80-5. Engeland JG, AK, R\u00f8nning M, Skurtveit S, Furu K. Prescription druguse among fathers and mothers before and during preg - nancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] Nor J Epidemiol 2008;18: 159-66. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, antipsychotic medication: linking population-based prescription data- base to the HUNT Pharmacoepidemiol Drug Saf 2008;17:372-7. Litleskare I, Blix H, norske kreftpasi - enter [Variable prescription of opioids cancer Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf 2008;17:926-933. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714-17. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor J Epidemiol 2008;18:191-94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161-6. Blix f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Laegeforen S. Carisoprodol use and abuse in Norway. pharmacoepidemiological Br Clin Pharmacol 2007;64: 210-8. H. Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203-9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of road traffic acci- after of A, Skurtveit S, M\u00f8rland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. Ann Epidemiol of anti-asthmatic medica- tions as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol S. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database N, Hausken T, P . A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. Torkildsen O, Grytten N, Myhr S, R\u00f8nning M. [Changes in the sale and use of flunitrazepam in Norway, 1999 - 2004]. Tidsskr Lindback M. Can antibi - otic prescriptions in respiratory tract infections be improved? A cluster- randomized educational intervention in general practice--the Prescription Peer Academic (Rx-PAD) Study [NCT00272155]. Dalen I. A cluster- randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. Sakshaug S, R\u00f8nning M. [How many and who are receiving for mellitus?] Nor Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53-56. 2001: Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor J Epidemiol 2001;11:55-60.Utgitt av Folkehelseinstituttet Published by Norwegian Institute of Public Health June 2018 Bestilling/Order: Kun tilgjengelig som PDF. Lastes ned fra www.fhi.no as PDF from "}